tag:blogger.com,1999:blog-201409332024-03-16T14:52:43.098-04:00Irv Arons' JournalThis journal will be a spot for me to comment about the world of ophthalmics and medical lasers. I intend to publish some of the more than 150 articles and columns that I have written on these subjects.
In addition, I will report on the latest information on new drugs and devices for the treatment of retinal diseases, including age-related macular degeneration (AMD).Irv Aronshttp://www.blogger.com/profile/05719664806219249867noreply@blogger.comBlogger308125tag:blogger.com,1999:blog-20140933.post-7663137448373485672017-05-31T17:45:00.001-04:002017-05-31T17:48:05.676-04:00A Most Memorable Trip: The Soviet Union Before the Breakup - The Interesting Adventures of A Consultant<div class="separator" style="clear: both; text-align: center;">
</div>
<div style="text-align: justify;">
Irv Arons<br />
<br />
In the summer of 1990, my wife and I were invited to
join a <b>People to People Ambassador Tour </b>to visit the <b>Soviet Union</b>. The
<b>USSR</b> didn’t break up into its member states until the following year,
late 1991. So, we got a look at what turned out to be a huge national
facade – a strong military front and a “third world” infrastructure.<br />
<br />
I
was part of a medical group (medical laser specialists) that visited
several hospitals and laser centers (?) within Moscow (Russia), Tbilisi (Soviet
Georgia), Kharkov (Ukraine) and in St. Petersburg (again, in Russia). Fortunately, my wife
was able to join up with a group of performing artists that were also on
an Ambassador tour and, while we (the medical group) were doing our hospital visits, they
visited their Soviet peers,.<br />
<br />
For the record, Moscow was bleak,
with the exception of our visit to the Kremlin, and the gift shopping –
my wife got a beautiful amber necklace from a street vendor for $20, and
I came back with a set of matryoshka (nesting) dolls, with Gorbachev on
top and Lenin deep inside at the bottom). In contrast, Tbilisi in Soviet Georgia
was colorful and hot (90 degrees when we were there). The Ukraine, our
next stop, was the food basket of Russia, but because they had few
refrigerated trucks, there was no way of moving the food into the
cities! Our final stop was St. Petersburg (or Leningrad, whichever you
prefer), which was beautiful. It is a land of rivers and bridges – and
the <a href="http://www.hermitagemuseum.org/html_En/"><b>Hermitage</b></a>, the most beautiful museum that we have ever visited!<br />
<br />
<br />
A
brief anecdote – the day before our visit to the Hermitage, one of my
colleagues ran out of 35 mm film and I gave him a couple of rolls of the
400 speed film that I was using. The next day, he replaced my rolls
with a couple of rolls of 1000 speed film, which enabled me to take some
beautiful pictures inside the Hermitage, including of the huge
malachite urns and a couple of Rembrandt paintings (one of a man in a
red coat - which I believe was a self-portrait, and Moses with his son
Isaac on the mount) without needing to use a flash, which was forbidden
inside the museum. I have included
a few of these photos for your enjoyment – actually, the Rembrandt’s are from
the web, as they are much better reproductions than I was able to
achieve from my 35mm slides.)<br />
<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiyh4rgoSgOBbGvjjOa0NrHFEfhjyHzi9f1E9Z7qoq-ktqQETTtx_ITJ4024viuG1YflDKYjqF8xgcRsIDORCZS_3HEVfUh9t9D5Er5IkrZMNLodTppkzKcryuETJx42aori7z1/s1600/image+of+Old+Man+in+Red.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" data-original-height="260" data-original-width="194" height="200" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiyh4rgoSgOBbGvjjOa0NrHFEfhjyHzi9f1E9Z7qoq-ktqQETTtx_ITJ4024viuG1YflDKYjqF8xgcRsIDORCZS_3HEVfUh9t9D5Er5IkrZMNLodTppkzKcryuETJx42aori7z1/s200/image+of+Old+Man+in+Red.jpg" width="149" /></a><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj8Te4ICTe4A9ugzmMqrW6Bh5jmIGVxOGaXBsokhFn2AKZi7maKjYTzW4RWt__3EJH5g5QLpcX56Ub4XR_x4yMNSgJr1CXU1o62ejFdj7Pe-h6kke1o2srCCKs5rc8l5O2lAIcI/s1600/Sacrifice+of+Isaac.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="246" data-original-width="167" height="200" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj8Te4ICTe4A9ugzmMqrW6Bh5jmIGVxOGaXBsokhFn2AKZi7maKjYTzW4RWt__3EJH5g5QLpcX56Ub4XR_x4yMNSgJr1CXU1o62ejFdj7Pe-h6kke1o2srCCKs5rc8l5O2lAIcI/s200/Sacrifice+of+Isaac.jpg" width="135" /></a></div>
<br />
<br />
<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjrmYZEQYJin5nnWRVOX-Hgfj8BcWmnm0VTxjCHh8YYv6-lvqrvSx3SbWqH-Ur2TmAJDH-6dFxkI7-YqPmEytFNNc5SALuYhCndTqjBZ64j6aHyFCgW77L4-W176uBAd0J2Gm_9/s1600/Malechite+Urn.JPG" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="1067" data-original-width="1600" height="213" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjrmYZEQYJin5nnWRVOX-Hgfj8BcWmnm0VTxjCHh8YYv6-lvqrvSx3SbWqH-Ur2TmAJDH-6dFxkI7-YqPmEytFNNc5SALuYhCndTqjBZ64j6aHyFCgW77L4-W176uBAd0J2Gm_9/s320/Malechite+Urn.JPG" width="320" /></a></div>
<br />
<br />
We flew Aeroflot within the
USSR – no seat belts, animals on board, and tea service served in
cracked cups by heavy-set women with gold teeth! The planes were flown
by military pilots, who were the first to get off, and the rear section
of the plane was unloaded first to keep the planes balanced!<br />
<br />
When we visited,
most people worked for the state – and there wasn’t any work! So they
would go to their jobs in the morning and, having nothing to do there,
would be back on the streets by noon. It just goes to prove that the
communist way of doing things didn’t work. There were no goods in the
stores, and what we did see was both sparse and of poor quality (paper
shoes?). And, long lines everywhere to get tobacco and vodka.<br />
<br />
Based
on my experiences, I published two articles about my trip; one about
the state of healthcare (and lack of lasers) in the USSR, and a second
on the state of eyecare in that part of the world. They are technical in
nature but illustrate the differences between what the Soviet Union was
telling the world and what we actually saw!<br />
<br />
<br />
<br />
Here, for your further enlightenment, are the two articles I wrote about our (the medical groups’) experiences. <br />
<br />
<br />
<b><a href="http://irvaronsjournal.blogspot.com/2005/12/state-of-healthcare-in-soviet-union.html">The State of Healthcare in the Soviet Union: The Lack of Medical Lasers</a></b><br />
This article was published in both <b>Medical Laser Industry Report</b>, October 1990 and <b>Laser Report</b>, December 15, 1990.<br />
<br />
Irving J. Arons<br />
Arthur D. Little<br />
<br />
During
late July 1990, I was privileged to join a delegation of medical laser
specialists and other health care professionals, under the auspices of
the <b>People to People Ambassador Program</b>, invited to tour the medical
community in the Soviet Union. Our group, organized by the <b>American
Society for Lasers in Medicine and Surgery</b>, was composed of specialists
in gynecology, plastic surgery, thoracic surgery, urology, general
medicine, and myself, representing the field of ophthalmology. In
addition to the <b>ASLMS</b> group, a veterinarian working with lasers, a
health care safety specialist, and two medical technical/clinical lab
specialists were included in our delegation.<br />
<br />
We were able to
visit a medical laser research institute in Moscow, and four hospitals,
one each in Moscow (Soviet Russia), Tbilisi (Soviet Georgia), Kharkov
(Soviet Ukraine), and Leningrad/St. Petersburg (Soviet Russia, again).<br />
<br />
Our
overall impression was that the facilities and equipment in use were
woefully decrepit and/or non-existent or years behind Western standards.
However, the medical personnel we met were dedicated professionals.<br />
<br />
Of
particular note, we found that the hospitals -- even one claimed to be
only three years old -- were ill kept and falling apart. The facades
were cracked and broken, the hallways and stairwells unswept, and the
grounds surrounding the buildings not cared for at all. In counterpoint,
we found the patient rooms were clean and staffed with dedicated nurses
and doctors doing their best with what they had. This was particularly
evident at the <b>Karzigan Childrens Hospital</b> in Moscow. The wards were
filled with children with trauma of all kinds, but they were all smiling
and very well cared for by an attentive staff of nurses and aides. It
was here that we learned that a typical doctor with less than 10 years
service earns between 240-260 rubles a month (the equivalent to about
$40 at the official exchange rate of 6 rubles to the dollar, and only
$20-30 at the black market exchange rate of 10-15 rubles to the dollar),
a beginning research worker earns 140-150 rubles per month, and a
surgical nurse get about 110 rubles for regular shifts. (In contrast,
the bus drivers providing our transportation were paid 400 rubles/month
and we were told that street sweepers earned as much as 700
rubles/month!)<br />
<br />
The hospital equipment, especially for diagnosis
and surgery, was particularly non-existent, and, according to our
laboratory clinicians, the clinical laboratory equipment was barely
adequate to care for the patients in the wards. But we must emphasize,
both the hospital administration and medical staff were dedicated to
providing the best care possible to their patients. What they lacked in
equipment they more than made up with in numbers and dedication.<br />
<br />
As
for medical lasers, and new medical treatments using lasers, except for
the laser institute in Moscow, the only lasers that the hospitals
seemed to have were low powered therapeutic types, basically HeNes and
GaAs infrared lasers. The hospital in Leningrad had several CO2 lasers,
and claimed to have other surgical equipment, but we only saw
therapeutic lasers in operation. We were told that only about 100 of
approximately 15,000 hospital-based physicians in Kharkov have access to
or use surgical lasers. We would guess that the percentages are not
much different in the other 14 Soviet Republics. At the hospitals we
visited, the majority of the half dozen lasers they claimed to have --
if they had any -- were either HeNe or GaAs therapy lasers, used to
treat open sores, pain, and in one hospital in Tbilisi (<b>Soviet Institute
of Clinical & Therapeutical Research</b>), for treating myocardial
infarctions by clearing viruses in the blood through intravenous use of a
HeNe laser connected to a fiber inserted through an arm vein. The same
hospital also used a scanning HeNe laser to alleviate angina chest pain
by scanning the laser beam across the patient's chest!<br />
<br />
At a
trauma hospital in Leningrad (<b>The Ambulatory Institute Hospital</b>), we saw
a 40-50 watt CO2 laser in the corner of an operating room, and another
upstairs in a storeroom along with the usual HeNe lasers. We saw no
evidence of a YAG laser although the laser specialist at this hospital
claimed to have just received one, but which he had not yet unpacked. In
the same storeroom with the spare CO2 laser, we were told that a small
laser sitting on top of packing crates was a new UV laser, apparently
solid-state since there was no evidence of any gas bottles or
connections for one. (An interesting side note, we observed a burn
therapy ward at this hospital, and it was disconcerting to see flypaper
strips hanging from the ceiling.)<br />
<br />
At the hospital in Kharkov (<b>The
Central Regional Hospital</b>), we were told that they had an Ar laser used
in ophthalmic treatments (but we did not see it).<br />
<br />
The <b>National
Research Institute of Laser Surgery</b> in Moscow claimed to be doing
considerable research with medical lasers, performing 47,000 laser
procedures annually. It is supposedly, one of 52 laser centers in the
Soviet Union. We were given a presentation about the clinical research
they were doing with five types of high power lasers, mostly CO2 and YAG
-- and two prototype free electron lasers, used for PDT studies. The
FELs, according to the slides shown us, may be revolutionary, in that
they appeared to be about the size of a large sized desk, much smaller
than any other FEL I have seen -- and I have seen the Stanford FEL and
pictures of others. Attempts to find out more about this laser
development were fruitless, however I plan to get back in touch with my
contact at the Institute to see if I can possibly learn more about this
exciting laser development. (Several weeks after my return to the
States, I received a call telling me that a defector from the Moscow
Laser Institute wanted me to know that he had built the laser in
question and it was not an FEL, but rather an electron beam generator
pumping a chemical laser use in their PDT work.) When we asked to see
their lasers, we were politely told that they were in another building
and couldn't be shown to us. Apparently, the person holding the key to
the lab was not available!<br />
<br />
According to a profile of the Soviet
healthcare community recently published by <b>Medistat</b>, a UK healthcare
publication, what we saw in the Soviet Union this summer is typical and
not out of line with what others have reported. The Medistat profile
stated that the Soviet Union has some 23,000 hospitals with 3.6 million
beds, and in addition, some 38,000 polyclinics and other outpatient
centers. Capital investment in recent years has concentrated on the
construction of new facilities to boost the number of beds, but many of
the new facilities have been built at unsuitable sites, and the majority
of Soviet hospitals having little in modern equipment with some lacking
the basic necessities of adequate sanitary facilities or even heating.<br />
<br />
The
polyclinic is the main unit in the primary healthcare network, and the
first point of contact for most Soviet patients. They serve districts of
50,000 to 60,000 inhabitants and are staffed by doctors responsible for
around 2000 patients. In addition to general doctors, each polyclinic
has specialists in area such as cardiovascular disease, oncology and
renal medicine.<br />
<br />
The Soviet Union has the highest number of
doctors per capita, with a total of 1.3 million doctors serving a
population of 275 million. In addition, there are 3.3 million medical
assistants. Women doctors are well represented, accounting for about 70%
of all doctors. (We were told the percentage was closer to 50%, at
least at the facilities we visited.)<br />
<br />
As you know, until recently,
all planning was done centrally, and for five years in advance -- the
so called <b>Five Year Plan</b>. The most recent healthcare plan was put
together in August 1987. That five-year plan attempted to address the
chronic underfunding of the healthcare system, calling for new hospitals
while neglecting older ones which will now need to undergo drastic
major refurbishment. Expenditures for medical equipment had also been
limited in the past, with the majority of funds allocated for new
buildings. But the new policy included allocation of more resources for
the purchase of modern equipment, in particular the polyclinic
facilities were to be upgraded with proper diagnostic and treatment
services to enable the patients to be treated at the clinic rather than
to be referred to local hospitals. According to Medistat, 5.4 million
rubles had been allocated for the purchase of new equipment over the two
year period 1988-1989.<br />
<br />
Discussing the state of the Soviet
medical equipment market, Medistat states that the USSR suffers from a
chronic shortage of equipment, particularly in the high tech areas such
as computerized scanning, ultra-sound, renal equipment, and as we found
out, laser treatment devices. Even basic equipment such as
electrocardiographs and routine surgical instruments and disposable
syringes are in short supply, with the problem being further aggravated
by the fact that much of the Soviet produced equipment is sub-standard.<br />
<br />
The
current five-year plan envisages accelerating development in the
medical industry and raising the technological level both within its
industry and in its healthcare facilities. We hope that this can be
accomplished. It is sorely needed.<br />
<br />
<br />
In the report above, I
discussed the state of healthcare in the USSR as we saw it in 1990. The
hospitals and care appeared to be at least thirty years behind similar
Western facilities, with a lack of instruments and supplies and
crumbling buildings, but with dedicated medical personnel.<br />
<br />
At the
urging of a friend, I have added a brief piece, taken from Wikipedia,
about how the healthcare system in the Soviet Union (and more
specifically Russia) has changed since I was there – and from the way it
is described below, it really hasn’t!<br />
<br />
<b>Healthcare in the Soviet Union and Russia</b><br />
Source: <a href="https://en.wikipedia.org/wiki/Healthcare_in_Russia"><b>Wikipedia</b></a><br />
<br />
<b>Pre-reform health care</b><br />
<br />
Pre-1990s
Soviet Russia had a totally socialist model of health care with a
centralised, integrated, hierarchically organised with the government
providing free health care to all citizens. All health personnel were
state employees. Control of communicable diseases had priority over
non-communicable ones. On the whole, the Soviet system tended to primary
care, and placed much emphasis on specialist and hospital care.<br />
<br />
The
integrated model achieved considerable success in dealing with
infectious diseases such as tuberculosis, typhoid fever and typhus. The
effectiveness of the model declined with underinvestment. Despite the
fact that the quality of care began to decline by the early
1980s,medical care and health outcomes were on par with western
standards. Despite a doubling in the number of hospital beds and doctors
per capita between 1950 and 1980, the lack of money that had been going
into health was patently obvious. Some of the smaller hospitals had no
radiology services, and a few had inadequate heating or water. A 1989
survey found that 20% of Russian hospitals did not have piped hot water
and 3% did not even have piped cold water. 17% lacked adequate
sanitation facilities. Every seventh hospital and polyclinic needed
basic reconstruction. Five years after the reforms described below per
capita spending on health care was still a meagre US$158 per year (about
8 times less than the average European social models in Spain, the UK
and Finland, and 26 times that of the U.S. which spent US$4,187 at that
time).<br />
<br />
<b>Reform in 1991-1993</b><br />
<br />
The new Russia has changed to a
mixed model of health care with private financing and provision running
alongside state financing and provision. Article 41 of the 1993
constitution confirmed a citizen's right to healthcare and medical
assistance free of charge. This is achieved through compulsory medical
insurance (OMS) rather than just tax funding. This and the introduction
of new free market providers was intended to promote both efficiency and
patient choice. A purchaser-provider split was also expected to help
facilitate the restructuring of care, as resources would migrate to
where there was greatest demand, reduce the excess capacity in the
hospital sector and stimulate the development of primary care. Finally,
it was intended that insurance contributions would supplement budget
revenues and thus help to maintain adequate levels of healthcare
funding.<br />
<br />
The OECD reported that unfortunately, none of this has
worked out as planned and the reforms have in many respects made the
system worse. The population's health has deteriorated on virtually
every measure. Though this is by no means all due to the changes in
health care structures, the reforms have proven to be woefully indequate
at meeting the needs of the nation. Private health care delivery has
not managed to make much inroads and public provision of health care
still predominates.<br />
<br />
The resulting system is overly complex and
very inefficient. It has little in common with the model envisaged by
the reformers. Although there are more than 300 private insurers and
numerous public ones in the market, real competition for patients is
rare leaving most patients with little or no effective choice of
insurer, and in many places, no choice of health care provider either.
The insurance companies have failed to develop as active, informed
purchasers of health care services. Most are passive intermediaries,
making money by simply channeling funds from regional OMS funds to
healthcare providers.<br />
<br />
<b>National Projects</b><br />
<br />
In 2006 a national
project 'Health' was launched to improve the country's healthcare
system through improved funding and healthcare infrastructure. This plan
helped equip hospitals and clinics with advanced, high-end equipment
and ambulance systems, build new medical centers, as well as launch
nation-wide vaccination programs and free health checks. The project has
also been working on developing medical technology market through
initiatives to blend healthcare and information technology. One of the
focuses was made on salary increase of medical staff working in the
primary care as well as their wider training programs.<br />
<br />
The
project was initiated by the Russian President Vladimir Putin and
coordinated by the Presidential administration. It was mostly financed
by the federal budget. However regional and municipal levels have also
contributed a lot to the financing of the program.<br />
<br />
<b>Reform in 2011</b><br />
<br />
After
Vladimir Putin became president in 2000, there was significant growth
in spending for public healthcare and in 2006 it exceed the pre-1991
level in real terms. Also life expectancy increased from 1991-93 levels,
infant mortality rate dropped from 18.1 in 1995 to 8.4 in 2008. Russian
Prime Minister Vladimir Putin announced a large-scale health-care
reform in 2011 and pledged to allocate more than 300 billion rubles ($10
billion) in the next few years to improve health care in the country.
He also said that obligatory medical insurance tax paid by companies for
compulsory medical insurance will increase from current 3.1% to 5.1%
starting from 2011.[27] Russia, anyhow, maintains several centers of
excellence, such as the <b>Fyodorov Eye Microsurgery Complex</b>, founded in
1988 by Russian eye surgeon Svyatoslav Fyodorov. (See my next writeup,)<br />
<br />
<a href="http://irvaronsjournal.blogspot.com/2005/12/state-of-eyecare-in-soviet-union.html">Eycare in the Soviet Union</a><br />
<br />
This article was published in <b>Vision Monday</b> in August 1990.<br />
<br />
Irving J. Arons<br />
Arthur D. Little<br />
<br />
I
have just returned from a two week tour of four cities within the
Soviet Union. I had anticipated telling you about the state of eyecare
within the USSR, but unfortunately, our visit to the premier <b>Moscow
Research Institute of Eye Microsurgery</b> was canceled at the last minute,
as we were informed by Dr. Fyodorov that the "Institute will be closed
in July for preventative maintenance," and that "your visit at the term
(sic) you have stated is inexpedient." We had originally been invited
following my February letter requesting to have our delegation visit the
clinic. In fact, in late June we were told that we were welcome to
visit the clinic, which was scheduled to shut down in August for
holiday.<br />
<br />
Apparently, the hotel we stayed at in Moscow, the
<b>Kosmos</b>, is part of the <b>Intourist</b> program to provide visitors with eye
care at Fyodorov's Moscow clinic. We found a brochure advertising
<b>"Beautiful Eyes for Everybody,"</b> and describing how the Moscow Research
Institute of Eye Microsurgery "treats 22,000 people annually, restoring
or improving vision and removing the need to wear eyeglasses for many."
In addition to RK (radial keratotomy), the clinic claims to do laser
treatment of secondary cataract, laser treatment of glaucoma, and laser
treatment of "complicated myopia of high degree." (It must be one of
the only facilities with surgical lasers in the USSR, as we visited a
laser research institute and three hospitals and saw very few surgical
lasers -- mostly therapeutic HeNe and GaAs biostimulation type devices.)<br />
<br />
The
brochure goes on to state that your pre-operative stay is arranged at
the Kosmos, and following the outpatient surgery, your post-operative
treatment is done at the hotel by a team of qualified doctors and
nurses. Foreign patients are offered a program of excursions, including
theater tickets (the ballet only costs 4 rubles -- the equivalent of 30
cents at the black market exchange rate) and other services offered by
Intourist. Fyodorov hopes to treat 20,000 foreigners a year by 1992.<br />
<br />
A
recent profile of Fyodorov in <b>Fortune </b>(May 1989) talked about the
Fyodorov entrepreneurship, with his clinic being a $75 million a year
business, and growing at 30% a year annually. The clinics have over
5000 employers located at nine treatment centers across the Soviet
Union, and include two factories producing eyeglasses and surgical
instruments. (In addition, Dr. Fyodorov recently spent some $12 million
outfitting an 11,000 ton "floating eye hospital" called the <b>Floks</b>,
which travels from port to port in the Persian Gulf offering RK and
other eye surgeries.)<br />
<br />
Having missed out on the opportunity to
visit with Dr. Fyodorov, I would like to offer some personal
observations about eye care in the Soviet Union. As previously
mentioned, our People-to-People delegation of medical laser specialists
visited Moscow (Soviet Russia), Tblisi (Soviet Georgia), Kharkov (Soviet
Ukraine), and Leningrad (back in Russia). We saw very few optical
shops (none that were open) and only a small number of Soviet citizens
wearing eyeglasses! One ophthalmologist at a central hospital in
Kharkov told me that 50% of the people need corrective lenses -- similar
to the percentages in the rest of the world -- but we saw very few
people wearing lenses. If 5% of the people in the streets had glasses,
that's a lot. This says that Western technology and entrepreneurship
could provide a needed service in the Soviet Union if a way could be
found to open (and stock) optical retail shops in the major cities.
However, you must remember that the average citizen only earns about 200
rubles per month (the equivalent of about $350/month at the "official"
business exchange rate or about $10-15/month at the black market
exchange rate of 10-15 rubles to the dollar). Therefore, the price of
eyewear would have to be low for the average person to be able to afford
it -- unless the health care system can be convinced to reimburse or
pay for the glasses. (The government health care system pays Fyodorov's
clinic the equivalent of $300 for each RK procedure carried out.)<br />
<br />
If
a Moscow McDonalds can generate hours long lines for a $5 "Big Mac",
why not $20-40 eyeglasses at a <b>Moscow Lenscrafters</b> or a <b>Leningrad Pearle
Vision Center</b>?<br />
<br />
<br /></div>
<br />
<br />
<br />Irv Aronshttp://www.blogger.com/profile/05719664806219249867noreply@blogger.com1tag:blogger.com,1999:blog-20140933.post-67274833041490976512017-05-31T16:58:00.004-04:002017-05-31T16:58:55.639-04:00A First Trip to Japan: The Interesting Adventures of A Consultant<div style="text-align: justify;">
Irv Arons<br /><br />In the summer of 1979, I had been hired to conduct a survey of all of the major contact lens companies operating around the world, for a US company interested in finding a partner for its contact lens company. I had completed my interviews of the companies in the US and Europe, and now had to interview the two companies producing lenses in Japan. Since this was my first trip to Japan, I decided to combine business with pleasure and took my wife along to spend a week on vacation, visiting Tokyo and Kyoto, before I was to meet up with a colleague from the <b>Arthur D. Little (ADL)</b> Tokyo office, who would act as my interpreter and take me to my meetings in Osaka and Nagoya.<br /><br />The first leg of the trip was a three-day contact lens conference being held in San Francisco. There, I met up with a friend who ran a contact lens practice in Hawaii. Since he had clients who were on the management staff of <b>Japan Airlines</b> (who would be flying us from San Francisco to Tokyo), he was kind enough to arrange for my wife and I to be upgraded to First Class for our flight to Tokyo. (That was our first experience flying internationally in First Class and we liked it so much that I decided to upgrade our return tickets – at a cost of $600 each, as I recall, to fly First Class on our return flight from Tokyo to Boston. An excellent decision, as it was about a twelve-hour flight.)<br /><br />We arrived in Tokyo and managed to find our way via bus from Narita airport to Tokyo Central Station, and to get a taxi to take us to our hotel, the Okura, in central Tokyo and near the ADL Tokyo office.<br /><br />Our first venture out of the hotel was to the downtown shopping district of Tokyo. We had learned from our travel guide books that the best place to eat was at the restaurants located within the major department stores, up on the fifth floor. What the guide books neglected to tell us was that very few people spoke English and since we spoke only a few words of Japanese, we were left with only hand gestures!<br /><br />At least at the restaurant, there were pictures of the several dishes available, and by pointing to the ones we wanted, we had a reasonable chance of getting something we could eat. But the next dilemma, the meals were served in a stack of bowls, and of course, with chop sticks. Was the top bowl broth or soup, or to wash your hands? And, if it is soup how do you eat it without spoons? Finally, another customer, sitting at a nearby table, sensing our discomfort, took pity on us and gestured to hold the bowl to your mouth and sip from it. So, that problem was solved.<br /><br />The next day, I wanted to walk to the ADL Tokyo office that I was told was close by, so that I would know where it was for the following week when I had to check in. The street signs were a complete mystery and I had no idea how to get from the hotel to the office, even though I had instructions and a map!<br /><br />Two Japanese men, passing by, sensed my dilemma and offered to help. After showing them the address of the office, they were kind enough to walk us right to the building, a very generous offer from strangers. The second offer of kindness to strangers from the Japanese people.<br /><br />We had planned on spending a few days exploring Tokyo and then take a trip via the bullet train to Kyoto, the Japanese shrine city. However, our plans got changed because of a chance meeting at a coffee shop that afternoon. <br /><br />An older gentleman introduced himself to us, while we were enjoying our coffee (or tea, I don’t recall). It turned out that he was a retired military officer, and also a former member of parliament. He offered to act as our tour guide and show us the real Tokyo and then take us to see Mount Fuji.<br /><br />Since our plans were flexible, we agreed to his offer and arranged to meet him the following morning at the coffee shop for a guided tour of Tokyo. We hired a taxi for the day and our new guide took us to see and walk through the Parliament building and showed us several historic sites around the city. We ended that day with a visit to the Kabuki theater, being taken in through the people’s entrance and were able to watch the show from the first balcony. Quite an experience.<br /><br />We enjoyed the tour so much, we agreed to let him be our tour guide the following day and take us to visit Mount Fuji, taking the bullet train (as long as we paid his fare). However, the weather didn’t cooperate and when we got to the mountain, it was completely fogged in. On the way back to Tokyo, we had another interesting experience. Three young women were on the opposite seats from us on the train and attempted to engage us in conversation. They claimed to be English teachers (or maybe students studying to be teachers) and wanted to practice their English with us. To be honest, we could barely understand them.<br /><br />Since that was our last day of sightseeing, our gentleman guide asked us to meet him at a local Chinese restaurant that evening for a farewell dinner and to meet a few of his friends from the Kabuki theater. Little did we know that he had arranged for us to get the bill at the end of the evening and I got hit with a $250 check! (Recall that this was 1979, and the exchange rate for the yen was quite in my favor, about 350 yen to the dollar, but this was still an expensive meal!) I guess that was his way of getting paid back for acting as our tour guide for the couple of days we spent with him.<br /><br />The next day, I left my wife at the hotel and made my way to the ADL Tokyo office to begin the business part of my trip, to visit the two contact lens companies in Nagoya and Osaka. (No wives allowed on business trips in Japan!)</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
Quite an interesting experience for my first trip to Japan!<br /><br /><br /><br /><br /><br /></div>
Irv Aronshttp://www.blogger.com/profile/05719664806219249867noreply@blogger.com0tag:blogger.com,1999:blog-20140933.post-86221850702673667872017-05-31T16:38:00.001-04:002017-05-31T16:38:29.198-04:00My First European Trip: The Interesting Adventures of A Consultant<div style="text-align: justify;">
Irv Arons<br /><br />Recall that I had toured Europe in the fall of 1979, visiting the various contact lens companies that were based there, as well as interviewing notable doctors involved in their use, on an assignment to assess the contact lens companies in both the U.S. and Europe for a Japanese client interested in acquiring technology for starting a contact lens business in Japan.<br /><br />This was my first trip to Europe and I kept a diary of my daily travels – the first and only time I have ever done so. It’s a good thing I did, because there were several interesting incidents that occurred that you might enjoy.<br /><br />I flew from Boston to JFK, to pick up my flight to London. I arrived in London at 10 PM, and quickly realized a had made a big mistake. I had a fairly large piece of luggage (I would be gone for over a week.), and hadn’t taken my wheels! (This was the fall of 1979, before wheeled luggage was in general use.) I made it onto the subway and got into London from Heathrow and finally found my hotel, the Bristol. Except they didn’t have my reservation! Luckily they had one room left and I took it and went to sleep without supper, as the kitchen wasn’t open at that time of night.<br /><br />The next morning, I met my ADL colleague from our London office, who would be my traveling companion (and translator). It turned out, the London office had made my hotel reservations at another hotel, and forgot to notify me. (Again, these were the days before email.) We then went on to the several meetings that we had arranged in the London area. I went to the final one that evening by myself – no problem – they speak Bloody English!<br /><br />That evening my colleague had arranged for us to meet at a nearby pub for a dinner show. I was quite surprised to find that he and his girlfriend had brought along another girl, his girlfriend’s roommate, whose boyfriend was out of town. After the dinner and show, I got dropped off at my hotel (alone) because we had a busy next day – four interviews and then flying off to Paris.<br /><br />After our interview in Paris, the next day, we flew on to Strasbourg and our drive to Freiberg for a contact lens conference. We drove through very beautiful farm land and took a local inland route to the Rhine river and across into Germany at a local crossing. The border guards stopped us, took our passports, and searched our luggage thoroughly. They were puzzled by my voltage converter (European to 110v for my electric shaver), but after about ten minutes, finally allowed us to proceed into Germany and we went on to Freiberg and the CL conference.<br /><br />I spent the weekend on my own, as my colleague took the train to Frankfort to spend some time with friends, after buying me a ticket for my Sunday train ride. Since I speak no German (although understand a little based on my Jewish background), I somehow managed to survive the weekend since I knew the word for chicken (hundchen!).<br /><br />When I got to the train station on Sunday morning, I couldn’t figure out which track the Frankfort train was on, but luckily, some English gentlemen saw my dilemma and helped me out. It turned out that they were the world famous <b>Amadeus Quartet</b> and also going to Frankfurt. I thoroughly enjoyed my train ride talking to them.<br /><br />Arriving at the Frankfurt station, I met my ADL colleague and we took the train to our next stop, Aschaffenburg. We arrived early in the evening, and after dinner, went to a movie and I saw Moonraker in German and didn’t understand a word of it!<br /><br />Following our nearly all day meeting in Aschaffenburg, we took a taxi to the Frankfurt airport for our flight back to London. After leaving my luggage to walk to the gate, I thought I heard my name over the loudspeaker, but since the announcement was in German, I wasn’t sure. Sure enough, when we arrived in London, I quickly discovered that my bag was still in Frankfort.<br /><br />I didn’t panic too much, but since we were going out of London the following day for two days of meetings, I decided all I needed was a clean shirt and some deodorant to get me through until my bag showed up in London. I quickly went out to try and find a shirt and the only store open had a dress shirt that set me back 27 pounds (or about $50). Finally, about 8 PM that night I got a call that my luggage had made its way to London and would be delivered to my hotel room. You can be sure I got up early the next morning, before our trip out of town and returned that $50 shirt! (I kept the deodorant.)</div>
<div style="text-align: justify;">
</div>
<br />After a few meetings in London, we took the train to Birmingham, had a couple of meetings there and on to Loughborough.<br /><br />After several meetings, it was on to Hitchins and then Hempel Hempstead. (Yes, I did get to see quite a bit of England on that trip.)<br /><br />The next day was my last in England and after several more meetings, I made my way via the subway to the airport and finally got on my flight back to the States.<br /><br />After what I saw of the beauty of Europe, I made a promise that someday I would return. (And, my wife and I did. A few years later we took a sixteen day tour of eight countries - “If it was Tuesday, it must be Belgium!” As it turned out, we did travel through Belgium on our way from Paris to Amsterdam on a Tuesday.)<br /><br />We have since gone back to Europe several times, particularly to Switzerland and to Spain, and even took a river boat trip down the great rivers of Europe, from Amsterdam to Vienna, passing through sixty-six locks along the way.<br /><br />Irv Aronshttp://www.blogger.com/profile/05719664806219249867noreply@blogger.com0tag:blogger.com,1999:blog-20140933.post-910402586152759112017-05-31T16:22:00.000-04:002017-05-31T16:41:00.700-04:00The Soft Contact Lens Industry and My Role in its Growth: The Interesting Adventures of A Consultant<div style="text-align: justify;">
Irv Arons<br />
<br />
The <b>Bausch & Lomb Soflens</b>, the original soft contact lens, was first approved for marketing in March 1972, My first contact lens assignment began in June of that year, an assessment of the “safety and efficacy” of the Soflens. Over the following fifteen years, I led over 150 assignments involving both soft and gas permeable contact lenses, becoming, in that period, the “guru” of the contact lens industry. <br />
<br />
But one of the most interesting assignments, in the fall of 1979, involved my traveling all over the United States and Europe to investigate possible technical partners for a Japanese company interested in entering the contact lens business.<br />
<br />
In September of that year, after completing my U.S. visits, I traveled to Europe, visiting London, Paris, Strasbourg, Frieburg, Frankfort, back to London and finally, home to Boston to prepare a final report. (For some anecdotes from my first trip through Europe, see the following writeup - <a href="http://tinyurl.com/EuropeAnecdotes"><b>My First European Trip</b></a>.) In November I traveled to Tokyo to present the results of my study. An <b>Arthur D. Little (ADL)</b> colleague and I flew to Tokyo via New York City on a Friday, arriving on Saturday. The following day, Sunday, I returned a phone call to another client who had left an urgent message that he desperately needed to speak with me and that I should call him at home over the weekend.<br />
<br />
At 8 AM Tokyo time, which was about 7 PM (the previous day) in the U.S., I reached Steve Martin of <b>Ciba Geigy</b> (the other client) and he asked me the strangest question. He told me that I was the No. 1 contact lens expert in the U.S., and he wanted to know who was No. 2? Apparently, his Swiss parent company had heard my name from so many people that they wanted another name to get another view of the industry. I told him that there wasn’t anyone else doing what I did and he agreed. He had himself made many calls around the industry and had only gotten my name. He said that he was going to let the Swiss people know this and would call me the following Thursday and probably give me another assignment.<br />
<br />
As it was, he called me back the following Wednesday while I was still in Tokyo (leaving the next day to return to the states), and told me that he needed me to travel to Germany the following Sunday to evaluate the technology of a German contact lens company (<b>Titmus Eurocon</b>) in which he was interested. (Since I was planning to recommend the same company to our Japanese client, I politely asked him not to buy them until, at least, I could deliver our final report to the Japanese client!)<br />
<br />
So, I arrived home that Thursday, wrote and sent my proposal to Steve (Ciba Geigy) and met him at the Newark airport that Sunday prior to my overnight trip to Germany. I was part of a four or five men team (the others being optometrists and ophthalmologists) who were being sent to Germany to evaluate the German company’s technology.<br />
<br />
We flew overnight, arrived in country early the next morning and immediately went to work at the German company. After spending the day in discussions, the company officials offered to take us out for dinner and entertainment. With all of my recent travels, I was literally out of it and politely declined and went to bed – I understand the rest of the group partied hard into the night – I have no idea how!<br />
<br />
To make a long story short, after spending about three days in Germany, I came home, wrote my report and later heard that it was the influential piece of Steve’s presentation to management that gave him the go ahead to acquire the German company’s technology and to start <b>CibaVision</b> in 1980. He became its first president.<br />
<br />
<br />
There are a couple of other stories about my role in advising companies that entered into the contact lens business. Here’s another that had an interesting twist.<br />
<br />
Besides Ciba Geigy (CibaVision), I was also involved in the technical assessment of <b>Frontier Contact Lens</b> in Jacksonville, FL, for <b>Johnson & Johnson</b>, which they later acquired, and which became <b>Vistakon</b>.<br />
<br />
In an earlier assignment for J&J, I did an assessment of <b>Wesley Jessen</b> in Chicago, but they passed on that company. However, about six months later, I was asked by <b>Schering-Plough</b> to visit in New Jersey about their potential acquisition of Wesley Jessen. I dutifully told them that yes, I had prepared a report on WJ, but I was under a confidentiality agreement not to discuss it. Schering said come on down anyway.<br />
<br />
Lo, to my surprise, when I got to their offices, I was presented with a copy of my report and asked to discuss it! My guess is that the president of WJ (Orrin Stine) had given them a copy, given to him by the people at J&J. (I recently asked Orrin, but he doesn’t recall having a copy of my report.) Since I now felt that the confidentiality agreement was no longer valid, I did discuss my report and Schering did acquire WJ, which, as I recall, they later sold to Ciba.<br />
<br />
So, I guess I did have quite an impact on the soft lens industry, both in the States and other parts of the world.<br />
<br />
One last case and I’ll call it quits.<br />
<br />
In August 1987, in a landmark case in the Tax Court in Wilmington, Delaware, ADL was hired by <b>Baker & McKensy</b> to assist in their representation of <b>Bausch & Lomb</b> in an international transfer pricing case against the <b>IRS</b>. It seems that B&L had transferred its technology to Ireland, where it was manufacturing most of its contact lenses then shipping them to the rest of Europe and to the U.S. for sale. This reduced substantially the amount of income B&L reported in the U.S. and allowed them to enjoy a much lower tax in Ireland. The questions before the Tax Court concerned the appropriate transfer price for the contact lenses and the royalty B&L Ireland owed to its U.S. parent company.<br />
<br />
I was B&Ls contact lens industry expert and my ADL colleague, Dr. Irving Plotkin, their expert on foreign transfer pricing and royalties. (In fact he frequently worked both sides of the aisle, sometime being an IRS expert and other times working for the taxpayers!)<br />
<br />
In any event, we prevailed and with a split decision by the tax court (mostly in B&L’s favor), saved B&L in the order of $15 million for the tax years in question, and perhaps tens of millions for succeeding years. This case set a precedent that became the law in international transfer pricing cases.<br />
<br />
It was quite an experience being on the witness stand and being cross examined by the Government’s lawyers. In fact, I was so excited being in that position that I inadvertently answered one of the lawyer’s questions with a “Yes sir!”, when she was obviously a woman, who was very pregnant, and within weeks of delivering her baby!</div>
<div style="text-align: justify;">
<br /></div>
<br />
If you are interested in reading more about my work in the contact lens industry, additional information can be found on my blog: <b><a href="http://irvaronsjournal.blogspot.com/2006/03/nature-and-evolution-of-soft-contact.html">The Nature and Evolution of the Soft Contact Lens Industry in the United States</a> </b>(the title of my expert report in the B&L vs IRS case).<br />
<br />
<br />
<br />
<br />
<br />Irv Aronshttp://www.blogger.com/profile/05719664806219249867noreply@blogger.com0tag:blogger.com,1999:blog-20140933.post-2385942752227063102015-12-31T18:30:00.000-05:002016-01-26T15:46:58.546-05:00Stem Cells in Ophthalmology Update 24: Current Tables Now Online<div style="text-align: justify;">
My current stem cell/cell therapy tables are now online for anyone interested to access. Here is a brief description of what is available and how to access them:<br />
<br />
</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Stem Cell/Cell Therapy Companies/Institutions Active in Ophthalmology</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
A list of forty-two companies and institutions working with stem cells/cell therapies for ophthalmic applications. The table lists collaborators, the cell type being used, and the applications for which the cells will be used.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Link: <a href="https://www.dropbox.com/s/qj3kwyvgggtqvio/Stem%20Cell%20Company%20Table.pdf?dl=0"><b>http://tinyurl.com/StemCellComp1231</b></a></div>
<div style="text-align: justify;">
<b><br /></b></div>
<div style="text-align: justify;">
<b>Stem Cell/Cell Therapy in Ophthalmology by Application</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
A list of eighteen ophthalmic applications being studied and/or in clinical trials. The table includes the companies/institutions involved, the clinical trial status, and an active link for the clinical trial for those listed. (sixty-one active and completed clinical trials are shown.)</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Link: <b><a href="https://www.dropbox.com/s/puvaxvkg9p8hjch/Stem%20Cell%20%20Application%20Table.pdf?dl=0">http://tinyurl.com/StemCellAppl1231</a></b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Stem Cell/Cell Therapy in Ophthalmology -- Ongoing & Completed Clinical Trial Details </b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
A list of the the eighteen ophthalmic applications and the sixty-one clinical trials showing the number of patients to be studied in each trial and the number studied to date (that I am aware of). Active links are provided for each ongoing or completed trial.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Link:<b> <a href="https://www.dropbox.com/s/ptahru1x2kg11ox/Stem%20Cell%20Clinical%20Trial%20Table.pdf?dl=0">http://tinyurl.com/StemCellClncl1230</a></b><br />
<br />
<b>Updated December 31, 2015. </b><br />
<br /></div>
Irv Aronshttp://www.blogger.com/profile/05719664806219249867noreply@blogger.com0tag:blogger.com,1999:blog-20140933.post-53569557881819669372015-12-01T18:14:00.000-05:002015-12-01T18:14:11.908-05:00Articles Published in Ophthalmic Journals in 2015<div style="text-align: justify;">
<i>In addition to the several updates posted on this blog in 2015 (see previous posting), I have prepared four articles that have appeared in ophthalmic journals this year.</i></div>
<div style="text-align: justify;">
<i><br /></i></div>
<div style="text-align: justify;">
<i>Here is a brief summary of the four articles, including links to the online versions:</i></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
<a href="https://theophthalmologist.com/issues/0215/regenerating-the-retina/"><b>Regenerating the Retina</b></a> - February 2015</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
This article, published in the February 2015 issue of <b>The Ophthalmologist</b>, describes the use of stem cell-derived retinal progenitor cells (RPCs), that are being investigated for reviving/repairing/rejuvenating damaged photoreceptors to bring back sight to those who have lost it due to a retinal degenerative disease, including choroideremeia (CHM), retinitis pigmentosa (RP), Leber’s congenital amaurosis (LCA) and Stargardt’s disease (Stargardt Macular Dystrophy - SMD). It discusses the four companies that are conducting clinical research, as well as the work underway at several university and institutional laboratories.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
To read the complete write up, please use the following link: <a href="https://theophthalmologist.com/issues/0215/regenerating-the-retina/">https://theophthalmologist.com/issues/0215/regenerating-the-retina/</a></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<i>Update: Since the article appeared, two of the companies discussed, <b>jCyte</b> and <b>ReNeuron</b> have either begun a clinical trial (<b>jCyte</b>), or announced the start of one (<b>ReNeuron</b>).</i></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<a href="http://tinyurl.com/GeneTherapyCosts"><b>What will Ophthalmic Gene Therapy and Stem Cell treatment cost and how will we and the healthcare system pay for it?</b></a> - May 2015</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
With the likelihood of a gene therapy and/or a stem cell treatment for retinal diseases to be approved for marketing within the next two to three years, it is time for the ophthalmic community – the suppliers, practitioners, patients and payers – to start thinking about how much these regenerative medicine treatments are likely to cost, and how patients and the healthcare system will pay for them..</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
In <a href="http://tinyurl.com/GeneTherapyCosts"><b>The Economics of Gene Therapy</b></a>, appearing in the May 2015 issue of <b>The Ophthalmologist</b>, I propose a pricing model for Regenerative Medicine in Ophthalmology, based on the population of patients to be treated, and suggest that an annuity program model, based on performance and duration of efficacy, could be used to pay for it.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Let the dialogue begin.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
To read all about it, please follow this link: <a href="http://tinyurl.com/GeneTherapyCosts">http://tinyurl.com/GeneTherapyCosts</a></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<a href="http://tinyurl.com/RetPhys-GT-Update"><b><br /></b></a></div>
<div style="text-align: justify;">
<a href="http://tinyurl.com/RetPhys-GT-Update"><b>What’s New in Gene Therapy for Ophthalmology</b></a> - October 2015</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
An update of the latest clinical information in the use of gene therapy in treating several retinal diseases, including <b>Leber’s Congenital Amaurosis (LCA)</b>; the wet form of <b>Age-Related Macular Degeneration (wet-AMD)</b>; <b>Choroideremia (CHM)</b>; <b>Stargardt’s Macular Dystrophy (SMD)</b>; <b>Retinitis Pigmentosa (RP)</b>; and <b>Ushers Syndrome (US)</b>. Included is the proposed model of pricing for some gene therapy treatments, based on the population of patients likely to be treated.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
To read the full article, published in the October issue of <b>Retinal Physician</b>, please follow this link: <a href="http://tinyurl.com/RetPhys-GT-Update">http://tinyurl.com/RetPhys-GT-Update</a></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<a href="http://tinyurl.com/OptogeneticsOption"><br /></a></div>
<div style="text-align: justify;">
<a href="http://tinyurl.com/OptogeneticsOption"><b>Optogenetics: Another Approach to Reversing Blindness</b></a> - November 2015</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Optogenetics is the introduction of protein-based, light-activated chemicals into still functional retinal cells in the vision chain, that upon activation, send electrical signals along the optic nerve to the brain, providing rudimentary vision, that was lost with the death or damage of the photoreceptors.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
This report, <a href="http://tinyurl.com/OptogeneticsOption"><b>The Optogenetics Option</b></a>, describes the efforts of four companies and ten universities, using either gene therapy, or other means, to deliver light-activatable proteins or chemicals (photoswitches) to still functioning cells within the retina (ganglion and/or bipolar cells) or, in some cases, the use of light activatable implants, that will deliver light signals to the brain to provide some rudimentary vision when the photoreceptors, that normally provide that function, cannot.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
To read the article, published in the November issue of <b>The Ophthalmologist</b>, please follow this link: <a href="http://tinyurl.com/OptogeneticsOption">http://tinyurl.com/OptogeneticsOption</a></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<br />Irv Aronshttp://www.blogger.com/profile/05719664806219249867noreply@blogger.com0tag:blogger.com,1999:blog-20140933.post-74507993651681693082015-12-01T17:42:00.001-05:002015-12-01T17:47:21.319-05:00Blog Articles Published in 2015<div style="text-align: justify;">
<i>2015 was another busy year in writing about new developments in treating retinal diseases. During the year, I published seven blog entries (and another four published articles - to be indexed separately). Here are the highlights of the blog writeups:</i></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<a href="http://tinyurl.com/IluvienUpdate9"><b>Additional Marketing Approvals for Iluvien; A New Ophthalmic Application; and An Interesting Human Interest Story</b></a> - January 7, 2015</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Since I last wrote about Iluvien, Alimera Sciences and pSivida have announced additional marketing approvals for its use in treating chronic DME. The product is now approved for use in fourteen countries, including the U.S. In addition, pSivida is about to begin a Phase III study of its Medidur device for the treatment of uveitis, which should lead to a fast-track to approval.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
But the real reason for this update was the recently published story about how an eye doctor reached out to Paul Ashton, CEO of pSivida, to package an old HIV anti-viral, ganciclovir, in his drug delivery system, to save the sight of a person undergoing chemotherapy for leukemia, who also needed a bone marrow transplant. The chemo and radiation treatment for the bone marrow transplant weakened his immune system, preventing control of his cytomegalovirus condition that began attacking his retina. Instead of painful weekly anti-viral injections, the doctor sought to use Paul’s drug delivery system to systemically treat the virus in the eye.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
To read the whole story and the results, and for the latest information about Iluvien, please follow this link: <a href="http://tinyurl.com/IluvienUpdate9">http://tinyurl.com/IluvienUpdate9</a></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<a href="http://tinyurl.com/OrayaUpdate3"><b>Oraya Therapeutics Now Operating at Nine European Centers and Strikes Partnership Deal with Carl Zeiss Meditec</b></a> - January 15, 2015</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
With the presentation of the three-year safety results of the INTREPID study (at EURETINA), to evaluate the safety and efficacy of the Oraya Iray Therapy in conjunction with as-needed anti-VEGF injections for wet AMD, and the recent collaboration agreement with Carl Zeiss Meditec, Oraya Therapeutics is well on its way in implementing its growth strategy in commercializing Oraya Therapy in Europe and, some day, in the U.S.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The company now has nine centers providing therapeutic treatment in Europe; four centers in the UK, one in Switzerland, and four in Germany.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
To read more about this combination treatment to reduce the number of anti-VEGF treatments needed to control wet AMD, and the collaboration agreement with Carl Zeiss Meditec, please see: <a href="http://tinyurl.com/OrayaUpdate3">http://tinyurl.com/OrayaUpdate3</a></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<a href="http://tinyurl.com/AvalancheBio2"><b>Avalanche and Univ. Of Washington Collaborate to Defeat Color Blindness</b></a> - March 27, 2015</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Avalanche Biotechnologies in Menlo Park and the University of Washington in Seattle announced a licensing agreement to develop the first gene therapy treatment for treating color blindness. The deal brings together a gene therapy technique developed by Avalanche with the expertise of vision researchers at the University of Washington.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
In addition, Avalanche will incorporate research licensed from UCal Berkeley to deliver the gene therapy treatment non-surgically via an injection into the vitreous, rather than into the retina.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
To read more, please follow this link: <a href="http://tinyurl.com/AvalancheBio2">http://tinyurl.com/AvalancheBio2</a></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<a href="http://tinyurl.com/brown-to-blue"><b><br /></b></a></div>
<div style="text-align: justify;">
<a href="http://tinyurl.com/brown-to-blue"><b>A New Laser Procedure to Turn Brown Eyes Blue</b></a> - April 8, 2015</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
As Crystal Gayle sang in her smash hit, `Don't It Make My Brown Eyes Blue', now (soon) you will be able to permanently change your brown eyes to blue. A California company has come up with a laser procedure that will safely accomplish this in about 30 seconds per eye. Human clinical testing is underway and the company, Strōma Medical, hopes to have the procedure on the market (outside of the U.S. first) in less than two years, once the clinical trials are completed.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
To read the rest of the story, please follow this link: <a href="http://tinyurl.com/brown-to-blue">http://tinyurl.com/brown-to-blue</a></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<a href="http://tinyurl.com/vitreolysis-Update"><b>Laser Vitreolysis Update: Ellex launches a “doctor finder” to find docs using its laser to treat floaters.</b></a> - June 30, 2015</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
My article about the use of lasers to treat floaters, written five year ago, remains the most widely read piece on my blog. I frequently am asked if I have updated the list of doctors who now use lasers to treat floaters - in addition to the three I profiled in my U.S. writeup (Using Lasers to Treat Vitreous Floaters: Laser Vitreolysis) and the six doctors in the UK/Europe piece (Using Lasers to Treat Vitreous Floaters: Laser Vitreolysis in the UK and Europe).</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
I took notice when Ellex Medical announced a new YAG laser specifically for treating floaters in the fall of 2012, and about six months ago, I decided to request a list of doctors who have obtained the laser, and were now treating patients’ floaters. Better than a list, Ellex decided, to respond to my request, by building an app to locate doctors using their laser and put it on their website. That app is now active and is applicable to doctors worldwide using the new Ultra Q Reflex YAG laser to treat floaters. As of June 30th, there are 58 physicians listed worldwide using this laser.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
To read more about the laser and use the app, see my update: <a href="http://tinyurl.com/vitreolysis-Update">http://tinyurl.com/vitreolysis-Update</a></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<a href="http://tinyurl.com/GeneTherapyUpdate22"><b>First Spark Therapeutic Phase III Clinical Trial Results and Phase I Longevity Data - Insight into the trial results</b></a> - October 14, 2015</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Some insight into the Spark Therapeutics Phase III clinical trial results and longevity data. In this report, the company’s principal investigator, Dr. Stephen Russell presented highlights of the initial findings in this important Phase III clinical trial, that could lead to the first gene therapy approval in the United States.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Basically, it was found that the injection of SPK-RPR65 did lead to increased functional vision for the treated patients, compared to the control subjects - and the effect appears to last for over three years, based on the original patients treated in the Phase I study.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Is this the “forever fix”, or a step along the way? To read the full story, please follow this link: <a href="http://tinyurl.com/GeneTherapyUpdate22">http://tinyurl.com/GeneTherapyUpdate22</a></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<a href="http://tinyurl.com/OrayaUpdate4"><b>Oraya Therapeutics Receives Guidance for Adjunctive Use in Germany for wet AMD</b></a> - October 20, 2015</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Three German ophthalmological groups provided guidance for German ophthalmologists to better identify those patients with wet AMD that might benefit from the use of the Iray Stereotactic Radiotherapy System as an adjuctive treatment to the use of anti-VEGFs in the treatment of neovascular macular degeneration, based on studies conducted by the company to date.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
To read the full story, please follow this link: <a href="http://tinyurl.com/OrayaUpdate4">http://tinyurl.com/OrayaUpdate4</a></div>
<br />
<br />Irv Aronshttp://www.blogger.com/profile/05719664806219249867noreply@blogger.com0tag:blogger.com,1999:blog-20140933.post-79483528665048451672015-10-20T16:50:00.002-04:002015-10-20T22:57:31.554-04:00Oraya IRay Update 4: Oraya Therapeutics Receives Guidance for Use in Germany<div style="text-align: justify;">
<i>When I last updated the progress of Oraya Therapeutics, in January of this year (<a href="http://tinyurl.com/OrayaUpdate3"><b>Oraya IRay Update 3: Oraya Now Operating at Nine European Centers and Partnership with Carl Zeiss Meditec</b></a>), I noted the collaboration agreement between Oraya and Carl Zeiss Meditec to provide funding to Oraya over a period of up to two years for the implementation of Oraya's growth strategy, and I reported on the three-year INTREPID safety results, presented the previous September. Here now is the latest information on the progress of the company to bring this adjunctive treatment for the wet form of AMD to the professions.</i></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>The German Ophthalmological Society, the Retina Society and the Professional Association of German Ophthalmologists (DOG) </b>have issued a joint opinion on the adjunctive use of radiotherapy with Oraya Therapeutics' IRay Stereotactic Radiotherapy System for wet AMD. Their opinion makes it possible for ophthalmologists throughout Germany to identify patients that can benefit from Oraya Therapy in conjunction with anti-VEGF treatment. </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Oraya Therapy is currently commercially available at eleven sites in Europe, with more than 550 patients treated to date with Oraya Therapy in three European countries - Germany, Switzerland and the United Kingdom.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
According to the opinion, which takes the study data published to date into account, adjunctive stereotactic radiotherapy of neovascular AMD with the IRay system can be considered on an individual basis. Some of the parameters that ophthalmologists should consider include:</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
● If symptoms of choroidal neovascularization (CNV) activity such as intra-retinal fluid of bleeding are present, corresponding to a recommendation of VEGF inhibitors;</div>
<div style="text-align: justify;">
● If the ongoing anti-VEGF therapy has taken place over a period of at least six months, thus ruling out undertreatment; and,</div>
<div style="text-align: justify;">
● If despite intensive injection therapy, no change in the activity state of the CNV is achieved and there is no reasonable expectation of a decrease of the required high frequency of retreatment for the future.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
"The joint opinion now provides guidance for ophthalmologists throughout Germany to identify those patients who can benefit from Oraya Therapy for wet AMD. There is a large patient population that does not respond well to anti-VEGF monotherapy, and our aim is to offer these patients in Germany an additional option to maintain their vision and also decrease the burden of frequent injections," said Oraya Therapeutics CEO Jim Taylor. "We are well positioned with our IRay system at major university eye clinics in Germany, and will continue to expand our presence to make the therapy available to the patients who qualify and elect to pursue this alternative."</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The full opinion, titled "Stellungnahme von DOG, RG und BVA zur Strahlentherapie bei neovaskulärer altersabhängiger Makuladegeneration" is accessible within the German Ophthalmological Society website at: <a href="http://www.dog.org/wp-content/uploads/2015/10/Stellungnahme-RG-DOG-BVA-zur-Strahlentherapie-bei-neovaskul%C3%A4rer-altersabh%C3%A4ngiger-Makuladegeneration.pdf.">http://www.dog.org/wp-content/uploads/2015/10/Stellungnahme-RG-DOG-BVA-zur-Strahlentherapie-bei-neovaskul%C3%A4rer-altersabh%C3%A4ngiger-Makuladegeneration.pdf.</a></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The IRay Radiotherapy system is a CE marked medical device. In the U.S., the IRay system is an investigational device and is not yet available for sale.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<i>For any of you reading this for the first time, please refer to my original full report describing the IRay system: <a href="http://tinyurl.com/ORAYAReport"><b>Oraya IRay In-office Stereotactic X-ray Treatment for AMD: A First Report</b></a>, written in January 2009.</i></div>
<div style="text-align: justify;">
<br /></div>
<br />Irv Aronshttp://www.blogger.com/profile/05719664806219249867noreply@blogger.com0tag:blogger.com,1999:blog-20140933.post-20870507167005428302015-10-14T17:47:00.000-04:002015-10-14T23:11:39.740-04:00Gene Therapy in Ophthalmology Update 22: First Spark Therapeutic Phase III Clinical Trial Results and Phase I Longevity Data<div style="text-align: justify;">
<i>My article updating the latest information on the status of gene therapy clinical trials, <a href="http://tinyurl.com/RetPhys-GT-Update"><b>What’s New in Gene Therapy for Ophthalmology? </b></a>was published in the October issue of <b>Retinal Physician</b>. The final draft was submitted just prior to this important news from <b>Spark Therapeutics</b> providing information about their Phase III clinical trial results.</i></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Principal Investigator Stephen R. Russell, MD, of the <b>Stephen A. Wynn Institute for Vision Research at the University of Iowa</b>, presented Phase III data highlighting the rate, breadth and magnitude of changes following administration of SPK-RPE65 to patients with Leber’s Congenital Amaurosis (LCA), at the <a href="http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NTk3NzUzfENoaWxkSUQ9MzA4MDEwfFR5cGU9MQ==&t=1"><b>Retina Society Meeting</b></a> held in Paris on <a href="http://ir.sparktx.com/mobile.view?c=253900&v=203&d=1&id=2095955">October 10th.</a> </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
In addition, Dr. Russell presented data on the three-year durability of improvements in the same measures of functional vision and light sensitivity in a cohort of subjects from the earlier Phase I trial.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
This presentation built on top-line results of a randomized controlled multi-center Phase III trial previously announced by <a href="http://ir.sparktx.com/phoenix.zhtml?c=253900&p=irol-newsArticle&ID=2093863">Spark on October 5</a>, which demonstrated a highly statistically significant improvement in the intervention group compared to the control group in the primary endpoint and two of three secondary endpoints.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Significant Improvements and Strong Parallels in Mobility and Light Sensitivity Testing</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Data presented highlighted a mean improvement in the functional vision of intervention subjects (n=20) of 1.9 specified lux levels, compared with an improvement of 0.2 specified lux levels in control subjects (n=9) as measured by the change in bilateral mobility testing (MT) between baseline and one year in the modified intent-to-treat (mITT) population. The mITT population (n=29) includes all subjects that received SPK-RPR65, and only those who continued beyond the baseline study visit. Two subjects in the intent-to-treat (ITT) population (n=31) that were randomized but never received SPK-RPE65 are excluded from this efficacy analysis population. Thirteen of the 20 subjects receiving SPK-RPE65 were able to pass the MT at one lux at year one, demonstrating maximum improvement measurable on the MT score. None of the nine control subjects followed was able to pass MT at one lux at year one.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
In a corresponding finding in the first secondary efficacy endpoint, full-field light sensitivity threshold testing (FST*) for white light, intervention subjects demonstrated a highly statistically significant mean improvement of -2.06 log10 (candela second/m2) compared with decline of 0.04 log10 (candela second/m2) among control subjects (all analyses in mITT population). </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<i>(*FST is a full-field light sensitivity threshold test. As RPE65-mediated retinal dystrophies primarily affect rod photoreceptors first, night blindness and loss of peripheral vision are typically the presenting symptoms; central vision may be relatively spared initially. Thus FST was the first hierarchically-arranged secondary as opposed, for example, to visual acuity. It is more reflective of the underlying pathophysiology of the disease.) </i></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
Dr. Russell presented additional top-line analyses from the pivotal Phase III trial showing the rapid and sustained impact of SPK-RPE65 throughout the entire one-year study period. Significant differences emerged in both MT and FST by the first study visit, at 30 days. These effects were reproduced consistently at each subsequent study visit (at days 90, 180 and one year).</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Dr. Russell said, "It's exciting to see a consistency of improvement between the functional vision and visual function. The parallel effect seen in the prompt response in both the primary and first secondary endpoints highlights a critically important finding from the trial: that functional improvements measured through the mobility test change score correspond closely with the physiologic impact seen through FST."</div>
<div style="text-align: justify;">
<br /></div>
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgegP0ENE4WCoQino6_mjv75q4SEZwZYaDHUBEUjS84OuIRjXp1og1415u5ahYgY8qSvmk9lsukKaK9_hKhNdPHBphU_UjzTYo0oZELH4DjZK_GFLV0PFgcYfZy5nAozM5x8-eC/s1600/phase3testresults.gif" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" height="223" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgegP0ENE4WCoQino6_mjv75q4SEZwZYaDHUBEUjS84OuIRjXp1og1415u5ahYgY8qSvmk9lsukKaK9_hKhNdPHBphU_UjzTYo0oZELH4DjZK_GFLV0PFgcYfZy5nAozM5x8-eC/s320/phase3testresults.gif" width="320" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Figure 1: Phase III Trial of SPK-RPE65: MT and FST Over Time (mITT)<br />
<div style="text-align: justify;">
<br /></div>
</td></tr>
</tbody></table>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
In addition, Dr. Russell presented data on the durability of effect after three years as measured by MT and FST in a cohort of subjects that participated in the Phase 1 open-label study, and would likely have met the eligibility criteria for the Phase 3 trial. All of these subjects continue to experience a durable improvement over three years from the time of administration to the contralateral, or second eye, with observation ongoing. These subjects received the same dose and volume of SPK-RPE65 that was used in the pivotal Phase 3 trial. The figures below reflect data from all subjects available for follow-up at each time point reported. Spark and the clinical investigators continue to follow study participants to evaluate the durability of response, and will provide further updates in the future through a series of peer-reviewed presentations and publications.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
"We are pleased to provide these additional informative data, the totality of which highlight the rapid, sustained and durable effect associated with SPK-RPE65 across multiple functional and physiological parameters, at time points ranging from 30 days to three years," said Jeffrey D. Marrazzo, co-founder and chief executive officer of Spark. "We will continue to analyze the data from our groundbreaking pivotal Phase 3 trial in order to further elucidate the potential positive, meaningful impact that SPK-RPE65 can have on the lives of patients with RPE65-mediated blinding conditions."</div>
<div style="text-align: justify;">
<br /></div>
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg_Xl67CQk8kjcdO6JkPUqsCeTaOGBUKqQga2bp3sMBSNJr0oWYSuUmJ5zXuktsK8JPprM7YXvWJj7gW0JJzOJMad_ZUTaAtL6oCnSdsV41nNmlxc7RtEMXWqgy9z_Sc51PGHoO/s1600/phaseilongevity.gif" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" height="218" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg_Xl67CQk8kjcdO6JkPUqsCeTaOGBUKqQga2bp3sMBSNJr0oWYSuUmJ5zXuktsK8JPprM7YXvWJj7gW0JJzOJMad_ZUTaAtL6oCnSdsV41nNmlxc7RtEMXWqgy9z_Sc51PGHoO/s320/phaseilongevity.gif" width="320" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Figure 2: Phase 1 Trial of SPK-RPE65: Durability of MT and FST Over Time<br />
<div style="text-align: justify;">
<br /></div>
</td></tr>
</tbody></table>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
<b>Pivotal, Phase 3 Trial Overview</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The pivotal Phase 3 trial of SPK-RPE65 is the first successful randomized, controlled Phase 3 trial ever completed in gene therapy for a genetic disease. The multicenter trial randomized 31 subjects with confirmed RPE65 (LCA) gene mutations. The ITT population included 21 subjects in the intervention group and 10 in the control group.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
For the primary endpoint, subjects were evaluated at multiple time points over the course of one year for their performance in navigating a mobility course under a variety of specified light levels ranging from one lux (equivalent to a moonless summer night) to 400 lux (a brightly lit office) using the bilateral testing condition. Each attempt was recorded, and the videos were sent to independent, centralized, masked graders to assign a pass/fail score based on speed and accuracy with which the subjects navigated the course.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
In addition to the primary endpoint, the statistical analysis plan included three secondary endpoints tested statistically in the following hierarchical order:</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
● FST (white light), which reflects underlying physiological function by measuring light sensitivity of the entire visual field.</div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
● Change in MT score for the assigned first eye, which compares the MT performance between baseline and year one for the first eye injected for the intervention group and, for the control group during the control year, the first eye injected after they crossed over.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
● Visual acuity (VA) testing, which measures changes in central vision by assessing the ability of the subject to read a standard eye chart.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
A summary of top-line efficacy results follows:</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Primary outcome (ITT) </b> </div>
<div style="text-align: justify;">
MT change score, bilateral p = 0.001</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Secondary outcomes (ITT)</b> </div>
<div style="text-align: justify;">
FST, averaged over both eyes p < 0.001</div>
<div style="text-align: justify;">
MT change score, first injected eye p = 0.001</div>
<div style="text-align: justify;">
VA, averaged over both eyes p = 0.17</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>So What Does All This Mean?</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
In a story about the trial results published by <a href="http://www.bloomberg.com/news/articles/2015-10-10/-holy-grail-seen-as-gene-drug-for-blind-produces-lasting-effect"><b>Bloomberg Business News</b></a>, the reporters commented, “A gene therapy maker showed this week it could make blind children and adults see. But the big question left is how long the effect will last.”</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
“Much depends on the answer, including how much the company can charge for the drug -- a price tag some say could be more than $1 million a patient.”</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The company has shown the effect has lasted for as long as three years without degradation of vision in some patients, providing back functional vision to those nearly blind children treated in the initial clinical trial.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
According to Dr. Russell, the principal investigator, "Investors will look at the data and are going to go, `Wow this is the best data we've seen, not just in the eye, but on gene therapy, period' and they're right,"</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Yet he cautioned that more information is needed before the drug can be considered a cure. While it produces a missing enzyme needed to sense light, it can't restore light-sensing cells that have already died off due to this progressive disease. In the initial study results, released on October 5th, one standard measure of vision, visual acuity, didn't improve by a statistically significant amount. (But, functional vision did!)</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Spark also hasn't finalized and published data on individual patients, and it's possible that some responded better than others. “Age in particular may be a factor in how much a patient can improve,” said Dr. Russell. The company said in its statement that no serious adverse events have been seen so far in the trial.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
So, the question remains, is this the <b>“forever fix”</b>, as author Riki Lewis has written in her book on gene therapy, or something less? Time will tell. But this is certainly an important step forward for the treatment of an inherited retinal disease.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>References:</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
1. <a href="http://tinyurl.com/RetPhys-GT-Update"><b>What’s New in Gene Therapy for Ophthalmology?</b></a>, Irv Arons, <b>Retinal Physician</b>, October 2015.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
2. <a href="http://ir.sparktx.com/mobile.view?c=253900&v=203&d=1&id=2095955"><b>Spark Therapeutics Announces Presentation of Additional Phase 3 and Durability Data on SPK-RPE65 at The Retina Society 48th Annual Scientific Meeting</b></a>, Company News Release, October 10, 2015.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
3. <a href="http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NTk3NzUzfENoaWxkSUQ9MzA4MDEwfFR5cGU9MQ==&t=1"><b>Presentation: Phase 3 Trial of AAV2-hRPE65v2 (SPK-RPE65) to Treat RPE65-Mediated Inherited Retinal Dystrophies (IRDs): Top-line Safety and Efficacy Results</b></a>, </div>
<div style="text-align: justify;">
Stephen R. Russell MD, Retina Society Meeting, Paris, Stephen R. Russell MD, October 10, 2015.</div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
4. <a href="http://ir.sparktx.com/phoenix.zhtml?c=253900&p=irol-newsArticle&ID=2093863"><b>Spark Therapeutics Announces Positive Top-line Results from Pivotal Phase 3 Trial of SPK-RPE65 for Genetic Blinding Conditions</b></a>, Company News Release, October 5, 2015.</div>
<br />
<div style="text-align: justify;">
5.<a href="http://www.bloomberg.com/news/articles/2015-10-10/-holy-grail-seen-as-gene-drug-for-blind-produces-lasting-effect"><b> 'Holy Grail' Seen as Gene Drug for Blind Produces Lasting Effect</b></a>, Caroline Chen &<b> </b>Robert Langreth, <b>Bloomberg Business News</b>, October 10, 2015.</div>
<br />
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<br />Irv Aronshttp://www.blogger.com/profile/05719664806219249867noreply@blogger.com0tag:blogger.com,1999:blog-20140933.post-7989047229676616242015-09-01T15:41:00.000-04:002016-02-14T17:39:50.417-05:00Gene Therapy in Ophthalmology Update 16: Current Tables Now OnlineMy current gene therapy tables are now online for anyone interested to access. Here is a brief description of what is available and how to access them:<br />
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Gene Therapy<br /><br />Gene Therapy Companies/Institutions Active in Ophthalmology</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The table lists more than <b>forty-two</b> companies and institutions actively pursuing gene therapy solutions to ophthalmic diseases. The table shows the delivery viral platform, the gene type being used (where known), the application, and clinical status.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Link: <a href="https://www.dropbox.com/s/qj7cn3wjv1g2mxi/Gene%20Therapy%20Company%20Table.pdf?dl=0">GeneTherapyCompanies 2/14</a></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Gene Therapy in Ophthalmology by Application</b></div>
<div style="text-align: justify;">
This table lists the <b>twenty</b>-<b>two</b> ophthalmic indications, the company/institutions involved, the clinical status, and the clinical trial number. (<b>Thirty</b> active clinical trials are listed, with live links.)</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Link: <a href="https://www.dropbox.com/s/9jxktmmr4ntv64f/Gene%20Therapy%20Application%20Table.pdf?dl=0">GeneTherapyApplications 2/14</a></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Gene Therapy in Ophthalmology -- Ongoing Clinical Trial Details</b></div>
<div style="text-align: justify;">
This table lists the <b>thirty </b>active and completed clinical trials, the number of patients to be treated and the number of patients treated to date (that I'm aware of).</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Link: <a href="https://www.dropbox.com/s/oz3umtqlb8xjzxm/Gene%20Therapy%20Clinical%20Trial%20Table.pdf?dl=0">GeneTherapyClinicalTrials 2/14</a></div>
<br />
<b></b><br />
<b></b><br />
<b>Updated February 14, 2016</b><br />
<br />Irv Aronshttp://www.blogger.com/profile/05719664806219249867noreply@blogger.com0tag:blogger.com,1999:blog-20140933.post-82085502402219864372015-06-30T16:11:00.000-04:002015-07-01T11:37:17.104-04:00Using Lasers to Treat Vitreous Floaters: An Update<div style="text-align: justify;">
Since my first article on the use of a YAG laser to treat floaters (<a href="http://tinyurl.com/vitreolysis"><b>Using Lasers to Treat Vitreous Floaters: Laser Vitreolysis)</b></a> appeared in this space in August 2010, it has become the most popular/read write-up that I have posted. About 10% of all visitors to my blog come to read that article - and I’ve had over 215,000 unique visitors. One of the most frequent questions I get asked is, is there anyone close to where I live that does the procedure? Since I haven’t kept track of who besides the three doctors I featured in that first write-up are now doing the procedure, and since <b>Ellex Medical</b> (Ellex) now produces and markets a specialized laser (the <b>Ultra Q Reflex</b>) specifically to treat floaters, I decided it was time for this update.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
As described by Ellex, <a href="http://www.ellex.com/media_releases/ellex-launches-multi-modality-yag-laser-at-the-american-academy-of-ophthalmology/">upon release of their new laser in the Fall of 2012</a>, here are its features: </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
"Featuring Ellex's proprietary Reflex light delivery system, our ophthalmologist customers can use the Ultra Q Reflex YAG laser to treat floaters in a medically-reimbursable procedure, known as YAG laser vitreolysis," according to Ellex CEO Tom Spurling.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>While there are several YAG lasers on the market, none until now were designed specifically for the treatment of floaters.</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
"The Ultra Q Reflex is optimized for performing YAG laser treatments both in the anterior segment and posterior segment - making it ideal for the all conventional YAG laser treatments such as capsulotomy and iridotomy, as well as YAG laser vitreolysis for the treatment of floaters," added Mr. Spurling.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Ultra Q Reflex for Nd:YAG Laser Vitreolysis</b></div>
<div style="text-align: justify;">
<b><br /></b></div>
<div style="text-align: justify;">
<b>Floaters (vitreous strands) are small bundles of collagen fibers located in the eye's vitreous, which cast visual shadows that impede quality of vision. Often considered benign, they are a result of degenerative vitreous syndrome (DVS; the natural breakdown and clumping of collagen in the vitreous) and posterior vitreous detachment (PVD; the age-related separation of the vitreous from the retina).</b></div>
<div style="text-align: justify;">
<b><br /></b></div>
<div style="text-align: justify;">
<b>To date, surgical removal of the vitreous (vitrectomy) has been the standard approach to the treatment of floaters. Highly invasive, the procedure carries a significant risk of complications, such as infection, retinal detachment, macular edema, anterior vitreous detachment and residual floaters.</b></div>
<div style="text-align: justify;">
<b><br /></b></div>
<div style="text-align: justify;">
<b>The proprietary slit lamp illumination tower design of the Ultra Q Reflex converges the operator's vision, the target illumination, and the treatment beam onto the same optical path, and focuses them onto the same optical plane as the treatment beam. This minimizes the potential for focusing errors and the risk of damage to the natural lens or the retina -- making the Ultra Q Reflex ideal for the treatment of floaters. In contrast, conventional YAG lasers offer a limited view of the vitreous, which can make it difficult to visualize vitreous strands and opacities.</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
I contacted Ellex Laser management and requested a list of the U.S. doctors who have purchased this laser and who now use it to treat their patient’s vitreous strands/floaters. The company, in response to my request, has set up an application on its website, called <a href="http://www.floater-vitreolysis.com/find-a-physician/"><b>“Find a Physician”</b></a>. </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
By entering your location, a map will appear which will locate doctors near you that have access to this specialized laser and use it to treat vitreous floaters by performing laser vitreolysis. The link to the app is: <a href="http://www.floater-vitreolysis.com/find-a-physician/">http://www.floater-vitreolysis.com/find-a-physician/</a></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
PS: The app works worldwide!</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
(As of June 30th, there are 58 physicians across North America, Australia, Asia, and parts of Europe who have decided to be referenced in the physician finder.)<br />
<br /></div>
<div style="text-align: justify;">
Good luck to all.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>References:</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<a href="http://tinyurl.com/vitreolysis"><b>Using Lasers to Treat Vitreous Floaters: Laser Vitreolysis</b></a>, August 4, 2010</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<a href="http://www.ellex.com/media_releases/ellex-launches-multi-modality-yag-laser-at-the-american-academy-of-ophthalmology/"><b>Ellex Launches Multi-Modality YAG Laser at the 2012 American Academy of Ophthalmology</b></a>, November 7, 2012</div>
<br />
<br />Irv Aronshttp://www.blogger.com/profile/05719664806219249867noreply@blogger.com0tag:blogger.com,1999:blog-20140933.post-68038659002195823092015-04-08T15:51:00.001-04:002015-04-08T15:55:06.358-04:00A Laser Process for Changing Brown Eyes Blue<div style="text-align: justify;">
<b>`Don't It Make My Brown Eyes Blue'</b> was a <a href="http://blogs.tennessean.com/tunein/2014/01/10/story-behind-the-song-don%E2%80%99t-it-make-my-brown-eyes-blue/">smash hit song(1)</a> for Crystal Gale in 1977. But it has been a wish for many a young girl with brown eyes (and even some older ones and perhaps some men) ever since. Over the years it has been possible to turn your brown eyes blue using contact lenses, first lightly tinted ones, which really didn’t do much for dark brown eyes, and later opaque tinted lenses, which would cover brown pigmented eyes and really turn them blue (or green or even other colors), although they created an opaque light eye, which does not exist in nature and thus looks contrived. There are even a couple of surgical procedures that can transform the iris, or enhance/darken the edge, but the question of safety quickly arises with any surgical procedure.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
So, a week ago, when my wife told me what she had just seen that there was a laser process to turn brown eyes blue, on <b>The View</b>, I replied, “No way”. You see, I was a consultant to the medical laser industry, involved in the use of lasers in both ophthalmology and cosmetic surgery, for over twenty years and had never heard of lasers used in this way. Just to be sure, I Googled it, and much to my surprise, yes, a company, <b>Strōma Medical Corporation</b>, in Laguna Beach California, is developing a permanent, non-surgical laser procedure that will turn brown eyes blue!</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
I found an article written for <a href="http://digital.ophthalmologybusiness.org/i/138484-jul-2013/8"><b>Ophthalmology Business</b>(2)</a> that explained how they were doing it. It also listed a couple of well-known ophthalmologists – Perry Binder and Marguerite McDonald, who I know on a personal basis – that are involved with the company, on their Medical Advisory Board, thus assuring me that this business was legitimate. I got in touch with my ophthalmologist friends and they put me in touch with the Chairman and Chief Scientific Officer of the company, Dr. Gregg Homer, to learn more.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
What I have learned is that the company has developed a unique, low intensity, highly specialized laser and diagnostic aiming system (with computerized iris mapping and tracking), that targets the brown pigment on the front surface of the iris, removing some or all of that pigment, thereby revealing the natural blue eye lying below. (The blue in an eye is actually the result of the scattering of white light entering the iris, by tiny grey collagen fibers called “stroma”, and the reflection of the shorter blue light, similar to the light scattering of sunlight by atmospheric molecules that makes the sky appear to be blue.)</div>
<div style="text-align: justify;">
<br /></div>
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiUODLl3Ki865QrH8TbdxN4mRpbYvkAcMSope1QnkT0x7XhxTvgq5SB2O9qhJzitJgm2gghkZHn1Z557hzvlD0Bcbhpd9N6sA27RVD_DTpa2H96kLfjCOIgcGemOBCnpmo09vGX/s1600/half+eye+treated.jpeg" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiUODLl3Ki865QrH8TbdxN4mRpbYvkAcMSope1QnkT0x7XhxTvgq5SB2O9qhJzitJgm2gghkZHn1Z557hzvlD0Bcbhpd9N6sA27RVD_DTpa2H96kLfjCOIgcGemOBCnpmo09vGX/s1600/half+eye+treated.jpeg" height="216" width="320" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">A half treated eye (for illustration purposes).</td></tr>
</tbody></table>
<div style="text-align: justify;">
<br />
<br />
As explained by Dr. McDonald in the <b>Ophthalmology Business</b> article, describing how the procedure works, “This is a Q-switched neodynmium YAG laser, which produces a very highly discriminatory photo-absorbed frequency. The laser fires a series of small, computer-guided pulses across the iris, to photo-disrupt the stromal melanocytes (the brown pigment). Because of the photo-absorption properties of this laser, the energy passes through the clear cornea and it very selectively hits the brown melanocytes, leaving the cornea and the posterior iris stroma totally undisturbed. The photo-disrupted melanocytes release cytokine protein molecules into the anterior chamber and the cytokine signal recruits macrophages...that engulf and digest the photo-disturbed melanocytes as cellular debris.”</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
To put it in simpler terms, the laser beam “breaks up” the brown pigment in the front part of the iris into much smaller particles, similar to the way lasers are used to remove tattoos, by a process known as <a href="http://www.sciencemag.org/content/220/4596/524.short"><b>“selective photothermolysis”(3)</b></a>. This phenomenon, invented by Drs. John Parrish and Rox Anderson of the <b>Wellman Laboratories of Photomedicine </b>at <b>Massachusetts General Hospital</b>, uses the principle of delivering pulsed laser energy to a selected chromaphore within the target tissue, without damaging surrounding tissue. </div>
<div style="text-align: justify;">
<br /></div>
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjw8y8zYIshVW6i2ICmPhuuV370-aYAunYHtODc4fmAdrWtcyvOnstLwgWyjvAXoNidF8LvaKYdmPWHzPidvnGuKkk_7gTl0SXYkGpR7Ew3JaAMWgp0KrncppQv-BjdEbPn92Cs/s1600/irislayers.gif" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjw8y8zYIshVW6i2ICmPhuuV370-aYAunYHtODc4fmAdrWtcyvOnstLwgWyjvAXoNidF8LvaKYdmPWHzPidvnGuKkk_7gTl0SXYkGpR7Ew3JaAMWgp0KrncppQv-BjdEbPn92Cs/s1600/irislayers.gif" height="165" width="320" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Illustration of the iris in cross section, showing the anterior border layer, which is the target of the Strōma Medical process.</td></tr>
</tbody></table>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
<br />
The smaller particles are then digested by the macrophages formed and eliminated from the iris and from the anterior chamber via the normal liquid outflow channels in the eye.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>The Story Behind the Story</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
According to Dr. Homer, he became interested in the concept of changing eye color in the late 1990s, discovering <a href="http://www.sciencemag.org/content/220/4596/524.short">a paper in the literature on iris pigmentation by RC Eagle Jr.(4)</a> “I finally found that paper, which wasn’t available digitally, and I thought, ‘Now that we’ve done so much work with lasers on dermal pigment, it should be fairly easy to remove that iris pigment safely, which should, in turn, reveal a blue eye.” He went on, “Around 2001, I personally funded a small study at Cedars-Sinai Eye Institute in Los Angeles. We took brown-eyed rabbits and proved the concept, showing that we could change an eye’s color. These rabbits don’t’ have blue eyes, but what we showed is we could (safely) remove the pigment.”</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
In 2009, Dr. Homer and his colleagues raised $2 million in a Series A round to form the company, build a prototype laser device, and open a clinical trial. They achieved their goals, successfully treating 17 patients in Mexico with solid efficacy and no adverse events.</div>
<div style="text-align: justify;">
<b><br /></b></div>
<div style="text-align: justify;">
<b>The Procedure</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The Strōma Medical procedure is non-invasive. It involves no incisions or injections of any kind. In fact, other than the use of a small device to help keep the patient's eyelid open during the procedure and the application of a mild topical medication, there is little or no contact with the patient's eye.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The patient sits in front of the Strōma laser, and his or her head is stabilized. The patient is instructed to direct the untreated eye toward a tiny animation, located about one foot from the patient's eye, while the procedure is completed. The procedure is then repeated to treat the other eye.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjjLGjdAQAXh2xUVYsuLy-7uL2amF7yGjtQWZylWHIaH99zvJRaK_UDTzBHcGat4d62P9ejf8GpE1b461Qib3sFLLDSWjfdcshXjgoKZniIjzumP6ickXxq75-thohhwrwdrx2N/s1600/stromalaser.gif" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjjLGjdAQAXh2xUVYsuLy-7uL2amF7yGjtQWZylWHIaH99zvJRaK_UDTzBHcGat4d62P9ejf8GpE1b461Qib3sFLLDSWjfdcshXjgoKZniIjzumP6ickXxq75-thohhwrwdrx2N/s1600/stromalaser.gif" height="320" width="194" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">The Strōma Medical Laser work station.</td></tr>
</tbody></table>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
<br />
The treating physician will inform the patient when he or she may drive and return to work. In most cases, the patient should be able to do so shortly after the procedure. For the first week or so following the procedure, the irises will get darker. Thereafter, they will grow progressively lighter, revealing the underlying natural blue color. The full color change process should take two to four weeks following the procedure.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Where Does the Process Stand?</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
According to Dr. Homer, the Strōma Medical laser process, which takes about 30 seconds per eye, is still being clinically tested before being released commercially, first outside of the U.S. </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
To date, the company has completed preclinical studies on 50 Dutch-belted rabbits, and clinical studies on 17 human subjects treated in Mexico. The company is preparing its’ first large-scale pilot clinical study in Costa Rica, involving about 20 patients. Following the successful completion of that pilot study, the company plans to treat about 100 additional patients in multiple countries and follow them for a predetermined length of time. </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The company plans to release the product when it and the governing regulatory bodies are satisfied with the safety and efficacy of the procedure. Due to the relative cost and complexity of releasing a cosmetic medical device in the United States, they expect to release the procedure outside the United States first. The order of release in the non-U.S. territories will depend upon the market demand and regulatory environment in each territory. </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Remaining Questions</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The technique appears to be non-invasive, safe, and painless. The laser treats only the front of the iris and does not enter the pupil or treat any portion of the inside of the eye where the nerves affecting vision are located.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
But several questions do remain:</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>1.What happens to the pigment debris that leaves the iris? Will that debris clog up the normal drainage channels in the front of the eye, which can in turn cause glaucoma?</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Strōma Medical claims that the digested particles released by the process are too fine to cause glaucoma and can easily pass through the trabecular meshwork and out into the anterior chamber -- and that even if there were any complications, they would be short-term and easily remedied, including the use of a standard laser procedure - selective laser trabeculoplasty (SLT), commonly used to eliminate pigment from the trabecular meshwork that might contribute to a rise in intraocular pressure. However, a small risk still remains, and the remaining studies are intended to address that risk prior to commercial release.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>2. Don’t the pigmentary layers of the iris provide ultra-violet and infrared light protection to the lens and the retina in the back of the eye? Won’t removal of one of the layers increase the likelihood of cataracts and increased retinal problems due to increased ultra-violet and infrared light exposure?</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Dr. Homer acknowledges that naturally light eyes tend to be more sensitive to bright light. He explains, however, that light eyes are not only less pigmented on the front surface of the iris, but throughout the eye, including the retinal nerves in the back of the eye that respond to light. Light sensitivity, he maintains, is the result of less retinal pigment, not less pigment on the front surface of the iris. Because the procedure is limited to the removal of pigment from the front surface of the iris, its removal would not increase light sensitivity. Instead, the procedure is able to achieve something that nature does not – a light eye without light sensitivity. </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>3. How much will the procedure cost?</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
According to Dr. Homer, the procedure would likely cost about $5,000 for both eyes in the U.S., but the physicians doing the procedure would set the price, not the company itself, and it would likely vary depending upon territorial demand curves and currency fluctuations.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>4. What will be the costs to the ophthalmologists?</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The financial model for the procedure will follow LASIK – the laser device (which will be sold or leased), a maintenance contract for the device, and a per-procedure fee. The pricing has not yet been determined, but the company expects the device and service contract to cost less than those for LASIK, and the per-procedure fee to cost more.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>5. Have you estimated the size of the market? Perhaps using the tinted contact lens market as an example?</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
According to market research done by the company, the relevant potential worldwide market for manufacturers of eye color changing products will be those people who have dark eyes (brown or hazel), are affluent enough to afford the procedure cost, and are 20-60 years of age. When the market is mature, 10.2 million people worldwide could have their eye color changed each year. The largest patient population for the Strōma Medical’s system may be in India and China, followed by Central and South America, Southern Europe, Japan, Korea, the Middle East, and the United States. </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Further, the company believes that the market for permanent eye color change will be the fastest growing segment of the aesthetics market over the next ten years. The market will be made up of individuals who have the money and the desire to change their eye color. The annual sustainable, and achievable market opportunity for companies in this space is estimated to approach $2.9 billion in five years. For physicians and their clinics, the market opportunity could be $9.3 billion. Early adapters of the technology will come from the 25 million patients who currently wear colored contact lenses, and the estimated 70 million patients who have stopped wearing them for aesthetic, comfort or an adverse response reason. But, the market could be much larger as the consistency of the results and a positive safety profile is confirmed through solid clinical studies.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>6. Finally, do you have any IP protection? What’s to prevent a laser manufacturer to build both a laser and a diagnostic and aiming system to compete directly with you - in fact, isn’t there an entity in Barcelona that is now providing the service?</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The company has an extensive international patent portfolio, which includes international patents covering several critical elements of the laser device and patents in the U.S., Singapore, and Australia covering any method or system using any form of electromagnetic radiation to alter iris color. The company also has additional protection covering various ancillary features of the procedure, such as its proprietary iris mapping and tracking technology, scan pattern, and beam profile. </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The company claims that the physician in Barcelona was using an off-the-shelf laser designed for laser iridotomy and posterior capsulotomy, which is ill-suited for iris color change. As a result, many patients were injured – the local medical societies opened an investigation, and the physician appears to have discontinued the procedure. </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
To obtain more information about the process and the Strōma Medical laser, please visit the company’s website at this <b><a href="http://www.stromamedical.com/page/about-us"><u>link</u></a></b>.</div>
<br />
<b>References:</b><br />
<br />
1. <a href="http://blogs.tennessean.com/tunein/2014/01/10/story-behind-the-song-don%E2%80%99t-it-make-my-brown-eyes-blue/"><b>Story Behind the Song: ‘Don’t It Make My Brown Eyes Blue’</b></a><br />
<b> </b> <br />
2.<a href="http://digital.ophthalmologybusiness.org/i/138484-jul-2013/8"><b> Brown to blue: Procedure changes eye color</b></a>, Erin Boyle, <b>Ophthalmology Business</b>, July 2013<br />
<br />
3. The theory of <b>selective photothermolysis</b> predicts that the selective thermal damage of a pigmented target structure will result when a sufficient fluence at a wavelength preferentially absorbed by the target is delivered during a time equal to or less than the thermal relaxation time of the target. (<a href="http://www.sciencemag.org/content/220/4596/524.short"><b>"Selective photothermolysis: Precise microsurgery by selective absorption of pulsed radiation"</b></a>, RR Anderson and JA Parish, <b>Science</b>, 220:524-527, 1983.)<br />
<br />
4. <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1298824/"><b>Iris pigmentation and pigmented lesions: an ultrastructual study</b></a>, Eagle RC Jr.,<b> Tran Am Ophthalmol. Soc.</b>, 1988;86:581-687.<br />
<br />
5. <a href="http://www.stromamedical.com/page/about-us"><b>Strōma Medical Website</b></a>.<br />
<br />Irv Aronshttp://www.blogger.com/profile/05719664806219249867noreply@blogger.com0tag:blogger.com,1999:blog-20140933.post-10879614309527057922015-03-27T20:35:00.000-04:002015-03-27T20:38:57.554-04:00Avalanche Update 2: Avalanche and Univ. Of Washington Collaborate to Defeat Color Blindness<div style="text-align: justify;">
<b>Avalanche Biotechnologies and the University of Washington Enter Into Exclusive License Agreement to Develop Gene Therapy Approach to Treat Color Blindness</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
As reported by <a href="http://www.npr.org/blogs/health/2015/03/25/395303785/university-and-biotech-firm-team-up-on-colorblindness-therapy?sc=tw"><b>NPR’s</b> health blog, <b>Shots</b></a>, on March 25th, <b>Avalanche Biotechnologies</b> in Menlo Park and the <b>University of Washington</b> in Seattle <a href="http://investors.avalanchebiotech.com/phoenix.zhtml?c=253634&p=irol-newsArticle&ID=2028354">announced a licensing agreement</a> to develop the first treatment for colorblindness. The deal brings together a gene therapy technique developed by Avalanche with the expertise of vision researchers at the University of Washington.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
"Our goal is to be treating colorblindness in clinical trials in patients in the next one to two years," said Dr. Thomas Chalberg, the founder and CEO of Avalanche. The company will be entering IND-enabling studies this year.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The agreement has its roots in a scientific breakthrough that occurred six years ago. That's when two vision researchers at the University of Washington used gene therapy to cure a common form of colorblindness in squirrel monkeys.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
"This opened the possibility of ultimately getting this to cure colorblindness in humans," says Jay Neitz, who runs the Color Vision Lab at UW along with his wife, Maureen Neitz.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The company also announced, that outside of the scope of the license agreement, Drs. Jay and Maureen Neitz, faculty in the UW's Department of Ophthalmology and color vision deficiency (CVD) experts, have joined its Scientific Advisory Board. They will be technical advisors to the company on the science of vision.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
"This agreement with the University of Washington and world-renowned vision scientists Drs. Jay and Maureen Neitz will help us further advance our goal of developing therapeutic products for the millions of people who suffer from CVD," said Dr. Chalberg. "Our proprietary technology enables us to target the retina through intravitreal adeno-associated virus delivery, presenting, for the first time, the opportunity to pursue previously untreatable ophthalmic conditions such as CVD."</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Avalanche will build on gene therapy research conducted by the Neitz research team, who used gene therapy to confer color vision in two adult male squirrel monkeys that had been color blind since birth. This groundbreaking work demonstrating proof-of-concept for treating CVD was published in the journal Nature (1).</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Curing color blindness involves delivering new genes to cells in the retina that respond to color. That's how Jay and Maureen Neitz cured the squirrel monkeys six years ago. But the technique they used involved a surgical procedure on the retina.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
For people, they desired a nonsurgical approach, something that had eluded researchers for years. Then a team at the University of California, Berkeley found a way to deliver genes using a simple injection into the vitreous, the clear gel that fills most of the eyeball.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Avalanche Biotechnologies has been working to improve and commercialize the Berkeley technique, said Chalberg. </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
So, Avalanche will combine the CVD gene therapy approach discovered by Drs. Jay and Maureen Neitz, with the licensed technology from the University of California at Berkeley and improved by Avalanche which will allow treatment via an intravitreal injection, similar to how wet AMD treatments are currently delivered in ophthalmologist’s offices, in a simple in-office procedure.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
(I described this latter new virus vector delivery system in an article written in June 2013 entitled: <a href="http://tinyurl.com/GeneTherapy19"><b>Gene Therapy in Ophthalmology Update 19: A New Virus Vector for Safer Delivery of Gene Therapies</b></a>)</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
According to Dr. Samuel Barone, Avalanche’s Chief Medical Officer, in response to my query if they were going to use the specific Berkeley vector research that I wrote about in <a href="http://tinyurl.com/GeneTherapy19"><b>Update 19</b></a>, Dr. Barone said, “We licensed that intellectual property from Berkeley, and it serves as the basis for the delivery. However, we have improved and optimized the technology, in better cone-specific transduction and protein expression.”</div>
<div style="text-align: justify;">
<b><br /></b></div>
<div style="text-align: justify;">
<b>About CVD/Color Blindness and Avalanche's Targeted Development Program</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Color vision deficiency (CVD), also known as red-green color blindness, is among the most common genetic diseases. CVD affects approximately 8 percent of males and 0.5 percent of females, or more than 10 million people in the U.S alone. CVD is a visual impairment that impacts many aspects of everyday life, resulting in limitations in professional choices, compromised health and safety, and the inability to perform many activities of daily living.</div>
<div style="text-align: justify;">
<br /></div>
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgdE8h2BasDrTg9QNvaqN91EFfu-3hdSMNJKWzOXbBNmg7b8TpI54ryBn6-BQB-CTB4qqF7CsVQG54dlF6HqvUURY3E4EccLwAmhAew4N-kr0JGCeJD2i_PlMY7LZfDDFCyZ1uP/s1600/color-blindness-1_wide-bf5c91a846f6e9f0fa01df588c4d6a1f59731e59-s1300-c85.jpg" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgdE8h2BasDrTg9QNvaqN91EFfu-3hdSMNJKWzOXbBNmg7b8TpI54ryBn6-BQB-CTB4qqF7CsVQG54dlF6HqvUURY3E4EccLwAmhAew4N-kr0JGCeJD2i_PlMY7LZfDDFCyZ1uP/s1600/color-blindness-1_wide-bf5c91a846f6e9f0fa01df588c4d6a1f59731e59-s1300-c85.jpg" height="179" width="320" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">A simulation from the Neitz lab of what color blindness looks like, with normal color vision on the left and red-green color blindness on the right.</td></tr>
</tbody></table>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Photopigments in the retina are crucial for perceiving color. People with normal color perception have three different types of photopigments. These photopigments are tuned to perceive either long wavelengths (red), middle wavelengths (green) or short wavelengths (blue), respectively.<br />
<br />
</div>
<div style="text-align: justify;">
The most common forms of CVD are due to genetic defects that lead to missing either the L-opsin (Type 1, or protan defects) or the M-opsin (Type 2, or deutan defects). Affected individuals have trouble distinguishing between red and green and between colors that contain red or green hues.</div>
<div style="text-align: justify;">
<br /></div>
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjQC-VL3zkHSax8zEow7S7sWgO_rrIb1f1p7lfVKUVG0joFzK_2AJndLXzH2X6uJk8qWZYUmgZvRZS3EAez7qzuOG5kQ5Dyeu5oB_M25eDuPGZ8iy8pCoNX5WDfi-BIkrEMZxzb/s1600/ishihara_9.png" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjQC-VL3zkHSax8zEow7S7sWgO_rrIb1f1p7lfVKUVG0joFzK_2AJndLXzH2X6uJk8qWZYUmgZvRZS3EAez7qzuOG5kQ5Dyeu5oB_M25eDuPGZ8iy8pCoNX5WDfi-BIkrEMZxzb/s1600/ishihara_9.png" height="320" width="320" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Ishihara plate, a typical test for red-green colorblindness.</td></tr>
</tbody></table>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
<a href="http://www.avalanchebiotech.com/pipeline-AVA-322-AVA-323.php">Avalanche has two drug candidates targeting these areas.</a> AVA-322 carries the gene for L-opsin and is being developed for the treatment of Type 1 color vision deficiency. AVA-323 carries the gene for M-opsin and is being developed for the treatment of Type 2 color deficiency.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Avalanche expects to file an IND in the second half of 2016 to support advancement of these drug candidates into clinical trials, using Avalanche’s breakthrough non-surgical intravitreal injection method to deliver genes directly to cone cells at the back of the eye. The company recently launched <a href="http://www.colorvisionarareness.com/">www.colorvisionawareness.com</a> for patients with color blindness to receive information about the condition and potential research study opportunities.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
To read more about Avalanche Biotechnologies and its research programs, please see: </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<a href="http://tinyurl.com/avalanchebiotech"><b>A Novel Gene Therapy Approach to Treating the Wet Form of AMD: The BioFactoryTM From Avalanche Biotech</b></a>, February 2012, and,</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<a href="http://tinyurl.com/AvalancheBiotech2"><b>An Update on Avalanche Biotechnologies: A Potential Longer-Lasting Wet AMD Treatment?</b></a> May 2014.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Reference</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>1. </b><a href="http://www.nature.com/nature/journal/v461/n7265/full/nature08401.html"><b>Gene therapy for red-green colour blindness in adult primates</b></a>, Mancuso, K. et al, <b>Nature</b>, 2009; 461:784-787. </div>
<br />
<br />Irv Aronshttp://www.blogger.com/profile/05719664806219249867noreply@blogger.com0tag:blogger.com,1999:blog-20140933.post-65687112023708518582015-01-15T18:12:00.000-05:002015-01-15T18:12:07.237-05:00Oraya IRay Update 3: Oraya Now Operating at Nine European Centers and Partnership with Carl Zeiss Meditec<div style="text-align: justify;">
The last time I checked in on Oraya, in March 2013 (<a href="http://tinyurl.com/OrayaUpdate2"><b>Oraya IRay Update 2: INTREPID Two-year Results Meet Primary Clinical Endpoint - Results in At Least 35% Fewer anti-VEGF Injections</b></a>), the company had just announced the two-year results of the INTREPID clinical study, showing favorable results in requiring fewer anti-VEGF treatments to treat wet AMD.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
With the recent announcement (January 7, 2015) of a collaboration agreement between Oraya and Carl Zeiss Meditec, to provide funding to Oraya over a period of up to two years for the implementation of Oraya's growth strategy, and a report of the three-year INTREPID safety results last September, I decided to publish this update.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>First, the three-year INTREPID trial safety results.</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The <a href="http://www.orayainc.com/wp-content/uploads/2012/02/EURETINA-Oraya_3yearDataResults_FINAL2.pdf"><u>three-year safety results</u></a> were presented on September 13, 2014, at a EURETINA seminar where physicians also discussed their clinical experiences treating patients with Oraya Therapy.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The three year safety evaluation consisted of detailed image analysis looking for the presence of microvascular changes related to radiotherapy. Although small localized changes were identified by the reading center in a quarter of the patients, they did not significantly affect vision.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Commenting on the INTREPID study, Professor Ian Rennie, Consultant Ophthalmologist and Professor of Ophthalmology and Orthoptics and International Expert in Treatments of Ocular Cancers at Sheffield Teaching Hospitals NHS Foundation Trust said, "Of the cases I reviewed that were identified by the study expert panel as having microvascular changes attributable to radiation, most cases were so subtle that I would consider them clinically insignificant."</div>
<div style="text-align: justify;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjiCzsmiSWV8GbiHQwQQPQWP0XLSENTjk8-mkXpTLVermbK-e7qiaYaUq470d2wucdePFbDHoeP-HIhyxSqZis9EBZRlQ-OacZuoSAx6s2gS56-MEFQqP62XnJTTo883PkjgCqk/s1600/OrayaTherapy_TreatmentRoom.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjiCzsmiSWV8GbiHQwQQPQWP0XLSENTjk8-mkXpTLVermbK-e7qiaYaUq470d2wucdePFbDHoeP-HIhyxSqZis9EBZRlQ-OacZuoSAx6s2gS56-MEFQqP62XnJTTo883PkjgCqk/s1600/OrayaTherapy_TreatmentRoom.jpg" height="267" width="320" /></a></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
The INTREPID study was the first to evaluate the safety and efficacy of Oraya Therapy in conjunction with as-needed anti-VEGF injections for patients with wet AMD, and is the only sham-controlled double-masked trial to assess stereotactic radiotherapy for wet AMD. The study met primary and secondary endpoints and showed that Oraya Therapy significantly reduces the need for anti-VEGF injections while maintaining vision in the presence of a favorable safety profile. A total of 21 sites in five European countries participated in the trial. Two-year results showed that a broadly inclusive cohort of previously treated Wet AMD patients continued to receive the benefits of a 25 % mean reduction in anti-VEGF injections over two years. Additionally, the targeted patient population maintained an impressive 45 % mean reduction in injections through the two-year visit, with stable vision.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
In simpler terms, as explained by Oraya President and CEO Jim Taylor, “The INTREPID trial enrolled a broad spectrum of patients, with some diagnosed out to 3 years prior (average ~15-18 months), and including many who's disease process had progressed to central scarring and other related conditions. In this broad cohort, we saw the 25% reduction of injections with equivalent vision outcomes to the controls.”</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Further, “In a subset of patients who had active leakage and lesions that had not grown so large as to extend outside the Oraya treatment zone, we saw the far more significant 45% reduction; and some suggestion of potential for positive vision benefit as well. This becomes our "target patient population" for commercial/clinical use, and it is important to note that our research suggests these patients make up 60%-70% of the patient population under wet AMD management in a typical clinic.”</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
These impressive results coupled with increasing interest from physicians and patients, have led the Heart of England NHS Foundation Trust to become the second NHS center to install the technology. Patient treatment at the Trust was due to commence in October 2014. The Heart of England closely follows the Royal Hallamshire Trust in Sheffield, which began offering this innovative therapy in July 2014. The commercial use of Oraya Therapy has been rapidly expanding in Europe, with the treatment available in a total of <i>eight centers</i> (see note below) across the United Kingdom, Germany and Switzerland. It is covered by insurance in all three countries.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
“As we conclude this ground-breaking three-year study of Oraya Therapy, results are showing that treatment can, and is, maintaining patients’ vision while significantly enhancing their quality of life,” said JimTaylor. “This result, coupled with the rapid expansion of the availability of the Oraya Therapy in the UK, and indeed across Europe, makes this a very exciting time for the company.” </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<i>(Editor’s Note: As of January 2015, there are now nine centers treating patients; <a href="http://www.orayainc.com/patients/treatment-location/united-kingdom/">four in the UK</a>,<a href="http://www.orayainc.com/patients/treatment-location/switzerland/"> one in Switzerland</a>, and <a href="http://www.orayainc.com/patients/treatment-location/germany/">four in Germany</a>. <a href="http://www.orayainc.com/patients/treatment-location/">See the company website for additional information</a>.)</i></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<a href="http://www.zeiss.com/meditec/en_de/media-news/press-releases/radiotherapy-solution-amd.html"><b>The Carl Zeiss Meditec Collaboration</b></a></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
On January 7, 2015, Carl Zeiss Meditec AG and Oraya Therapeutics, Inc. (Oraya) jointly announced that the companies had entered into a collaboration agreement under which Carl Zeiss Meditec will provide funding to Oraya over a period of up to two years for the implementation of Oraya's growth strategy, and in turn receive rights in the company reaching up to a majority stake after two years.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The Oraya Therapy is available commercially in Germany, the UK and Switzerland, and the collaboration is intended to accelerate and expand these initial European market developments. While specific terms of the agreement were not disclosed, the companies noted that Carl Zeiss Meditec will be making a meaningful strategic investment in Oraya, and that further opportunities to leverage the companies' respective technical and market expertise and resources will be reviewed.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
In discussing the transaction, Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG, stated<b>,</b> "The current pharmaceutical treatment regimens for wet AMD are exceptionally costly and burdensome, and Oraya's unique therapy offers a significant potential to positively impact the management of this debilitating disease." He went on to add that, "ZEISS has a long tradition of bringing new and innovative technologies to the ophthalmic market, from the earliest slit lamps, to category leading products such as glaucoma field analyzers, Optical Coherence Tomography (OCT) and innovative femtosecond laser platforms. These types of technology innovations, all offering significant provider and patient benefits, are part of the core strategy of Carl Zeiss Meditec AG."</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Commenting on the agreement, Jim Taylor, CEO of Oraya, stated, "It is exceptionally rewarding to have the support and validation that are inherent in this commitment by Zeiss, a company universally recognized for its commitment to excellence in science as well as in patient-focused and physician-focused products and innovations. As a result of this collaboration, we have effectively enhanced our potential to positively impact patient outcomes, while significantly reducing the therapy burden for clinicians and providers as well."</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
In the USA the Oraya IRay is still an investigational device and is not yet available for sale.</div>
<br />Irv Aronshttp://www.blogger.com/profile/05719664806219249867noreply@blogger.com0tag:blogger.com,1999:blog-20140933.post-1707643397989722972015-01-07T15:31:00.001-05:002015-01-08T12:15:43.341-05:00Iluvien Update 9: Additional Marketing Approvals; A New Ophthalmic Application; and An Interesting Human Interest Story<div style="text-align: justify;">
Since I last wrote about Iluvien back in September (<a href="http://tinyurl.com/Iluvienupdate8"><b>Iluvien Update 8: Alimera Sciences Receives FDA Approval of Iluvien for Treatment of DME</b></a>), when Alimera Sciences and pSivida announced the FDA approval of Iluvien for treating chronic DME, adding the U.S. to the approvals or pending approvals obtained in seventeen European countries – approved in thirteen and pending approval in an additional four others, the product has become commercially available in the UK and Germany and is scheduled to become available in Portugal shortly. </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
With the FDA approval, Iluvien should also become commercially available in the U.S. in early 2015.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<a href="http://psdv.client.shareholder.com/releasedetail.cfm?ReleaseID=885441">In a recent news release</a>, Dr. Paul Ashton, President and CEO of pSivida, said, "We continue to be pleased as Iluvien gains additional marketing approvals in Europe. We believe Iluvien’s efficacy and three-year duration make it an attractive treatment option for many DME patients, particularly in the U.S. where the drug has broader labeling."</div>
<div style="text-align: justify;">
<a href="http://www.psivida.com/about.html"><b><br /></b></a></div>
<div style="text-align: justify;">
<a href="http://www.psivida.com/about.html"><b>Pursuit of A Potential Treatment for Posterior Uveitis</b></a></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
In addition to the application of Iluvien for the treatment of DME licensed to Alimera, pSivida is independently developing the product for the treatment of posterior uveitis. The FDA recently cleared the company's Investigational New Drug (IND) application to treat posterior uveitis with its injectable, sustained-release micro-insert, permitting pSivida to move directly to two Phase III trials under which it would enroll a total of 300 patients. However, the FDA approval of Iluvien for DME opens up the potential for pSivida to seek FDA approval on Medidur for uveitis with only one Phase III clinical trial, similar to what occurred with Allergan’s Ozurdex and its FDA approvals. The FDA is allowing pSivida to reference much of the data, including the clinical safety data, from the clinical trials of Iluvien for DME previously conducted by Alimera. Under the terms of its collaboration agreement with Alimera, pSivida has joint ownership of, and reference rights to, all clinical data and regulatory filings generated by Alimera, including its New Drug Application (NDA) for DME.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
pSivida’s injectable micro-insert (Medidur) to treat posterior uveitis is a tiny tube about the size of an eyelash. It releases the off-patent steroid fluocinolone acetonide at a consistent rate over a period of approximately 36 months. The micro-insert is injected into the back of the eye during an office visit through the use of a fine gauge needle. </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>And, An Interesting Human Interest Story </b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
What caught my attention, and brought me back to Iluvien (and the company, pSivida, that produces it and licenses it to Alimera Sciences for marketing) was a story that recently appeared in the <b>Kansas City Star:</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<a href="http://www.kansascity.com/news/local/article5358792.html"><b>Tiny device and lots of teamwork save Olathe leukemia patient's sight.</b></a> </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
This is a story about a software engineer from Olathe, Kansas. </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
David Jiang was in danger of losing vision in his left eye when his eye specialist tracked down the inventor of a tiny eye implant that releases an anti-viral drug. </div>
<div style="text-align: justify;">
</div>
<br />
<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgS6l_QDQp3wHi2UmEpVOhvVB5wMUHKZxmv1XRdBhjmBGtQ0uKq24852V51maLo3XelJt4zXmVpU7rX6QejvH8D3lsUWI95d7Vvn5K_xPDEBX7GdxaqCk_L1HlWPlwx3rA9JRNL/s1600/BLIND+ME+123014+DRE+0055f.jpg" imageanchor="1" style="clear: left; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgS6l_QDQp3wHi2UmEpVOhvVB5wMUHKZxmv1XRdBhjmBGtQ0uKq24852V51maLo3XelJt4zXmVpU7rX6QejvH8D3lsUWI95d7Vvn5K_xPDEBX7GdxaqCk_L1HlWPlwx3rA9JRNL/s1600/BLIND+ME+123014+DRE+0055f.jpg" height="206" width="320" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Jiang was examined recently by Siddhartha Ganguly (left) at the University of Kansas Cancer Center. </td><td class="tr-caption" style="text-align: center;"></td><td class="tr-caption" style="text-align: center;"></td><td class="tr-caption" style="text-align: center;"><br /></td><td class="tr-caption" style="text-align: center;"><br /></td></tr>
</tbody></table>
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh5l695mC40Xnheyt33jmyJX1ZA8fwygjpt3_6nnoZ6nkl6mKcw-T-yK7hjR4EAe2VUO6AOzUWxhOHHso6d0GXQ03MiJKTqCmh_4R4aZLw9syGqR5SkXxxVfD3R2ELeXaENqV6Y/s1600/BLIND+ME+123014+DRE+0149f.jpg" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh5l695mC40Xnheyt33jmyJX1ZA8fwygjpt3_6nnoZ6nkl6mKcw-T-yK7hjR4EAe2VUO6AOzUWxhOHHso6d0GXQ03MiJKTqCmh_4R4aZLw9syGqR5SkXxxVfD3R2ELeXaENqV6Y/s1600/BLIND+ME+123014+DRE+0149f.jpg" height="209" width="320" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">David Jiang (left) says his vision remains slightly blurry but his retina is recovering after receiving the implant. </td><td class="tr-caption" style="text-align: center;"><br /></td><td class="tr-caption" style="text-align: center;"><br /></td></tr>
</tbody></table>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
A year ago, after a routine physical, Jiang got the disturbing news that he had leukemia.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
"I was shocked," he said, when his doctor called him with the diagnosis. His life was in danger, the doctor warned him. Jiang had been heading out the door to lunch. He changed his destination to the University of Kansas Cancer Center. The next morning, he started chemotherapy.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
But the chemo wasn't doing the job of ridding Jiang's body of his cancerous bone marrow and the abnormal white blood cells they were producing. Doctors decided he needed a bone marrow transplant, a tough and sometimes risky course of treatment. A bone marrow donor was found, and Jiang received the transplant in April.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
So, what does this have to do with Jiang's eyesight?</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Before cancer patients undergo a bone marrow transplant, they must go through a rigorous course of chemotherapy or radiation to eliminate their own diseased marrow from their bones. The donated marrow is infused into their bloodstream and migrates to their bones, where it grows and begins producing healthy blood cells.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
But bone marrow cells are also the source of the body's immune system. Until new marrow can renew patients' immune systems, they're exceedingly vulnerable to all kinds of infections. And as with other kinds of transplants, there's the potential for rejection, which can slow recovery.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
When kidneys, livers and other organs are transplanted, the immune system of their new owner may sense them as foreign objects and launch a search and destroy mission. But with bone marrow transplants, rejection comes with a twist. It's the bone marrow itself, the person's new immune system, that sees its new home as the alien and attacks the patient. It's called graft versus host disease.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
That's what happened to Jiang. "After the transplant, I was exhausted," he said. "I had one complication after another." There were headaches and stomach pain. To keep his graft versus host reaction in check, Jiang had to take drugs to suppress his immune system.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
And that is how his eyesight was put in jeopardy.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Like most adults, Jiang is a carrier of cytomegalovirus, also called CMV. It's scary-sounding, and the virus can be life-threatening. But people with healthy immune systems generally keep it in check and never know they carry it. But in people with compromised immune systems, such as those with AIDS or bone marrow transplants, cytomegalovirus can cause big trouble.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Depending on which organs CMV attacks, it can cause inflammation of the brain, seizures, coma, ulcers in the digestive tract, pneumonia or inflammation of the liver. The virus also can attack the eyes.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
For Jiang, it began a painful attack on the retina of his left eye, blurring his vision.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
"We needed to stop this virus where it was or it was going to eat away the center of his vision," said Ajay Singh, Jiang's eye specialist at the University of Kansas Hospital. Singh started twice weekly injections of an anti-viral drug (ganciclovir) directly into Jiang's eyeball. The injections were painful and risked causing an infection. Singh couldn't give Jiang an oral version of the drug because it could damage his new bone marrow.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
But Singh knew that during the AIDS epidemic, CMV eye infections were so common that a tiny device was created that could be loaded with medication and implanted directly into a patient's eye where it would slowly release the drug. Singh wanted one of these implants for Jiang - his patient was an ideal candidate - but they were nowhere to be found. It turned out that AIDS treatment had advanced so far that people with AIDS no longer were developing CMV eye infections. The implant manufacturer had pulled it off the market about a year or two ago, he found.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Singh was worried: The infection was a millimeter from the center of vision of Jiang's retina. If he didn't get an implant within a month, his vision could be lost. "The odds were stacked against him."</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Early in October, Singh started making calls to Singapore, India and Mexico City, searching for an implant. He emailed the CEO of the company that discontinued the device but never received an answer. Eventually, the people Singh was contacting told him of an eye doctor in Kentucky who knew the original inventor of the implant. The Kentucky doctor put the two in touch. And it is here that the inventor-entrepreneur enters the picture.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
"Dr. Singh somehow rooted me out," said Paul Ashton, CEO of Massachusetts-based pSivida. While pSivida had licensed its CMV implants to another company, it was still making other drug-dispensing eye implants.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Its newest is the size of an eyelash and can hold enough medication to treat diabetic eye disease for three years. Ashton offered Singh a slightly larger implant, about the size of a grain of rice, that would hold enough of the ganciclovir anti-viral drug.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
"It was simply a matter of putting in a different drug," Ashton said. "We were changing the ammunition but keeping the same gun."</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Singh recalled Ashton saying: "If you can send me the drug and get approval from the Food and Drug Administration, I will make you the implant." So Ashton went to his laboratory, testing the permeable ends of the tiny tube to be sure they would allow the drug to ooze out at the right speed. "It was a month of many sleepless nights. It was a race against time," Ashton said. "You can't keep injecting someone in the eye. Something bad is going to happen." Singh marveled at the speed with which Ashton's laboratory worked. "It's not like a car engine part" off the shelf, Singh said. "They have to test it. To do it in four weeks is a big deal."</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
In early November, the implant was ready. Singh called the FDA for emergency approval for the implant. "The FDA responded at lightning speed," he said. "I got an answer in four hours."</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
On Nov. 5, Singh implanted the device in Jiang's eye at KU Hospital.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
"Now his cancer doctors can keep working on getting his bone marrow up and running," Singh said. The implant will continue delivering the drug to Jiang's eye for nine months to a year. "By that time, his immune system can recover and get the virus under control again."</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Jiang said his vision is still a bit blurry, but his retina is recovering. Singh has assured him that in a few months, with new prescription glasses, he will be seeing well again. So far, his cancer hasn't returned and his graft versus host disease is well-controlled.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Jiang is grateful to the far-flung team that saved the vision in his left eye. "They all worked together. They worked so well together. I'm so fortunate."</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<i>To read more about how the pSivida drug delivery system works, please take a look at my initial writeup of Iluvien:</i> <a href="http://tinyurl.com/Iluvien"><b>Iluvien and the Future of Ophthalmic Drug Delivery Systems</b></a>.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Reference:</b></div>
<div style="text-align: justify;">
<a href="http://www.kansascity.com/news/local/article5358792.html"><br /></a></div>
<div style="text-align: justify;">
<a href="http://www.kansascity.com/news/local/article5358792.html"><b>Tiny device and lots of teamwork save Olathe leukemia patient's sight</b></a>, Alan Bailey, <b>The Kansas City Star,</b> January 2, 2015.</div>
<br />
<br />Irv Aronshttp://www.blogger.com/profile/05719664806219249867noreply@blogger.com0tag:blogger.com,1999:blog-20140933.post-91617306785840129912014-12-24T17:21:00.000-05:002015-02-20T12:19:32.120-05:00Stem Cells in Ophthalmology Update 28: First Ophthalmic Stem Cell Treatment Recommended for Approval<div style="text-align: justify;">
On December 19th, the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) recommended the stem cell product <b>Holoclar</b> (<b>Chiesi Farmaceutici S.p.A.</b>) as a first-ever medicinal treatment for severe limbal stem cell deficiency, a condition caused by physical or chemical burns to the eye or eyes in adults, which can result in blindness.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The EMA has designated Holoclar as both an orphan medicine and an advanced therapy medicinal product, which enabled the manufacturer to receive free scientific advice and protocol assistance for drug development. The CHMP recommendation was based on an assessment by the expert Committee for Advanced Therapies. Such steps are taken to promote the development of medicines for rare diseases and to encourage innovative medicinal products, according to the EMA statement.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Holoclar is produced by Chiesi under an agreement with <b>Holostem Terapie Avanzate</b>, an Italian biotechnological company devoted to the development, manufacture, registration and distribution of Advanced Therapy products based on cultures of epithelial stem cells both for cell therapy and gene therapy. Holoclar was designed specifically for the treatment of severe limbal stem cell deficiency (LSCD).</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The transparency of the cornea is essential to ensure the ability to see properly. Corneal cell renewal and repair are dependent upon the cells present in the limbus, which is found in a small area of the eye between the cornea and the conjunctiva.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Thermal or chemical burns to the eye can destroy the corneal surface (epithelium) and the limbus, causing a deficiency of limbal cells. If this happens, the cornea is covered by a different epithelium following an invasion of cells from the conjunctiva. This process leads to neovascularization, chronic inflammation and stromal scarring, rendering the cornea opaque and results in subsequent loss of vision. Conventional corneal transplants are an ineffective treatment in such cases.</div>
<div style="text-align: justify;">
<br /></div>
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgA2ZZh7ts6GJMMechyUVtihlpZIEo4kDPkTcJUX8kRLTst4LnGXOJQTyDhLUBdZZYT7-C7uDJcZfoMms3A8OBx3hvcl-9Tabkd9ub2o0NUzEXfSsbgeEh0tGxMAvDR19KDlVFn/s1600/Figure+1.jpg" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgA2ZZh7ts6GJMMechyUVtihlpZIEo4kDPkTcJUX8kRLTst4LnGXOJQTyDhLUBdZZYT7-C7uDJcZfoMms3A8OBx3hvcl-9Tabkd9ub2o0NUzEXfSsbgeEh0tGxMAvDR19KDlVFn/s1600/Figure+1.jpg" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Fig 1 Damaged eye before treatment</td></tr>
</tbody></table>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
<br />
The therapy is based on cultures of limbal cells taken from the patient, which, once they have successfully grafted, regenerate the corneal epithelium and restore its functions. Limbal cell cultures even allow the possibility of treating patients with a loss of corneal epithelium in both eyes, provided that a small portion of limbus remains in one of the eyes.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Holoclar, is an autologous culture of limbal stem cells. It is made from a biopsy taken from a small undamaged area (minimum of 1-2 mm2) of the patient's cornea and grown in the laboratory using cell culture, and transplanted in the affected eye or eyes after removal of the damaged area. Such cultures engraft and permanently regenerate a functional corneal epithelium allowing recovery of visual acuity. replacing damaged limbal stem cells. </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjMyPt-POHLUYMUDJbFwI2GKHFKcOrjcMen5SlxlS39kW-Fo-oNVhOZJ0W9PZoVc5I0118XWF-9l4HiQLvGL67r1LRY1tG-XvRBh41L9u9wIOBiJ0Da6cOkNS9NHJkc9yS3jqoy/s1600/Figure+2.jpg" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjMyPt-POHLUYMUDJbFwI2GKHFKcOrjcMen5SlxlS39kW-Fo-oNVhOZJ0W9PZoVc5I0118XWF-9l4HiQLvGL67r1LRY1tG-XvRBh41L9u9wIOBiJ0Da6cOkNS9NHJkc9yS3jqoy/s1600/Figure+2.jpg" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Fig 2 A cultured sheet of corneal epithelium</td></tr>
</tbody></table>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
<br />
Holoclar can offer an alternative to corneal transplantation for replacing altered corneal epithelium in some cases, and it has been shown to increase the chances of a successful corneal transplant where the injury has caused extensive eye damage. It reduces the risk of rejection compared with transplanting tissue from a donor and does not require surgery on the patient's other eye as only a small biopsy is performed to collect the cells, thus reducing the risk of damage to the healthy eye. Therefore, Holoclar may also be suitable where both eyes are affected by moderate to severe LSCD.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Limbal stem cell deficiency is estimated to affect about 3.3 per 100,000 people in the EU, causing pain, photophobia, inflammation, corneal neovascularization, loss of corneal transparency, and eventually blindness.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The recommendation was made by the Committee for Medicinal Products for Human Use (CHMP) based on a robust assessment carried out by the Committee for Advanced Therapies (CAT), the Agency's expert committee for ATMPs.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
“This recommendation represents a major step forward in delivering new and innovative medicines to patients,” says Enrica Alteri, Head of EMA's Human Medicines Evaluation Division. “EMA has used all available support tools to facilitate the development and assessment of Holoclar. It is an advanced therapy medicinal product that has been designated as an orphan medicine. This allowed the Agency to provide support including several rounds of free scientific advice to the applicant during Holoclar's development.”</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The Committee for Advanced Therapies and the CHMP panels determined that although the product's benefits outweigh its risks, the marketing authorization should be conditional because the data thus far are retrospective and not yet comprehensive. Therefore, the EMA says, "an additional study on the use of Holoclar should be conducted."</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The opinion adopted by the CHMP at its December 2014 meeting is an intermediary step on Holoclar's path to patient access. The CHMP opinion will now be sent to the European Commission for the adoption of a decision on an EU-wide marketing authorization. After that, decisions about price and reimbursement will take place at the level of each member state, taking into account the potential role/use of this medicine in the context of the national health system of that country.<br />
<br />
<b>Update: On February 20, 2015, the EMA approved European marketing for Holoclar. Chiesi said that Holclar would be available to all suitable patients in Europe "in the near future".</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>References:</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
1. <a href="http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/12/news_detail_002239.jsp&mid=WC0b01ac058004d5c1"><b>First stem-cell therapy recommended for approval in EU</b></a>, European Medicines Agency Press Release, December 19, 2014</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
2. <a href="http://www.medscape.com/viewarticle/836969"><b>First-Ever Stem Cell Therapy Recommended in EU</b></a>, Miriam E. Tucker, <b>Medscape</b>, December 19, 2014</div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
3. <a href="http://www.chiesigroup.com/en/about-us"><b>Chiesi website</b></a></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
4. <a href="http://www.holostem.com/en/Homepage.html"><b>Holostem website</b></a><br />
<br />
5.<b> </b><a href="http://www.reuters.com/article/2015/02/20/health-stemcells-europe-idUSL5N0VU2VP20150220">Europe approves Western world's first stem-cell therapy for rare eye condition</a>, Reuters Press Release, February 20, 2015</div>
<br />
<br />Irv Aronshttp://www.blogger.com/profile/05719664806219249867noreply@blogger.com0tag:blogger.com,1999:blog-20140933.post-8453175549128287212014-10-15T20:29:00.001-04:002014-10-16T18:14:38.788-04:00Stem Cells in Ophthalmology Update 27: ACT Interim Clinical Results Are Outstanding<div style="text-align: justify;">
Having treated 36 patients in two clinical trials for Stargardt’s Macular Dystrophy (SMD - 24 patients to date) and for dry Age-Related Macular Degeneration (AMD - 12 patients to date), <b>Advanced Cell Technology</b> reported the interim results obtained with 18 of these patients (9 in each trial) in the US-based studies. Both trials (NCT01345006 - Stargardt’s, and NCT01344993 - AMD) began in July 2011, giving the company up to three-year’s data for the earliest patients, and a median of 22 months followup for all. The <a href="http://download.thelancet.com/flatcontentassets/pdfs/S0140673614613763.pdf">interim results were reported</a> in <b>The Lancet</b>, published online October 14, 2014 in: “<b>Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: follow-up of two open-label phase 1/2 studies</b>”. </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
An additional Stargardt’s trial, being conducted at two clinics in the United Kingdom, with 12 patients enrolled (NCT01469832), along with 3 of the 4 patients treated in each of two trials with better vision candidates, as part of the two clinical trials in the publication (Phase IIa), were not included in The Lancet results.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
As noted by Paul K. Wotton, Ph.D., President and Chief Executive Officer of Advanced Cell Technology, "These study results represent an important milestone and strengthen our leadership position in regenerative ophthalmology. We would like to thank the patients for their willingness to participate in these studies. Our findings underscore the potential to repair or replace tissues damaged from diseases. We plan to initiate comprehensive Phase 2 clinical trials for the treatment of both AMD and SMD, two disease states where there is currently no effective treatment." </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<i>Editors Note: As announced on October 15th by the company, the Phase II dry AMD clinical trial (50 Patients) will start during the 1st Half of 2015 and is expected to be completed in the middle of 2016, taking place at 10 Trial Sites across North America. The Phase II SMD clinical trial (100 patients) will start during the 4th Quarter of this year or by the end of the year. It will take 18-24 months to complete, taking place at 30 sites across North America and Europe.</i></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Robert Lanza, M.D., Chief Scientific Officer of ACT and co-senior author of the paper, commented, "Diseases affecting the eye are attractive first-in-man applications for this type of investigational therapy due to the immune-privileged nature of the eye. Despite the degenerative nature of these diseases, the vision of 10 of 18 patients showed measurable improvement at the six month follow up, after transplantation of the RPE cells. Furthermore, the cells have been well tolerated for a median period of 22 months with two of the patients treated more than three years ago. We are pleased that there have been no serious safety issues attributable to the cells observed in any of the patients."</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Steven Schwartz, M.D., Ahmanson Professor of Ophthalmology at the David Geffen School of Medicine at UCLA and retina division chief at UCLA's Jules Stein Eye Institute, principal investigator and co-lead author of the publication said, "The data published in The Lancet support the potential safety and biological activity of stem cell-derived retinal tissue. Once again, surgical access to the subretinal space has proven safe. However, for the first time in humans, terminally differentiated stem cell progeny seem to survive, and do so without safety signals. Combined with the functional signals observed, these data suggest that this regenerative strategy should move forward. This is a hopeful and exciting time for ophthalmology and regenerative medicine."</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
These two studies provide the first evidence of the mid- to long-term safety, survival, and potential biologic activity of pluripotent stem cell progeny into humans with any disease. In addition to showing no adverse safety issues related to the transplanted tissue, anatomic evidence confirmed successful engraftment of the RPE cells, which included increased pigmentation at the level of the RPE layer after transplantation in 13 of 18 patients.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
There was no evidence of adverse proliferation, rejection, or serious ocular or systemic safety issues related to the transplanted tissue. Adverse events were associated with vitreoretinal surgery and immunosuppression. Thirteen (72%) of 18 patients had patches of increasing subretinal pigmentation consistent with transplanted retinal pigment epithelium. Best-corrected visual acuity, monitored as part of the safety protocol, improved in ten eyes, improved or remained the same in seven eyes, and decreased by more than ten letters in one eye, whereas the untreated fellow eyes did not show similar improvements in visual acuity. Vision-related quality-of-life measures increased for general and peripheral vision, and near and distance activities, improving by 16–25 points 3–12 months after transplantation in patients with atrophic age-related macular degeneration and 8–20 points in patients with Stargardt’s macular dystrophy.</div>
<div style="text-align: justify;">
<br /></div>
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiVaJdO4v3IU7ksJDQj5Xsq99qhLfFXjOX8ktgoTmOkjISN6cAo3R1R4gXL8fLpelg0Fn24Lm9EfrDzc0Qyo3uEDbmGgCAKu45NAUG6C9DLQnO3gL6PG3II_eVqGg-xPYsCEObi/s1600/graphs.gif" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiVaJdO4v3IU7ksJDQj5Xsq99qhLfFXjOX8ktgoTmOkjISN6cAo3R1R4gXL8fLpelg0Fn24Lm9EfrDzc0Qyo3uEDbmGgCAKu45NAUG6C9DLQnO3gL6PG3II_eVqGg-xPYsCEObi/s1600/graphs.gif" height="320" width="265" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Figure 3: Change from baseline in best-corrected visual acuity in patients with age-related macular degeneration (A) and Stargardt’s macular dystrophy (B) Median change in best-corrected visual acuity was expressed as number of letters read on the Early Treatment of Diabetic Retinopathy Study visual acuity chart in patients with age-related macular degeneration (A) and Stargardt’s macular dystrophy (B). Red lines show treated eyes and blue lines show untreated eyes of patients during the first year after transplantation of the cells derived from human embryonic stem cells. Green lines show the difference between the treated and untreated eyes. Patients who underwent cataract surgery after transplantation are not included in the graph. There was a significant difference in the letters read in transplanted eyes of patients with age-related macular degeneration versus non-transplanted controls at 12 months (median 14 letters vs –1 letter; p=0·0117). There was an increase in letters read in transplanted eyes of patients with Stargardt’s macular dystrophy versus non-transplanted controls at 12 months (median 12 letters vs two letters, although the sample size was too small to allow reliable calculation of the Wilcoxon signed-rank test).</td></tr>
</tbody></table>
<div style="text-align: justify;">
The SMD and dry AMD trials are prospective, open-label studies designed to evaluate the safety and tolerability of human embryonic stem cell (hESC)-derived RPE cells following sub-retinal transplantation into patients at 12 months, the studies' primary endpoint. Three dose cohorts were treated for each condition in an ascending dosage format (50,000 cells, 100,000 cells, and 150,000 cells). Both the SMD and dry AMD patients had subretinal transplantation of fully-differentiated RPE cells derived from hESCs.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Dr. Anthony Atala, a surgeon and director of the Wake Forest Institute for Regenerative Medicine at Wake Forest University in an accompanying commentary in The Lancet said:</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<i>"It really does show for the very first time that patients can, in fact, benefit from the therapy.</i></div>
<div style="text-align: justify;">
<i>That allows you to say, 'OK, now that these cells have been used for patients who have blindness, maybe we can also use these cells for many other conditions as well, including heart disease, lung disease and other medical conditions.' " </i></div>
<div style="text-align: justify;">
<i><br /></i></div>
<div style="text-align: justify;">
<i>Human embryonic stem cells have the ability to become any kind of cell in the body. So scientists have been hoping the cells could be used to treat many diseases, including Alzheimer's, diabetes and paralysis. But the study is the first human embryonic stem cell trial approved by the Food and Drug Administration that has produced any results.</i></div>
<div style="text-align: justify;">
<i><br /></i></div>
<div style="text-align: justify;">
<i>"It is really a very important paper."</i></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The co-authors of the study summarized their interpretation of their results in this way:</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<i>“The results of this study provide the first evidence of the medium-term to long-term safety, graft survival, and possible biological activity of pluripotent stem cell progeny in individuals with any disease. Our results suggest that human-embryonic-stem-cell-derived cells could provide a potentially safe new source of cells for the treatment of various unmet medical disorders requiring tissue repair or replacement.”</i></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<i><b>My takeaway from reading The Lancet article (and several of the accompanying writeups about the study) is, the use of RPE derived from embryonic stem cells is safe and efficacious, particularly in the eye. But most of all, this important study shows that Advanced Cell Technology is able to safely stop the progression of to-date untreatable dry AMD and SMD retinal diseases (17 of 18 patients) and to improve the vision in those who have lost considerable sight (10 of 18 patients).</b></i></div>
<div style="text-align: justify;">
<i><b><br /></b></i></div>
<div style="text-align: justify;">
<i><b>Finally, the two clinical trials that are reported on in The Lancet, were done on patients with nothing to lose (with vision no better than 20/400), whereas patients in the Phase IIa study, still in progress, have vision no worse than 20/100. It is anticipated that even better results will be shown with this better vision group.</b></i></div>
<div style="text-align: justify;">
<b><br /></b></div>
<div style="text-align: justify;">
<b>References</b>:</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
1. <a href="http://ir.advancedcell.com/press-releases/detail/2604"><b>ACT Announces Positive Results from Two Clinical Trials Published in The Lancet Using Differentiated Stem Cell-Derived Retinal Pigment Epithelium (RPE) Cells for the Treatment of Macular Degeneration</b></a>, ACT Press Release, October 14, 2014</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
2. <a href="http://download.thelancet.com/flatcontentassets/pdfs/S0140673614613763.pdf"><b>Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: follow-up of two open-label phase 1/2 studies</b></a>, Schwartz, SD, Lanza R, et al, <b>The Lancet, Online,</b> October 14, 2014.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Other Resources:</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<a href="http://www.ipscell.com/2014/10/encouraging-new-paper-on-act-stem-cell-based-trial-for-macular-degeneration/"><b>Encouraging New Paper on ACT Stem Cell-Based Trial for Macular Degeneration</b></a>, Paul Knoepfler, <b>Knoepfler Lab Stem Cell Blog</b>, October 14, 2014</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<a href="http://www.npr.org/blogs/health/2014/10/14/346174070/embryonic-stem-cells-restore-vision-in-preliminary-human-test"><b>Embryonic Stem Cells Restore Vision In Preliminary Human Test</b></a>, Rob Stein, <b>NPR Health Blog</b>, October 14, 2014</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Disclosure: As of September 17, 2014, I own a small number of shares of the company’s stock.</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
Irv Aronshttp://www.blogger.com/profile/05719664806219249867noreply@blogger.com0tag:blogger.com,1999:blog-20140933.post-28250668351316095692014-09-26T17:13:00.001-04:002014-09-29T11:53:25.177-04:00Iluvien Update 8: Alimera Sciences Receives FDA Approval of Iluvien for Treatment of DME<div style="text-align: justify;">
After several attempts to gain approval for its NDA for Ilunien, the FDA has finally seen the light (after approval in the UK, Germany, and marketing or pending approvals in seventeen other EU countries).</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
I first began writing about Iluvien in July 2010 – see my comprehensive writeup about the technology behind this and other sustained delivery drug systems – <a href="http://tinyurl.com/Iluvien"><b>Iluvien and the Future of Ophthalmic Drug Delivery Systems</b></a>. In addition I have written about the products progress in seven updates, the latest in August 2012, <a href="http://tinyurl.com/IluvienUpdate7"><b>Iluvien Update 7: Alimera Sciences to Re-File for FDA Approval of Iluvien for Chronic DME</b></a></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Here are the statements from the two companies involved in bringing Iluvien to the market, Alimera Sciences, the marketing arm, and pSivida the licensor of the technology to Alimera:</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Alimera Sciences</b> <a href="http://investor.alimerasciences.com/releasedetail.cfm?ReleaseID=873403">announced</a> that the U.S. Food and Drug Administration (FDA) has approved ILUVIEN for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP). Alimera currently intends to begin selling ILUVIEN in the U.S. in the first quarter of 2015.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
"We are very excited with this news from the FDA and thank the many people who contributed to this outcome and believed in ILUVIEN, including the retinal specialists, clinical site personnel, reading centers, and the many patients and their caregivers for helping us bring this long-term treatment to people in the U.S. with DME," said Dan Myers, president and chief executive officer of Alimera. "The approval of ILUVIEN under this broader label brings a DME treatment to the U.S. that lasts years, not months, after a single injection and greatly expands the addressable market opportunity in the U.S."</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
"The approval of ILUVIEN is wonderful news for the retinal community, as recent studies have indicated that as many as 50 percent of DME patients are not optimally managed with today's standard of care known as anti-VEGF therapies," said Pravin Dugel, M.D., Retinal Consultants of Arizona and clinical associate professor, Doheny Eye Institute, Keck School of Medicine, University of Southern California. "Having a multi-year delivery, low-dose corticosteroid drug will provide an additional treatment option for patients with this disease."</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant approved in the U.S. to treat diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. Each ILUVIEN implant is designed to release submicrogram levels of fluocinolone acetonide (FAc), a corticosteroid, for 36 months. The ILUVIEN approval was based on clinical trial data that showed that at month 24 after receiving the ILUVIEN implant, 28.7 percent of patients (p value .002) experienced an improvement from baseline in their best corrected visual acuity on the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart of 15 letters or more. Patients treated with ILUVIEN experienced a statistically significant improvement in visual acuity compared to the control group by week three of follow up, and maintained a statistically significant advantage over the control through completion of the trial at month 36.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
"As the role of inflammation in DME becomes more clearly understood, the use of a continuous, long-term, low-dose anti-inflammatory, such as ILUVIEN, is an important option for patients who have DME that persists," said Barry Kuppermann, M.D., Ph.D., professor and chief of the Retina Service at University of California, Irvine.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
"As the glaucoma specialist on the FAME Study Data Safety Monitoring Board, I have extensive familiarity with the IOP data related to ILUVIEN," said Richard Parrish, M.D., Professor and Director of the Glaucoma Service at the University of Miami Miller School of Medicine, Bascom Palmer Eye Institute. "I am confident that the benefits of this important treatment for DME will outweigh concerns related to elevated IOP in the indicated patients."</div>
<br />
<div style="text-align: justify;">
And, from pSivida:</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>pSivida</b> <a href="http://investors.psivida.com/releaseDetail.cfm?ReleaseID=873289">today announced</a> that the U.S. Food and Drug Administration (FDA) has approved ILUVIENr for the treatment of diabetic macular edema (DME). It is indicated for patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP). A single injection of the ILUVIEN micro-insert provides sustained treatment of DME for 36 months. Approximately 560,000 people in the U.S. are estimated to have clinically significant DME, the most frequent cause of vision loss in individuals with diabetes and the leading cause of blindness in young and middle-aged adults in developed countries. ILUVIEN is expected to be commercially available in the U.S. in early 2015.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
FDA approval of ILUVIEN entitles pSivida to a $25 million milestone from its licensee Alimera Sciences. pSivida will also be entitled to 20% of the net profits from sales of ILUVIEN in the U.S.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
"FDA approval of ILUVIEN, our third FDA-approved product for retinal disease, provides an important treatment option for DME patients in the U.S., the majority of whose DME, despite anti-VEGF intra-ocular injections as frequently as monthly, is not optimally managed. ILUVIEN's clinical trials showed that ILUVIEN can actually reverse vision loss in many DME patients. Another advantage of ILUVIEN over existing therapies is that a single injection provides sustained therapy for three years," said Paul Ashton, Ph.D., president and chief executive officer of pSivida.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
"The $25 million milestone will help finance our ongoing product development program, including MedidurT for posterior uveitis and TethadurT for the sustained delivery of biologics," added Dr. Ashton. pSivida is independently developing Medidur, an injectable, sustained release micro-insert of the same design and delivering the same drug as ILUVIEN, for the treatment of chronic posterior uveitis, the third largest cause of blindness in the U.S. The Company plans to seek FDA approval of this product on the basis of its ongoing single Phase III clinical trial. Enrollment of this study is expected to be completed by the end of the first quarter of calendar 2015.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
ILUVIEN is already commercially available in the U.K. and Germany, and has received or is pending marketing approval in seventeen other EU countries, for the treatment of patients with the chronic DME insufficiently responsive to available therapies. "We are very pleased that the FDA's approval of ILUVIEN is not limited, as in the EU, to the subset of patients with chronic DME, patients who have failed other therapies, or patients who have had cataract surgery," continued Dr. Ashton.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
ILUVIEN is an injectable micro-insert that provides sustained treatment through continuous delivery of a submicrogram dose of the corticosteroid fluocinolone acetonide for 36 months. Current standard-of-care therapy requires anti-VEGF injections into the eye as frequently as monthly, and studies show that over 50 percent of patients are not optimally managed with this treatment. FDA approval was based on clinical trial data that showed that at month 24, 28.7 percent of patients receiving ILUVIEN experienced an improvement from baseline in their best corrected visual acuity on the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart of 15 letters or more. This improvement in vision was maintained through 36 months, the end of the trials. </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
Irv Aronshttp://www.blogger.com/profile/05719664806219249867noreply@blogger.com0tag:blogger.com,1999:blog-20140933.post-31992731794772424512014-09-15T15:05:00.003-04:002014-09-15T15:05:49.141-04:00Retina Revealed<div style="text-align: justify;">
<i>Over the weekend, I read an excellent account of how the various parts of the retina work. Ben Shaberman, the senior science writer for the <b><a href="http://www.blindness.org/blog/">Eye on the Cure</a> blog</b> (<a href="http://www.blindness.org/"><b>Foundation Fighting Blindness</b></a>), put together an easy to read and understand overview of what the various cell layers of the retina do and how they interact. Since the retina is the focus of most of what I write about, I asked Ben for his permission to reproduce the writeup in this space. Permission was granted and here is what he wrote:</i></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<a href="http://www.blindness.org/blog/index.php/fascinating-facts-about-retinal-cells/"><b>Fascinating Facts About Retinal Cells</b></a></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
By Ben Shaberman, September 8, 2014</div>
<div style="text-align: justify;">
<b>Eye on the Cure - Foundation Fighting Blindness</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Your eyes are not just windows to your soul, but to your health as well. People rarely pay attention to their eyes, until something goes wrong. The eye is a delicate organ, and vision is a complex process involving various components.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Photoreceptors, in particular, get a lot of attention from researchers because they're the main cells in the retina that make vision possible. They convert light into electrical signals, which are sent to the brain and used to construct the images we see. Also, many retinal diseases begin with loss of photoreceptors.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
However, the retina is like a multi-layer cake, with each layer comprised of different types of cells, all playing important roles in retinal health and vision. While preserving and restoring photoreceptors is often job number one for scientists, they also explore ways to protect other retinal cells from deterioration and even harness them to restore vision.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Here's a summary of the major retinal cell types, their functions and their potential roles in future treatments of diseases:</div>
<div style="text-align: justify;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhSZiT8QQtLGvX3EaEDqACxUAHQ4yUthk8oL36Vt76d9qE9OYH0qnhts6rbqVywX9WQnPMXOA7xZAf2wpuLMCgHUhd8-5FbCQl7xXdlbZFfy6Ftnej5nFUzPDjE8_Huwr6Svz3y/s1600/EyeCure-retinal-cells-2.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhSZiT8QQtLGvX3EaEDqACxUAHQ4yUthk8oL36Vt76d9qE9OYH0qnhts6rbqVywX9WQnPMXOA7xZAf2wpuLMCgHUhd8-5FbCQl7xXdlbZFfy6Ftnej5nFUzPDjE8_Huwr6Svz3y/s1600/EyeCure-retinal-cells-2.jpg" height="255" width="320" /></a></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
<b>Choroid</b> - The choroid is a layer of blood vessels that supplies oxygen and nourishment to the retina. Defects in the CHM gene cause choroideremia, a disease characterized by deterioration of the choroid, retinal pigment epithelium (RPE) and photoreceptors. In the wet form of age-related macular degeneration, leaky blood vessels expand from the choroid into the retina – a process called choroidal neovascularization – which causes loss of photoreceptors and central vision.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Retinal pigment epithelium</b> - Also known as the RPE, this is a single layer of cells above the photoreceptors that provides them with essential nutrition and waste removal. In age-related macular degeneration (AMD) and Stargardt disease (SMD), toxic waste products accumulate in the RPE or between the RPE and photoreceptors. Subsequently, the RPE deteriorates, leading to loss of photoreceptors.</div>
<div style="text-align: justify;">
<b><br /></b></div>
<div style="text-align: justify;">
<b>Photoreceptors</b> -These are the retinal cells, known as rods and cones, that initiate the vision process by converting light into electrical signals. Rods provide low-light and peripheral vision. Cones are concentrated in the macula, the central region of the retina, and provide central and color vision. The outer segments of rods and cones are antenna-like projections that absorb light and convert it into electrical signals. Inner segments are the cell bodies where other supportive functions are performed. The adult human retina has approximately 125 million photoreceptors.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Bipolar cells</b> - Their job is to receive electrical information on lighting intensity from photoreceptors and pass it along to other retinal cells. Bipolar cells often survive after photoreceptors are lost to disease. This makes them an attractive target for emerging optogenetic treatments, which are designed to provide light sensitivity and restore vision.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Ganglion cells</b> - Ganglion cells receive input from many different cells in the inner retinal layers and process visual information, including detection of edges, contrast and colors. Ganglion cells extend to form an optic nerve, a million-fiber cable that conveys visual information from the eye to the brain. In people with advanced retinal disease, ganglion cells often survive longer than bipolar cells, making them a potential target for optogenetic therapies. Currently, scientists believe that bipolar cells may provide a more detailed visual experience than ganglion cells when treated with a light-sensing therapy, because they reside in layers of the retina closer to photoreceptors.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Muller glia</b> - Muller cells extend through the retina, like spokes of a wheel, providing structural support and guiding light through the inner retina. They also transport molecules critical to retinal health and vision. Researchers believe Muller cells may even have the capacity to become new photoreceptors, which could lead to restoring vision. The research is still new, but success might someday have a big impact on the vision of people with advanced diseases.</div>
<div style="text-align: justify;">
<b><br /></b></div>
<div style="text-align: justify;">
<b>A final note</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The processing of visual information in the retina-beginning with 125 million photoreceptors and converging on a one-million-fiber optic nerve-remains a subject of intense research. There's still much that scientists don't know about the retinal cells and their roles. For example, little is known about the processing activities of amacrine and horizontal cells, which reside between bipolar and ganglion cells. However, advancing imaging technologies, including adaptive optics and optical coherence tomography, are helping complete the picture.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
For additional information about retinal anatomy and function, please see the <b>Eye on the Cure</b> post <a href="http://www.blindness.org/blog/index.php/appreciating-the-beauty-of-the-retina/"><b>"Appreciating the Beauty of the Retina."</b></a> The University of Utah's <a href="http://webvision.med.utah.edu/"><b>Webvision</b></a> is one of the best online sources for detailed information about the retina. I also want to thank John Flannery, Ph.D., at the University of California, Berkeley, for his editorial input.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
Irv Aronshttp://www.blogger.com/profile/05719664806219249867noreply@blogger.com0tag:blogger.com,1999:blog-20140933.post-79660371580248237032014-09-13T15:37:00.002-04:002014-09-13T15:37:47.926-04:00Stem Cells in Ophthalmology Update 26: First Wet AMD Patient Treated With RPE Derived from iPS Cells<div style="text-align: justify;">
Earlier this week, <a href="http://www.nature.com/news/next-generation-stem-cells-cleared-for-human-trial-1.15897"><u>it was reported</u></a> that Masayo Takahashi, an ophthalmologist at the RIKEN Center for Developmental Biology (CDB) in Kobe had appeared in front of a 19-member health-ministry committee for the safety of the clinical use of stem cells. She was flanked by Shinya Yamanaka, the biologist who first created iPS cells. Yamanaka shared the 2012 Nobel Prize in Physiology or Medicine for his breakthrough and now heads the Center for iPS Cell Research and Application in Kyoto. Takahashi was seeking approval to implant a retinal pigmented epithelial (RPE) sheet made from induced pluripotent stem (iPS) cells into a human patient.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Takahashi and her collaborators had shown in monkey and mice studies that iPS cells generated from the recipients' own cells did not provoke an immune reaction that causes them to be rejected. There had been concerns that iPS cells could cause tumours, but Takahashi's team found that to be unlikely in mice and monkeys.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
To counter further fears that the process of producing iPS cells could cause dangerous mutations, Takahashi's team had performed additional tests of genetic stability. Guidelines covering the clinical use of stem cells require researchers to report safety testing on the cells before conducting transplants. The health ministry said that no problems were found and that the human trial could commence.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Only four days later (Friday, September 12th), <a href="http://www.nature.com/news/japanese-woman-is-first-recipient-of-next-generation-stem-cells-1.15915"><u>the first patient was treated</u></a> with the implanted sheet of RPE cells. She derived them from the patient's skin cells, after producing induced pluripotent stem (iPS) cells and then getting them to differentiate into retinal cells.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
This is a major first for the stem cell and regenerative medicine fields.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Takahashi and her collaborators have been using induced pluripotent stem (iPS) cells to prepare a treatment for age-related macular degeneration. Unlike RPE derived from embryonic stem cells (i.e., as being done by Advanced Cell Technology), iPS cells are produced from adult cells, so they can be genetically tailored to each recipient. They are capable of becoming any cell type in the body, and have the potential to treat a wide range of diseases. The CDB trial will be the first opportunity for the technology to prove its clinical value.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
A Japanese woman in her 70s is the world's first recipient of cells derived from induced pluripotent stem cells, a technology that has created great expectations since it could offer the same advantages as embryo-derived cells but without some of the controversial aspects and safety concerns.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
In a two-hour procedure starting at 14:20 local time, a team of three eye specialists lead by Yasuo Kurimoto of the Kobe City Medical Center General Hospital, transplanted a 1.3 by 3.0 millimeter sheet of retinal pigment epithelium cells into an eye of the Hyogo prefecture resident, who suffers from age-related macular degeneration.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The procedure took place at the Institute of Biomedical Research and Innovation Hospital, next to the RIKEN Center for Developmental Biology (CDB) where ophthalmologist Masayo Takahashi had developed and tested the epithelium sheets.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Afterwards, the patient experienced no effusive bleeding or other serious problems, as reported by RIKEN.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Another important element to this story is that Japan has a clinical translation pipeline that is now faster with recent changes in regulations than that of the US. For example, this and future iPS cell-based transplants were approved as part of a clinical study, a type of clinical research mechanism that doesn't exist in the US. It is safe to say that the same technology with the same research team and outstanding level of funding would still be at least a few years away from their first patient in the US due to the different regulatory scheme.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
As noted by Dr. Paul Knoepfler, <a href="http://www.ipscell.com/2014/09/stem-cell-landmark-patient-receives-first-ever-ips-cell-based-transplant/"><u>in his writeup about the procedure</u></a>:</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
“The patient is clearly a brave hero. The team transplanted a huge (from a bioengineering perspective) 1.3 x 3.0 mm sheet of RPEs into the retina of the patient, who did not have any clear immediate side effects from the procedure. Keep in mind again that this sheet was made indirectly from the patients own skin cells so it is an autologous (or self) transplant, a notion that 10 years ago would have seemed entirely like sci-fi.”</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
“This is not only a huge milestone, but also an astonishingly fast translation of iPS cell technology from the bench to the bedside.”</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
“Also, on the positive side we have the encouraging results from the ongoing clinical trials from Advanced Cell Technology (ACT) using a similar approach to macular degeneration, but employing human embryonic stem cells to make the RPEs.”</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
“For the vision impaired and the broader stem cell field, it is heartening to have two such capable teams working to cure blindness with pluripotent stem cells.”</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b><br /></b></div>
<div style="text-align: justify;">
<b>Sources:</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
1.<a href="http://www.nature.com/news/next-generation-stem-cells-cleared-for-human-trial-1.15897"><b>Next-generation stem cells cleared for human trial: Japanese team will use 'iPS' cells to treat patient with degenerative eye disease</b></a>, <b>Nature</b>, David Cyranoski, September 10, 2014.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
2. <a href="http://www.nature.com/news/japanese-woman-is-first-recipient-of-next-generation-stem-cells-1.15915"><b>Japanese woman is first recipient of next-generation stem cells: Surgeons implanted retinal tissue created after reverting the patient's own cells to 'pluripotent' state</b></a>, <b>Nature</b>, David Cyranoski, September 12, 2014.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
3. <a href="http://www.ipscell.com/2014/09/stem-cell-landmark-patient-receives-first-ever-ips-cell-based-transplant/"><b>Stem cell landmark: patient receives first ever iPS cell-based transplant</b></a>, <b>Knoepfler Lab Stem Cell Blog</b>, Paul Knoepfler, Septermber 12, 2014.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
Irv Aronshttp://www.blogger.com/profile/05719664806219249867noreply@blogger.com0tag:blogger.com,1999:blog-20140933.post-22719313847474800622014-08-21T16:44:00.004-04:002014-08-21T16:44:44.029-04:00A Potential New Approach to the Treatment of Retinitis Pigmentosa<div style="text-align: justify;">
<i>In a recently published study (1), researchers at the Columbia University Medical Center (CUMC) have come up with a novel approach in developing an individualized treatment for RP patients, using the patients' own cells transformed into an in vitro model for studying the disease and developing a potential treatment.</i></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<i>While RP can begin during infancy, the first symptoms typically emerge in early adulthood, starting with night blindness. As the disease progresses, affected individuals lose peripheral vision. In later stages, RP destroys photoreceptors in the macula, which is responsible for fine central vision. RP is estimated to affect at least 75,000 people in the United States and 1.5 million worldwide.</i></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<i>Mark Hillen, editor of <b>The Ophthalmologist</b> has written about this new approach, and I have reproduced the writeup, with his permission.</i></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<a href="https://theophthalmologist.com/issues/0714/the-retina-renewed-thanks-to-your-own-skin-cells/"><b>The Retina, Renewed. Thanks to Your Own Skin Cells</b></a></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Might you soon take a skin cell from a patient with retinitis pigmentosa, roll it back to a pluripotent state, culture it to become retinal cells and trial gene therapy on it in vitro?</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
By Mark Hillen</div>
<div style="text-align: justify;">
<b>The Ophthalmologist</b>, July/August 2014</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Personalized medicine is a particularly hot topic in medicine. Take cells from a patient, modify or grow them, and return them to the patient for their therapeutic effects. What a team of Manhattan-based researchers are doing at the Columbia University Medical Center (CUMC) is something rather special. They take skin epithelial cells from patients with retinitis pigmentosa (RP), turn them into induced pluripotent stem (iPS) cells, then differentiate them into retinal cells in cell culture, enabling them to examine what the structural and functional defects of these retinal cells really are - without having to perform a dangerous (and ethically dubious) excision of a section of a patient's retina to do so (1).</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
More than 60 different genes have been linked to RP, making it a challenge to go to a mouse model to study the disease. Making a genetically-modified mouse is time consuming enough, but there's the additional confounding factor that the retinae of mice and men have enough interspecies differences to induce a great depression in researchers. This is why the ability to study the patient's own retinal cells in culture is so valuable.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Using this approach, the CUMC researchers examined cells from a patient with RP that resulted from a mutation in the MFRP (membrane frizzled-related protein) gene. Analysis of these cells showed that the primary effect of MFRP mutation is to disrupt the regulation of the major cytoskeletal protein, actin (Figure 1). "Normally, the cytoskeleton looks like a series of connected hexagons," said lead researcher, Stephen Tsang. "If a cell loses this structure, it loses its ability to function."</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
In the next phase of the study, the CUMC team used adeno-associated viruses to introduce normal copies of MFRP into the iPS-derived retinal cells (in cell culture), successfully restoring the cells' function. The team went on to successfully use gene therapy to rescue the "normal" phenotype in mice with MFRP mutation-induced RP.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Does this herald a future of personalized medicine, where patients can have their retinae reproduced from skin cells, their disease state assessed, and potential gene therapy options trialled, all in vitro, in order to choose the most effective gene therapeutic option? Tsang believes so, concluding that, "The use of patient-specific cell lines for testing the efficacy of gene therapy to precisely correct a patient's genetic deficiency provides yet another tool for advancing the field of personalized medicine. iPS cells can help us determine whether these genes do, in fact, cause RP, understand their function, and, ultimately, develop personalized treatments."</div>
<br />
<br />
<br />
<br />
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhwgFgQwT_SchTUVSYTXEEZpkBKfWKMDbN-6zl829ygqN3NFA4w1bznGaqrdKlvGICJj1wpv4duV4CMxIch7zU6kwoqJ5CAxjLhx1fvB_OSLKO274NWWB0SQwRr9N234GZe7U52/s1600/0714-202-fig.1.png" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhwgFgQwT_SchTUVSYTXEEZpkBKfWKMDbN-6zl829ygqN3NFA4w1bznGaqrdKlvGICJj1wpv4duV4CMxIch7zU6kwoqJ5CAxjLhx1fvB_OSLKO274NWWB0SQwRr9N234GZe7U52/s1600/0714-202-fig.1.png" height="114" width="400" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><b>Figure 1. a. Normal (wild-type) retinal cells: the protein actin forms the cell's cytoskeleton, creating an internal support structure that looks like a series of connected hexagons; b. This structure fails to form in cells with MFRP mutations, compromising cellular function; c. Diseased retinal cells, when treated with gene therapy to insert normal copies of MFRP, have normal-looking cytoskeletal structures and function.</b></td></tr>
</tbody></table>
<br />
<br />
<b>Reference</b><br />
<br />
1. Y. Li, W.-H. Wu, C.-W. Hsu, et al.,<a href="http://www.nature.com/mt/journal/vaop/ncurrent/abs/mt2014100a.html"><b> "Gene Therapy in Patient-specific Stem Cell Lines and a Preclinical Model of Retinitis Pigmentosa With Membrane Frizzled-related Protein Defects"</b></a>, Mol. Ther. Epub ahead of print (2014). doi:10.1038/mt.2014.100.<br />
<br />Irv Aronshttp://www.blogger.com/profile/05719664806219249867noreply@blogger.com0tag:blogger.com,1999:blog-20140933.post-68476458928798852612014-05-25T15:30:00.000-04:002014-05-26T16:23:15.486-04:00Menu 21: A List of Writeups on Gene Therapy Used in Ophthalmology<div style="text-align: justify;">
As with my menu on stem cells used in ophthalmology (<a href="http://tinyurl.com/blogmenu20"><b>Menu 20</b></a>), here is one for the current articles on the use of gene therapy in ophthalmology, with links to the full writeups.</div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
<br />
<b>(Updated May 25, 2014) </b></div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Gene Thearpy</b></div>
<div style="text-align: justify;">
<b><br />
</b></div>
<div style="text-align: justify;">
<a href="http://tinyurl.com/GeneTherapy-RP-AMD"><b>The Use of Gene Therapy in Treating Retinitis Pigmentosa and Dry AMD</b></a><b> </b>Nov. 2010<br />
<br /></div>
<div style="text-align: justify;">
After several discussions with Sean Ainsworth, the founder of RetroSense, and much online research, I think I have learned a little about what gene therapy is about, and its application in ophthalmology, especially in the possible restoration of vision in those who suffer from retinitis pigmentosa (RP). Thanks to Sean for whetting my appetite -- here is what I have learned.</div>
<br />
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<a href="http://tinyurl.com/genetherapyUpdate1"><b>Gene Therapy Update 1: First Clinical Trial for a Form of Retinitis Pigmentosa (RP) Approved to Begin</b></a><b> </b>Oct. 2010</div>
<div style="text-align: justify;">
<br />
In an announcement today, Oxford BioMedica said that it had gained approval from the FDA to begin a Phase I/IIa Clinical Trial for a form of Usher’s Syndrome, Type 1B, which leads to progressive retinitis pigmentosa combined with a congenital hearing defect. </div>
<br />
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
<a href="http://tinyurl.com/genetherapy-Update2"><b>Gene Therapy in Ophthalmology Update 2: Foundation Fighting Blindness Funds Six New Gene Therapy Projects </b></a><b></b> Oct. 2010<br />
<br /></div>
<div style="text-align: justify;">
In a news release that I found on the net, I learned that the Foundation Fighting Blindness was going to put $8.25 million into six gene therapy projects, either already underway or about to start. The release contains good information about several projects that I knew about, and others that I did not.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
<a href="http://www.blogger.com/%20http://tinyurl.com/genetherapy-Update3"><b>Gene Therapy in Ophthalmology Update 3: Genetic Testing of RP Patients Necessary in Order to Direct Treatment </b></a>Nov. 2011</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
In another of the presentations made during the Retina SubSpecialty Day Meeting, Dr. Stephen Tsang presented on factors and the genetics of retinitis pigmentosa. His paper was based on the article previously published by he and his co-author, Kyle Wolpert, that appeared in the November 2010 issue of Retinal Physician.</div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Gene Therapy in Ophthalmology Update 4: Table of Companies and Institutions Participating </b>Nov. 2011</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Again, this table is currently out-of-date. See Update 16.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
<a href="http://www.blogger.com/%20http://tinyurl.com/genetherapy-Update5"><b>Gene Therapy in Ophthalmology Update 5: A Complement-Based Gene Therapy for AMD</b></a> Dec. 2011<br />
<br /></div>
<div style="text-align: justify;">
A writeup about a start-up company, Hemera Biosciences, with a gene therapy approach to treating dry AMD.</div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
<a href="http://tinyurl.com/genetherapy-Update6"><b>Gene Therapy in Ophthalmology Update 6: First-Ever Clinical Trial for the Autosomal Recessive Form of Retinitis Pigmentosa (arRP) is Underway</b></a><b> </b>Dec. 2011<br />
<br /></div>
<div style="text-align: justify;">
Thanks to my friends at the Foundation Fighting Blindness, I learned about this first human clinical trial using gene therapy for treating recessive retinitis pigmentosa.</div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<a href="http://tinyurl.com/genetherapy-Update7"><b>Gene Therapy in Ophthalmology Update 7: 2012 the Year for Gene Therapy?</b></a> Jan. 2012<br />
<br /></div>
<div style="text-align: justify;">
In this opus, I discuss my reasons why I think 2012 is going to be the year for gene therapy and also presented my table of current clinical trials underway. (Again, note there is now an updated table available via Update 16.)</div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
<br />
<br /></div>
<div style="text-align: justify;">
<a href="http://tinyurl.com/genetherapy-Update8"><b>Gene Therapy in Ophthalmology Update 8: Promising Results in the Treatment of Leber’s Congenital Amaurosis (LCA) </b></a><b></b>Jan. 2012<br />
<br /></div>
<div style="text-align: justify;">
A report on the progress being made in treating Leber’s using gene therapy, as reported by the Foundation Fighting Blindness.</div>
<br />
<br />
<a href="http://tinyurl.com/genetherapyUpdate9"><b>Gene Therapy in Ophthalmology Update 9: Oxford BioMedica/OHSU Preparing to Treat First Usher Syndrome Patient & Oxford BioMedica Ophthalmic Program Update </b></a><b></b>Mar. 2012<br />
<br />
A report on the start of the program to treat Usher Syndrome patients at OSHU, and an update on other ophthalmic programs underway by Oxford BioMedica.<br />
<br />
<br />
<a href="http://tinyurl.com/genetherapyUpdate10"><b>Gene Therapy in Ophthalmology Update 10: Gene Therapy Research in Dogs Cures X-Linked Retinitis Pigmentosa – Paves the Way for Similar Treatment in Humans </b></a><b></b>Mar. 2012<br />
<br />
Researchers at several universities and laboratories collaborated to treat dogs afflicted with the x-linked form of retinitis pigmentosa, to deliver the therapeutic RPGR gene specifically to the diseased rods and cones, which led to functional and structural recovery. This is the first proof that this condition is treatable in an animal model and the researchers feel the results are promising and relevant for translation to humans afflicted with this disease.<br />
<br />
<br />
<b>Gene Therapy in Ophthalmology Update 11: Clinical Trial Details </b>May 2012<br />
<br />
In attempting to determine how many patients had been treated with gene therapy for eye disorders, I quickly found that no one was keeping track – at least no one that I could find.<br />
<br />
So, I decided to try and get this data. I have now found reliable data for more than two-thirds of the 16 clinical trials underway and present this information in my new table. My latest table (available via Update 16) contains all of the newest data.<br />
<br />
<b>Editors Note: See Update 16 for access to the latest versions of the three tables. </b><br />
<br />
<br />
<a href="http://tinyurl.com/GeneTherapy12"><b>Gene Therapy in Ophthalmology Update 12: First Gene Therapy Approval on the Horizon </b></a>Jul. 2012<br />
<br />
As Andrew Pollack writes in today’s NYTimes, “After more than two decades of dashed expectations, the field of gene therapy appears close to reaching a milestone: a regulatory approval. The European Medicines Agency has recommended approval of a gene therapy to treat a rare genetic disease.”<br />
<br />
The therapy recommended for approval in Europe, called Glybera, was developed by uniQure, a Dutch company. It treats lipoprotein lipase deficiency, a disease that affects only several hundred people in the European Union and a similar number in North America.<br />
<br />
People with the disease have a genetic mutation that prevents them from producing an enzyme needed to break down certain fat-carrying particles that circulate in the bloodstream after meals. Without the enzyme, so much fat can accumulate that the blood looks white rather than red.<br />
<br />
<b>The reason I believe that this is important is because it brings “legitimacy” to the whole field of regenerative medicine. As readers of this online Journal are aware, my interest is in the field of ophthalmology. As you may be further aware, I am currently tracking eleven clinical trials involving the use of stem cells to treat ophthalmic disorders and sixteen gene therapy clinical trials. Several of these are showing promising results and the above approval, when it comes, will bring increased attention to the whole of this field, including the ophthalmic trials.</b><br />
<br />
<a href="http://tinyurl.com/GeneTherapy13"><b>Gene Therapy in Ophthalmology Update 13: New Clinical Site for Usher Syndrome Clinical Trials </b></a>Jul. 2012<br />
<br />
The Foundation Fighting Blindness and Oxford BioMedica announced funding for a second clinical site to conduct a gene therapy trial for Ushers Syndrome. The site will be the Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts in Paris, and will join the ongoing clinical trial being held at the Oregon Health & Science University's Casey Eye Institute.<br />
<br />
<a href="http://tinyurl.com/GeneTherapyUpdate14"><b>Gene Therapy in Ophthalmology Update 14: Early Positive Results in Ongoing Gene Therapy Wet AMD and Stargardt’s Disease Studies </b></a>Aug. 2012<br />
<br />
Last week, Oxford BioMedica and its partner Sanofi announced positive results in their ongoing gene therapy clinical trials for wet AMD and Stargardt’s disease. In an interim review of their Phase I (RetinoStat) and Phase I/IIa (StarGen) trials, the Data Safetly Monitoring Board (DSMB), an independent panel of specialists in the fields of ophthalmology, virology and vectorology, gave the go ahead to proceed to a final patient cohort in the Phase I study in the case of the RetinoStat trial, and to a third patient cohort in the Phase I/IIa study of the StarGen trial.<br />
<br />
<div style="text-align: justify;">
<a href="http://tinyurl.com/GeneTherapy15"><b>Gene Therapy in Ophthalmology Update 15: First Gene Therapy Treatment Approved! </b></a>Nov. 2012<br />
<br />
As I first wrote back in July (<a href="http://tinyurl.com/GeneTherapy12"><b>Update 12: First Gene Therapy Approval on the Horizon</b></a>), the first approval of a gene therapy application in medicine was expected soon. It has now been accomplished. On November 2nd, the European Medicines Agency gave final approval to a gene therapy approach to treat a rare genetic disease.<br />
<br />
The therapy, given approval in Europe, called Glybera, was developed by uniQure, a Dutch company. It treats lipoprotein lipase deficiency (LPLD), a disease that affects only several hundred people in the European Union and a similar number in North America. <br />
<br />
The reason I am noting this accomplishment in this space, where I normally write about treatments for ocular diseases is, <b>because it brings “legitimacy” to the whole field of regenerative medicine. As readers of this online Journal are aware, my interest is in the field of ophthalmology. As you may be further aware, I am currently tracking twenty one clinical trials involving the use of stem cells (or cell threapy) to treat ophthalmic disorders and sixteen gene therapy clinical trials. Several of these are showing promising results and the above approval will bring increased attention to the whole of this field, including the ophthalmic trials.</b><br />
<br />
<br />
<a href="http://tinyurl.com/GeneTherapyTbls"><b>Gene Therapy in Ophthalmology Update 16: Current Tables Now Online </b></a>Jan. 2013/May 2014 <br />
<br />
Access to the three updated tables of information about the companies and institutions active in gene therapy, the ophthalmic applications being pursued, and the clinical trials underway and completed.<br />
<br />
<br />
<a href="http://tinyurl.com/GeneTherapy17"><b>Gene Therapy in Ophthalmology Update 17: Hemera Biosciences Obtains Initial Funding </b></a>Mar. 2013<br />
<br />
Hemera biosciences has obtained initial funding, along with the issuance of a US Patent covering their technology and can now begin manufacturing its drug, soluble CD59 (protectin), perform animal toxicology, and initiate a phase 1 clinical study.<br />
<br />
To review, HMR59 is a gene therapy using an AAV2 vector to express a soluble form of a naturally occurring membrane bound protein called CD59 (sCD59), which blocks MAC. Membrane attack complex is the final common pathway of activation of the complement cascade, and is composed of complement factors C5b, C6, C7, C8 and C9 that assemble as a pore on cell membranes. The MAC pore induces ionic fluid shifts leading to cell destruction and ultimate death. <br />
<br />
HMR59 works by increasing the production of sCD59 by ocular cells. The sCD59 released from the cells will circulate throughout the eye and penetrate the retina to block MAC deposition and prevent cellular destruction. By blocking MAC, the remainder of the upstream complement cascade is left intact to perform its normal homeostatic roles. <br />
<br />
<br />
<a href="http://tinyurl.com/GeneTherapy18"><b>Gene Therapy in Ophthalmology Update 18: A RetroSense Update </b></a>Mar. 2013<br />
<br />
Since I first wrote about RetroSense in November 2010, I have learned that they are using a unique technology, called Optogenetic Therapy to treat retinitis pigmentosa and dry AMD. Optogenetics combines gene therapy and optical methods to provide vision where there is none.<br />
<br />
The gene therapy allows the delivery of an “opsin” that converts second- or third-order non-light sensitive cells to become light sensitive to mimic the function of rods and cones.<br />
<br />
<br />
<a href="http://tinyurl.com/GeneTherapy19"><b>Gene Therapy in Ophthalmology Update 19: A New Virus Vector for Safer Delivery of Gene Therapies </b></a>Jun. 2013<br />
<br />
Researchers at UCal Berkeley have found a gene therapy vector that can deliver genes deep into the retina via intravitreous delivery, instead of using a needle to deliver the virus sub-retinally.<br />
<br />
This eliminates the need for a vitrectomy, anesthesia and a hospital stay to treat patients, allowing for a simple short office visit and injection into the vitreous, similar to the way anti-VEGF drugs for age-related macular degeneration are currently delivered.<br />
<br />
<br />
<a href="http://tinyurl.com/GeneTherapy20"><b>Gene Therapy in Ophthalmology Update 20: Oxford BioMedica Gene Therapy Clinical Trials Resume </b></a>Oct. 2013<br />
<br />
As I have recently noted, both Oxford BioMedica and Genzyme had stopped recruiting for their respective gene therapy clinical trials this summer. Oxford announced the reason for its stoppage, but no word from Genzyme (and no response to my attempts to find out).<br />
<br />
Well, Oxford announced today that it had resumed its clinical trial after receiving clearances from both the FDA and the French regulatory agency, ANSM. <br />
<br />
<br />
<a href="http://tinyurl.com/GeneTherapy21"><b>Gene Therapy in Ophthalmology Update 21: New Gene Therapy Company, Spark Therapeutics, Launches </b></a>Oct. 2013<br />
<br />
Children’s Hospital of Philadelphia has spun out a new gene therapy company, Spark Therapeutics, that has taken over CHOP’s gene therapy programs. The new company takes over the advanced clinical trial for treating Leber’s Congenital Amaurosis, as well as an earlier stage trial for treating hemophilia B.<br />
<br />
The Phase III clinical trial for Leber’s, is expected to be completed in mid-2015, and could become the first FDA-approved gene therapy treatment in the U.S.<br />
<br />
<br /></div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
<b>Miscellaneous</b></div>
<div style="text-align: justify;">
<b><br />
</b></div>
<div style="text-align: justify;">
<a href="http://tinyurl.com/GeneTherapyTrevor"><b>A Golden Retriever Named Trevor and Retinitis Pigmentosa</b></a><b> </b>Apr. 2011<br />
<br /></div>
<div style="text-align: justify;">
Recently, I encountered a unique referral source, goldenretrevor/pra-research. This piqued my curiosity and I went to the site and took a look. It turns out that the site is run by the owner of a Golden Retriever, named Trevor, along with two Labrador Retriever siblings. It seems that Trevor had been diagnosed with photo receptor cone disease (prcd), associated with progressive retinal atrophy (PRA). This was discovered when the dog was a puppy and the owner decided to look into this disease to see if there was anything that could be done to prevent him from going blind.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
In doing extensive research, the owner, Katie McCormick, discovered that there was little research being done in the field of PRA in animals, but that PRA is genetically similar to retinitis pigmentosa (RP) in humans, as one study noted, "Identical mutation in a novel retinal gene causes progressive rod-cone degeneration (prcd) in dogs, and retinitis pigmentosa in man." And, there was lots of research being done on RP.</div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
In her blog entry on PRA Research, Katie describes how she set up a “Google Alert” using the terms “progressive retinal atrophy” and “retinitis pigmentosa” – which is how she found my Journal article on The Use of Gene Therapy in Treating RP and Dry AMD.<br />
<br />
<br />
<a href="http://tinyurl.com/avalanchebiotech"><b>A Novel Gene Therapy Approach to Treating the Wet Form of AMD: The BioFactoryTM From Avalanche Biotech </b></a><b></b>Feb. 2012<br />
<br />
I originally contacted this company in November 2010, when they were still in “stealth mode” and weren't able to share details about what they were doing. Recently, the company got back in touch to provide an update, having announced, in December 2011, a clinical trial of their gene therapy approach to treating the wet form of AMD.<br />
<br />
Since their approach is unique, and possibly “game changing” for the treatment of the wet form of AMD, I asked if I could prepare a writeup about the company and its technology for publication in my online Journal, and the co-founder and CEO Tom Chalberg agreed to answer my questions, as best as he could. So, here in their own words is what Avalanche Biotech is all about.<br />
<br />
<br />
<a href="http://tinyurl.com/AvalancheBiotech2"><b>An Update on Avalanche Biotechnologies: A Potential Longer-Lasting Wet AMD Treatment? </b></a>May 2014<br />
<b> </b><br />
With the news of a collaboration between Avalanche and Regeneron, we decided to update our initial report on Avalanche to describe what the collaboration is all about, as well as a brief update of the clinical trial underway using Avalanche’s Ocular BioFactory. Could this approach to treating wet AMD lead to fewer injections – once every 18 months or several years – in controlling this sight-robbing disease?<br />
<br />
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
<br /></div>
Irv Aronshttp://www.blogger.com/profile/05719664806219249867noreply@blogger.com0tag:blogger.com,1999:blog-20140933.post-35934862185310961492014-05-08T18:03:00.000-04:002014-05-08T18:03:08.438-04:00An Update on Avalanche Biotechnologies: A Potential Longer-Lasting Wet AMD Treatment?<div style="text-align: justify;">
There is breaking news this week about Avalanche Biotechnologies and I would like to share it, as well as a brief update on the clinical trial underway using their proprietary gene therapy approach to treating the wet form of AMD.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<i>(Editors Note: For a comprehensive look at the company, its people, and technology, please take a look at my original writeup, placed online in late February 2012: <a href="http://tinyurl.com/avalanchebiotech"><b>A Novel Gene Therapy Approach to Treating the Wet Form of AMD: The BioFactory<span style="font-size: x-small;">TM</span> From Avalanche Biotech</b></a>.)</i></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Now for the breaking news. On May 5th, <a href="http://investor.regeneron.com/releaseDetail.cfm?ReleaseID=845170">in a joint announcement</a>, Avalanche and Regeneron Pharmaceuticals said that they were undertaking a broad collaboration “to discover, develop and commercialize novel gene therapy products for the treatment of ophthalmic diseases. The collaboration covers novel gene therapy vectors and proprietary molecules, discovered jointly by Avalanche and Regeneron, and developed using the Avalanche Ocular BioFactory<span style="font-size: x-small;">TM</span>, an adeno-associated virus (AAV)-based, proprietary, next-generation platform for the discovery and development and delivery of gene therapy vectors for ophthalmology.”</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Under the terms of the agreement, Avalanche will receive an upfront cash payment, contingent payments of up to $640 million upon achievement of certain development and regulatory milestones, plus a royalty on worldwide net sales of collaboration products. The collaboration covers up to eight distinct therapeutic targets, and Regeneron will have exclusive worldwide rights for each product it moves forward in clinical development. In addition, Avalanche has the option to share in development costs and profits for products directed toward two collaboration therapeutic targets selected by Avalanche. </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
As part of the agreement, Regeneron has a time-limited right of first negotiation for certain rights to AVA-101, Avalanche's gene therapy product targeting vascular endothelial growth factor (VEGF) currently under development for the treatment of wet age-related macular degeneration (AMD), upon completion of the ongoing Phase 2a trial. </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
"We look forward to the opportunity to collaborate with Avalanche, a leader in the field of next-generation gene therapy technologies," said George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer of Regeneron and President of Regeneron Laboratories. "This collaboration highlights the commitment by Regeneron to invest in potentially breakthrough therapies that could benefit patients with sight-threatening diseases."</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
"We are excited to work with Regeneron to discover and develop novel gene therapy medicines for serious eye diseases," said Thomas W. Chalberg, Ph.D., co-founder and Chief Executive Officer of Avalanche Biotechnologies. "The collaboration will bring together Avalanche's novel platform technology with Regeneron's proprietary molecules and research capabilities, with the goal of creating a new class of next-generation biologics in ophthalmology. Regeneron is a terrific partner for their scientific leadership, as well as their product development capabilities and commercialization track-record."</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
For those of you not familiar with Regeneron Pharmaceuticals, they are a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition, and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma, and atopic dermatitis. </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
In the eye disease field, their major product is Eylea, an anti-vascular endothelial growth factor (VEGF) agent that is intravitrealy injected for the treatment of wet AMD, in competition with Roche/Genentech's Avastin, and Lucentis.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The problem with the use of the current anti-VEGF drugs is the need for up to eight to twelve injections yearly, to maintain the gains in visual acuity and/or prevent the re-occurrence of the underlying neovascular degeneration. The reason for the collaboration with Avalanche is that its BioFactoryTM is expected to deliver a therapeutic protein to combat wet AMD for at least 18 months and, potentially for several years, from a single injection. (For more about this technology, again, please see my<a href="http://tinyurl.com/avalanchebiotech"> initial writeup</a>.)</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
And that leads to the recent clinical trial update provided by founder and CEO, Thomas Chalberg at the the <b>Angeogenisis, Exudation and Degeneration 2014 Conference</b>, held in Miami, FL on February 8, 2014:</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<a href="http://www.bmctoday.net/retinatoday/2014/04/article.asp?f=ocular-gene-therapy-showed-fewer-injections-needed-increased-visual-gain"><b>Ocular Gene Therapy Showed Fewer Injections Needed, Increased Visual Gain</b></a></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Retina Today</b>, April 2014</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<i>Subretinal delivery of an ocular gene therapy drug was well tolerated, required fewer injections of anti-VEGF, and improved visual acuity in a phase 1 randomized clinical trial, reported Thomas W. Chalberg, PhD, at <b>Angiogenesis, Exudation, and Degeneration 2014</b>.(1)</i></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
One hundred microliters of AVA-101 (Ocular BioFactoryTM, Avalanche Biotechnologies) was injected subretinally in patients. Anti-VEGF protein levels ramp-up over 6 to 8 weeks, during which 2 injections of ranibizumab (Lucentis) were given. After 8 weeks, ranibizumab was only given to the treatment group on a prn basis as rescue therapy.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Patients were tracked for 12 months after injection and came in for monthly visits. The control group, which did not receive an injection of AVA-101, required a mean 3 injections of ranibizumab during the 12-month period. The treatment group required a mean 0.3 ranibizumab injections over the same period.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Patients received ranibizumab injections if fluid appeared on OCT or fluorescein angiography, or if there was vision loss attributable to increased area of choroidal neovascularization.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Patients in the study had experience with anti-VEGF treatment, averaging 18 intravitreal anti-VEGF treatments prior to study enrollment.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
“Because these patients are coming heavily pre-treated, we didn’t necessarily expect them to gain additional vision,” Dr. Chalberg said. “But treated patients actually gained between 9 and 12 letters over 12 months.”</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Dr. Chalberg reported no drug-related adverse events, retinal tears, or retinal detachments. Procedure-related adverse events were minor and self-resolving.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
“Ocular gene therapy might be a long-term viable option for patients with wet AMD,” Dr. Chalberg said.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
AVA-101 is a strand of therapeutic DNA packaged inside an adeno-associated virus (AAV), which, when injected subretinally, up-regulates the body’s production of anti-VEGF. Subretinal injection appeared to be safe and was well tolerated, Dr. Chalberg reported, and allowed AVA-101 injections to better stimulate anti-VEGF production than if delivered intravitrealy.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Dr. Chalberg reported that an on-going phase 2A study currently has 40 patients enrolled.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Reference:</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
1. Chalberg TW. <b>Anti-VEGF gene therapy: early clinical results using the Ocular BioFactory<span style="font-size: x-small;">TM</span> in wet AMD</b>. Paper presented at: <b>Angiogenesis, Exudation, and Degeneration 2014</b>; February 8, 2014; Miami, FL.</div>
<br />Irv Aronshttp://www.blogger.com/profile/05719664806219249867noreply@blogger.com0tag:blogger.com,1999:blog-20140933.post-32706081917126834882014-04-10T18:06:00.000-04:002014-04-14T16:39:07.704-04:00A New Approach for Repairing/Rejuvenating Damaged Photoreceptors and Other Retinal Tissue for Restoring Vision<div style="text-align: justify;">
<i>Over the past several years, I have written about new technologies for treating retinal diseases, including the use of drugs (Avastin, Lucentis and Eylea for wet AMD), laser treatment (Ellex’s 2RT - Retinal Regeneration, for dry AMD), and the use of stem cells and gene therapy for a wide range of ophthalmic diseases.</i></div>
<div style="text-align: justify;">
<i><br /></i></div>
<div style="text-align: justify;">
<i>Earlier this year, I became aware of a new company, jCyte, who was investigating the use of retinal progenitor cells to replace damaged or destroyed photoreceptors to restore vision to those whose photorecptors had stopped working, especially in those with the latter stages of retinitis pigmentosa (RP). I was aware that Advanced Cell Technology was also in the early stages of doing research with retinal progenitor cells. I decided the best way of learning about this unique approach to restoring photoreceptor activity (and perhaps, vision) to those afflicted with RP and other retinal degenerative diseases, was to undertake some research and write about it.</i></div>
<div style="text-align: justify;">
<i><br /></i></div>
<div style="text-align: justify;">
<i>In doing the background research, I discovered that two other companies, ReNeuron and California Stem Cell, are also involved in this area of technology. Here is what I have learned to date.</i></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Introduction</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
In order to learn about jCyte, I contacted Dr. Henry Klassen, it’s founder and Associate Professor of the Gavin Herbert Eye Institute and its Stem Cell Research Center at the University of California, Irvine (UCI), and learned about his new company and about how its program to restore vision to those with RP will evolve.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
In doing additional background research, I quickly discovered that ReNeuron, a UK biotechnology company, was also working towards that same goal and, in fact, was working with Dr. Michael Young of Schepens Eye Research Instititute who, it turned out, was a past co-author with Dr. Klassen’s in working on pre-clinical animal studies in this field.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
In this writeup, I intend to tell you what retinal progenitor cells are, what they can do, and why this might be an important technique for restoring vision in those with damaged or destroyed photoreceptors.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
I will also tell you about the companies involved, where the state of development stands and provide a possible timetable to the future, including the pre-clinical work underway and the road to human clinical trials.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
I have also included some information about competitive activities, and where these alternative techniques/technologies for restoring vision for those with damaged photoreceptors stand.</div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>The Problem</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
There is a group of retinal degenerative diseases that constitute a significant source of visual disability in both the developed and undeveloped world, and where current therapeutic options are quite limited. </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
For instance, the loss of photoreceptor cells, as seen in the later stages of retinitis pigmentosa (RP), geographic atrophy (GA) in dry AMD, and the late stages of Stargardt’s disease (SMD), results in permanent visual loss for which no restorative treatment is as yet available. But, the notion that photoreceptor cells might be replaceable in therapeutic settings has been given recent support by experimental work in animal models [1].</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>The Technology</b></div>
<div style="text-align: justify;">
<b><br /></b></div>
<div style="text-align: justify;">
<b>What are progenitor cells and what can they do?</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
A progenitor cell is a biological cell that, like a stem cell, has a tendency to differentiate into a specific type of cell, but is already more specific than a stem cell and, can be pushed to differentiate into its "target" cell. The most important difference between stem cells and progenitor cells is that stem cells can replicate indefinitely whereas progenitor cells can divide only a limited number of times. </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Most progenitors are described as multipotent, not pluripotent. In this point of view, they may be compared to adult stem cells, but progenitors are said to be in a further stage of cell differentiation. They are in the "center" between stem cells and fully differentiated cells. The kind of potency they have depends on the type of their "parent" stem cell and also on their niche, in this case, eye-derived progenitor cells that have partially differentiated into retinal cells.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Retinal progenitor cells (RPCs)</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Retinal progenitor cells are self-renewing cells capable of differentiating into the different retinal cell types including photoreceptors (rod and cone cells), even neuron cells, and they have shown promise as a source of replacement cells in experimental models of retinal degeneration.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>The Companies Involved</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Advanced Cell Technology (ACT)</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
ACT’s primary research program uses retinal pigment epithelium (RPE) cells derived from embryonic stem cells in the treatment of dry AMD, Stargardt’s disease, and soon myopic macular degeneration (MMD). The company is currently injecting these hESC-derived RPE cells subretinally into humans in three clinical trials, in which more than 30 patients have been treated to date, with no reported problems of safety and, in most cases, with reported improved vision. In one case, a dry AMD patient reportedly went from 20/400 vision, to 20/40 vision within several weeks of treatment. [2]. We believe that in this case, his dormant (but still alive) photoreceptors were re-activated by the RPE cell treatment. </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The MMD clinical trial has received IND approved and is expected to begin shortly.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The company is also undertaking early pre-clinical animal studies in their laboratories with several types of progenitor cells. </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
As reported by Dr. Robert Lanza, the company’s CSO at the last shareholder’s meeting in October 2013 [3]:</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
“We have, as I mentioned earlier, a number of other cell types that we are studying in the eye field, including our retinal neural progenitors, photoreceptor progenitors, and also ganglion progenitors. As regard to the retinal neural progenitors, we have looked at these cells in animals that have retinal degeneration...and we can see very significant rescue of their activity.”</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
“We also have a program that we are pursuing using these photoreceptor progenitors. When you inject these into animals subretinally, what we were able to actually see here in the first week...the cells incorporating into the retina and within only three weeks you can see them moving into the outer nucleated layer and integrating.”</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
“We are also studying the photoreceptor progenitors. We are also looking to see if we can recover visual function and retinal structure using those. We also want to test those both in vitro and in vivo in terms of using conditioned media in the secreted factors. We are also studying our ganglial progenitors and we are continuing to look at those in animals for prolonged term survival of the transplanted cells, as well as for the protection or replacement of the host ganglial cells. We are also looking at using these cells in the optic nerve regeneration model.”</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhzou3n1bTP7ABbENXbxvKY0rYSBF_SN6ynpuvmqANBUwTj2uuG3LYoc6Q1QwibN-QlL4IhzR8_lArpA_yFRPnIpnIhp-0u6Ec0W_BaP5yvdK10YYw7IiiLO719BISd7oJ0yKXr/s1600/document6.gif" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhzou3n1bTP7ABbENXbxvKY0rYSBF_SN6ynpuvmqANBUwTj2uuG3LYoc6Q1QwibN-QlL4IhzR8_lArpA_yFRPnIpnIhp-0u6Ec0W_BaP5yvdK10YYw7IiiLO719BISd7oJ0yKXr/s1600/document6.gif" height="196" width="320" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Systemically delivered Photoreceptor Progenitor cells reversed the
progression of photoreceptor degeneration – and promoted regeneration of
both Rods and Cones.[4]</td></tr>
</tbody></table>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
More recently, the company updated the status of its progenitor programs in its recent Form 10-K for 2013[5]:</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Photoreceptor Progenitor Program</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
We have developed a human photoreceptor progenitor cell. We believe that our photoreceptor progenitor cells, [derived from embryonic stem cells (hESCs)], are unique with respect to both the markers they express as well as their plasticity, meaning that they can differentiate into both rods and cones, and therefore provide a viable source of new photoreceptors for retinal repair. In addition, the photoreceptor progenitors appear to secrete neuroprotective factors, and have the ability to phagocytose (digest) such materials as the drusen deposits that build up in the eyes of dry AMD patients, and so may provide additional benefits beyond forming new photoreceptors when injected into the subretinal space in the eyes of patients. We will continue our preclinical investigation in animal models, establish appropriate correlation between integration of the transplanted cells and visual function in the animals, and then consider preparation of an IND and/or IMPD application to commence clinical studies with these cells.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Retinal Ganglion Cell Progenitor Program</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
In the United States alone, approximately 100,000 people are legally blind from glaucoma. The only proven treatment is drug therapy or surgically lowering the intraocular pressure, but many patients lose vision despite receiving these treatments. In glaucoma, retinal ganglion cells degenerate before photoreceptors are lost. We are currently conducting pre-clinical research and development activities regarding differentiation of stem cells into retinal ganglion cells and demonstration of the ability of those cells to protect against elevated intraocular pressure in glaucoma models. We have succeeded in generating a unique human ganglion progenitor cell which, when injected in animal models of glaucoma, appear to protect against damage and to form new ganglion nerve cells. We will continue our preclinical investigation in animal models, establish appropriate correlation between integration and visual function in the animals, and then consider preparation of an IND and/or IMPD application to commence clinical studies with these cells.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Neuroprotective Biologics</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
In the course of our work with various progenitor cells for treating ocular degenerative diseases, we have discovered that certain progenitor cells not only have the ability to participate directly in the formation of new tissue in the eye, but also were able to exert a neuroprotective effect that reduces the rate of degeneration of native photoreceptors in the animals' eyes, for example, in animal models of macular degeneration. These cells appeared to also be a source of neuroprotective paracrine factors; biological agents which may themselves be useful as drugs. Further, we observed that these protective effects were uniquely produced by particular progenitor cell sub-types. The restriction of this protective activity to only a certain progenitor cell type permits us to examine which factors are differentially produced by these cells as compared with other closely related progenitor cells which do not seem to secrete any protective agents. We anticipate that the neuroprotective agent(s) that we may ultimately develop as drug candidates may be useful not only in retinal diseases and dystrophies, but may have broader applications in central nervous system and peripheral nervous system diseases and disorders, including diseases causing cognitive function impairment, movement disorders such as Parkinson's Disease, and ischemic events such as caused by stroke.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
This progenitor cell work is in the pre-clinical stages and not yet ready for human clinical testing.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Californis Stem Cell, Inc. (CSC)</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
In early February, California Stem Cell, Inc. (CSC) announced the initiation of a collaborative study with the University of California, Irvine (UCI), to create a transplantable 3D retinal tissue.[6] The study, funded by a $4.5 million grant from the California Institute of Regenerative Medicine (CIRM), is a continuation of methods pioneered by CSC scientists and researchers at UCI in 2010 [7], and will investigate the potential of improving a patient's visual function by transplanting human stem cell-derived three-dimensional (3D) retinal tissue into their retina.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
California Stem Cell, using its specialized cGMP manufacturing facility and regulatory personnel, will differentiate human stem cells into retinal progenitor cells. These cells will then be co-cultured with stem cell-derived retinal pigment epithelium to create a 3D tissue structure suitable for transplantation. Proof of concept in-vivo studies will take place at UCI's Sue & Bill Gross Stem Cell Research Center, under the auspices of Dr. Magdalene J. Seiler. Transplants are expected to develop into mature retina, interact with the host tissue, and subsequently improve the vision of retinal degenerative recipients. The study, if successful, could lead to new treatments for incurable retinal diseases such as retinitis pigmentosa and age-related macular degeneration, leading causes of vision loss for people age 50 and older.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
CSC President & CEO Hans Keirstead, Ph.D. (formally with UCI) will lead the study's work at CSC. "This study establishes a valuable partnership between ourselves and a team of very talented scientists at a university known for its excellence in research," said Keirstead. "California Stem Cell looks forward to making a meaningful contribution to work that has the potential to help millions suffering from life-altering retinal diseases."</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
This work is in the very early pre-clinical animal testing stages.<br />
<br />
<b>Editors Note: In <a href="http://www.genengnews.com/gen-news-highlights/neostem-to-acquire-csc-in-potential-124m-plus-stem-cell-deal/81249742/?kwrd=NeoStem"><u>late breaking news</u></a>, it was announced on April 14th that CSC has been acquired by NeoStem, Inc. The deal is expected to close in May.</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>jCyte</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
jCyte has developed methods, that utilize human, fetal-derived, retinal progenitor cells (hRPCs), that have been partially developed into retinal cells, to activate degenerating host photoreceptors and replace and/or reactivate, in this case the cones, lost to disease, in those with retinitis pigmentosa (RP). </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
JCyte’s work will initially target cone cells because they provide central vision and the ability to read, drive and recognize faces. (Although, rod cells should also be affected.) The work will include growing pharmaceutical-grade progenitors, testing them for safety and efficacy in animal models, and then launching a clinical study for severely impaired RP patients, to prove safety and efficacy in humans.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
jCyte's research is currently supported by several resources including The Discovery Eye Foundation and two awards from CIRM (the California Institute for Regenerative Medicine), including a $4 million CIRM's Early Translation II Award [8] and more recently a $17 million Therapy Development grant [9]. Dr. Klassen's project was also accepted into the Therapeutics for Rare and Neglected Diseases (TRND) program established by the National Institutes of Health to speed the development of new treatments for rare and neglected diseases. TRND will provide him with specialized expertise and resources to help advance his efforts [10].</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Dr. Klassen intends to seek further funding to translate this cutting-edge discovery into clinical drug and cell therapy, via submission to the FDA to launch a clinical trial.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
In an update posted on his website in November 2013 [11], Dr. Klassen reported that, “The team remains hard at work in the effort to bring retinal progenitor cells to clinical trials. The work being conducted now is centered on accumulating the evidence we need to provide to the FDA in order to get approval. Prior work has set the stage by showing what is possible using these cells, but now everything has to be repeated on a larger scale, with extensive documentation, and using the same cells that will be used in patients. This is known as the Pre-Clinical Phase of the project and, as such, it is the stage just before trials begin. The major objective of the Pre-Clinical Phase is to demonstrate safety and efficacy of the product in animal models as a basis for initiating studies in humans. It is a lot of work and would take a long time if everything was done sequentially so, with the help of CIRM, we are approaching the various projects in parallel to accelerate progress. Still, it can be expected to take about a year to complete. As the results of theses studies come in, they will be collected to form the body of what is known as an Investigational New Drug (IND) application, which is the formal document that goes to the FDA.”</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
If things go as planned, jCyte should complete its pre-clinical work and be prepared to submit its NDA by late 2014, for a human clinical trial for patients with severe RP. The patients will be injected with hRPCs in their worst-seeing eye to determine safety and efficacy, hopefully, beginning sometime in early 2015.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Other targeted conditions, once safety and efficacy are shown in the RP trial, could include geographic atrophy (GA) found in dry AMD, and replacing destroyed photoreceptors in those suffering from Stargardt’s Disease (Stargardt’s Macular Dystrophy [SMD]).</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>ReNeuron</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
One of the more ambitious stem-cell treatments nearing human study is being developed by ReNeuron, a company from the United Kingdom. Its retinal progenitor treatment replaces photoreceptors lost to retinitis pigmentosa. When transplanted in the retina, ReNeuron researchers believe that the partially developed cells will mature into fully functional photoreceptors. The company hopes to launch a clinical trial this year. Previously funded by the Foundation Fighting Blindness, Michael Young, Ph.D., of Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, conducted much of the research making this treatment approach possible. His work included the development of a biodegradable scaffold for growing and organizing the cells prior to transplantation. The structure increases the chances of survival and integration of the therapeutic cells.[12]</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
In September 2013 [13], ReNeuron was granted an orphan designation by the U.S. Food and Drug Administration (FDA) and the European Commission for its emerging retinitis pigmentosa (RP) treatment, known as ReN003 (hRPCs derived from fetal tissue). Given to potential treatments for rare conditions that are life-threatening or chronically debilitating, "orphan" status provides a company with development incentives, tax credits and market protections for therapy development.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The designation bolsters ReNeuron's plan to launch a Phase I/II clinical trial for ReN003 in mid-2014. The company is partnering with the Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, to develop the treatment. According to Dr. Young, a lead investigator on the project at Schepens, ReNeuron plans to initiate the study at the Mass Eye & Ear Infirmary in the United States, and later extend it to sites in Europe.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Other Research Programs:</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
There are also several university-based projects underway, including that of Prof. Robin Ali at University College London [14], and in the lab of Thomas Reh at the University of Washington in Seattle [15].</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Competing Technologies for Restoring Vision to Those with Damaged/Destroyed Photoreceptors</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
In addition to the programs using retinal progenitor cells, there are several efforts underway to provide vision to those who have lost it because of damaged or destroyed photoreceptors.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
I will list just a few of these:</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>The Use of Stem Cells</b> – Several companies/institutions are in clinical trials [16] using stem cells to treat those with Stargardt’s disease, dry AMD, and retinitis pigmentosa.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>The Use of Gene Therapy</b> – Gene therapy is also actively being used [17] in the treatment of dry (and wet) AMD, Stargardt’s disease, and retinitis pigmentosa.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Optogenetics</b> – An offshoot of gene therapy, wherein a photoactive dye is delivered via a virus carrier into neural tissue (ganglion cells, bypassing damaged photoreceptors) and is activated by light signals sent into these activated tissues, which in turn sends electrical signals along the optic nerve to the brain [18]. Several companies and institutions are currently doing animal work in preparation for undertaking human trials, including Eos Neuroscience, Gensight Biologics, RetroSense Therapeutics, and the Institute de la Vision in Paris [19], along with work being done at Cornell Univ. by Dr. Sheila Nirenberg [20].</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Retinal Implants</b> – Several companies have developed and are currently marketing devices that sit on the surface of the retina and use cameras, or other optical means to send a signal to the electrodes implanted on the retinal surface that in turn sends a signal to the brain simulating visual inputs [21].</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Retinal Regeneration</b> – a laser treatment whereby a mild laser dose is imposed onto the RPE layer as a means of “stimulating” the RPE cells to release enzymes that are capable of “cleaning” Bruchs membrane, thereby rejuvenating the retina and restoring vision [22].</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Commentary</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
I personally believe that the use of retinal progenitor cells to rejuvenate or repair damaged photoreceptor cells in those people with degenerative retinal diseases, is an important step in the right direction. If, in the clinical trials scheduled to begin in late-2014 or 2015, this technique does restore vision in people that have lost it due to damaged or destroyed photoreceptors, it will become one of the great advances in the battle of fighting blindness.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>References:</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
1. <a href="http://www.hindawi.com/journals/sci/2012/939801/"><b>Photoreceptor Differentiation following Transplantation of Allogeneic Retinal Progenitor Cells to the Dystrophic Rhodopsin Pro347Leu Transgenic Pig</b></a>, Klassen &Young, et al, <b>Stem Cells Int.</b>, Vol 2012, January 2012. </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
2. <a href="http://tinyurl.com/StemCellUpdate25"><b>Stem Cells in Ophthalmology Update 25: ACT Patient in Dry AMD Trial Goes from 20/400 to 20/40!</b></a>, <b>Irv Arons’ Journal</b>, May 17, 2013</div>
<div style="text-align: justify;">
</div>
<br />
<div style="text-align: justify;">
3. <a href="http://investorstemcell.com/forum/act-main-forum-general-topics-science-press-releases-media/36531.htm"><b>Transcript of ACT’s Annual Shareholder Meeting</b></a>, October 22, 2013</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
4. <a href="http://www.advancedcell.com/documents/0000/0479/2014-biotech-showcase-presentation,-january-13,-2014.pdf"><b>Slide 26 from ACT’s Presentation at BioTech Showcase 2014</b></a>, January 14, 2014.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
5. <a href="http://filings.irdirect.net/data/1140098/000101968714001176/act_10k-123113.pdf"><b>ACT Form 10-K</b></a>, April 1, 2014</div>
<div style="text-align: justify;">
</div>
<br />
<div style="text-align: justify;">
6. <a href="http://www.cirm.ca.gov/our-progress/awards/restoring-vision-sheet-transplants-retinal-progenitors-and-retinal-pigment"><b>Restoring vision by sheet transplants of retinal progenitors and retinal pigment epithelium (RPE) derived from human embryonic stem cells (hESCs)</b></a>, <b>CIRM Grant</b>.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20447416"><b>Three-dimensional early retinal progenitor 3D tissue constructs derived from human embryonic stem cells</b></a>, Gabriel Nistor et al, <b>Journal of Neuroscience Methods</b>, April 2010.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
8. <a href="http://www.cirm.ca.gov/our-progress/awards/human-retinal-progenitor-cells-candidate-therapy-retinitis-pigmentosa"><b>Human retinal progenitor cells as candidate therapy for retinitis pigmentosa: Early Translational II, CIRM</b></a>. October 2010</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
9. <a href="http://www.cirm.ca.gov/our-progress/awards/retinal-progenitor-cells-treatment-retinitis-pigmentosa"><b>Retinal progenitor cells for treatment of retinitis pigmentosa: Disease Team Therapy Development - Research, CIRM</b></a>, September, 2012</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
10. <a href="http://jcyte.com/2013/10/four-new-pre-clinical-drug-development-projects-at-nih-develop-treatment-for-rare-disease/"><b>Use of retinal progenitor cells for the treatment of retinitis pigmentosa</b></a></div>
<div style="text-align: justify;">
Henry J. Klassen, M.D., Ph.D.,, <b>Therapeutics for Rare and Neglected Diseases(TRND) program at the NIH's National Center for Advancing Translational Sciences (NCATS)</b>, October 2, 2013</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
11. <a href="http://jcyte.com/2013/11/november-2013-update-from-dr-henry-klassen/"><b>November 2013 Update from Dr. Henry Klassen</b></a>, <b>jCyte News</b>, November, 2013</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
12. <a href="http://www.blindness.org/blog/index.php/several-new-stem-cell-clinical-trials-poised-to-begin-in-two-to-three-years/#more-2660"><b>Several New Stem Cell Clinical Trials Poised to Begin in Two to Three Years</b></a>, Dr. Stephen Rose, <b>Eye on the Cure (FFB)</b>, July 12, 2013</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
13. <a href="http://www.blindness.org/index.php?option=com_content&view=article&id=3626:orphan-designation-boosts-clinical-development-of-rp-stem-cell-therapy&catid=65:retinitis-pigmentosa&Itemid=121"><b>Orphan Designation Boosts Clinical Development of RP Stem Cell Therapy</b></a>, <b>FFB News</b>, September 11, 2013</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
14. <a href="http://blogs.ucl.ac.uk/eyetherapy/new-breakthrough-transplantation-of-photoreceptors-from-retina-grown-in-a-dish/"><b>New Breakthrough: transplantation of photoreceptors from retina grown `in a dish'</b></a>, Prateek Buch, <b>UCL EyeTherapy blog</b>, July 22, 2013</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
15. <a href="http://www.pnas.org/content/103/34/12769"><b>Efficient generation of retinal progenitor cells from human embryonic stem cells</b></a>, Lamba et al, University of Washington, Seattle, WA, <b>PNAS</b>, July 2006</div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
16. <a href="http://tinyurl.com/StemCellClncl423"><b>Stem Cell/Cell Therapy in Ophthalmology -- Ongoing & Completed Clinical Trial Details</b></a>, <b>Irv Arons’ Journal</b>, January 2014</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
17. <a href="http://tinyurl.com/GeneTherapyClncal"><b>Gene Therapy in Ophthalmology -- Ongoing Clinical Trial Details</b></a>, <b>Irv Arons’ Journal</b>, April 2014</div>
<div style="text-align: justify;">
</div>
<br />
<div style="text-align: justify;">
18. <a href="http://tinyurl.com/GeneTherapy18"><b>Gene Therapy in Ophthalmology Update 18: A RetroSense (and Optogenetics) Update</b></a>, <b>Irv Arons’ Journal</b>, March 20, 2013</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
19. <a href="http://tinyurl.com/GeneTherapyComp422"><b>Gene Therapy Companies/Institutions Active in Ophthalmology</b></a>, <b>Irv Arons’ Journal</b>, January 2014</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
20. <a href="http://tinyurl.com/NirenbergTechnique"><b>A New Technique for Restoring Normal Vision to the Blind: The Technology of Prof. Sheila Nirenberg of Weill Cornell Medical School</b></a>, <b>Irv Arons’ Journal</b>, May 7, 2013</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
21. <b>Ibid, section on Retinal Prostheses</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
22. <a href="http://tinyurl.com/Ellex4"><b>Ellex 2RT Updated Clinical Results: ARVO 2011</b></a>, <b>Irv Arons’ Journal</b>, May 2011</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<br />Irv Aronshttp://www.blogger.com/profile/05719664806219249867noreply@blogger.com0tag:blogger.com,1999:blog-20140933.post-87377497776689038622014-03-10T16:04:00.000-04:002014-03-10T16:08:03.686-04:00Reversing Retinal Cell Death With Inkjet Printing? <div style="text-align: justify;">
<i>For the past several months, I have been working with Mark Hillen, the editor of <b>The Ophthalmologist</b>, in providing him with background information about stem cells and gene therapy used in ophthalmology to treat various retinal diseases. Articles, based on my information, along with material developed by Mark, have been published in past issues of his magazine. (<a href="https://theophthalmologist.com/issues/0313/stem-cell-clinical-trials/"><b>Stem Cell Clinical Trials</b></a> and <a href="https://theophthalmologist.com/issues/0114/gene-therapy-clinical-trials/"><b>Gene Therapy Clinical Trials</b></a>.)</i></div>
<div style="text-align: justify;">
<i><br /></i></div>
<div style="text-align: justify;">
<i><a href="https://theophthalmologist.com/"><b>The Ophthalmologist</b></a> is a new professional journal, published by Texere Publishing, for a target audience of ophthalmologists and industry professionals, mainly based in Europe.</i></div>
<div style="text-align: justify;">
<i><br /></i></div>
<div style="text-align: justify;">
<i>The latest issue (February 2014) contains an interesting interview with Keith Martin, Professor of Ophthalmology at the University of Cambridge, about how he and his colleagues have adapted an inkjet printer to be capable of printing live retinal ganglion and glia cells that someday, might be used to treat and reverse retinal diseases.</i></div>
<div style="text-align: justify;">
<i><br /></i></div>
<div style="text-align: justify;">
<i>With the permission of <a href="https://theophthalmologist.com/"><b>The Ophthalmologist</b></a>, here is their story:</i></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<a href="https://theophthalmologist.com/issues/0214/inkjet-interventions/"><b>Inkjet Interventions</b></a></div>
<div style="text-align: justify;">
<b><br /></b></div>
<div style="text-align: justify;">
<b>Can you envisage a future in which deploying a tiny cell-spraying device during vitreoretinal surgery reverses years of retinal cell death? Keith Martin can.</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
By Mark Hillen, Editor</div>
<div style="text-align: justify;">
<b>The Ophthalmologist</b>, February 12, 2014</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
When a man tells you that, in ten years' time, he envisages treating retinal diseases with a tiny inkjet printer head, you begin to wonder if he's been drinking strong coffee with too much gusto that morning. But if that man is Keith Martin, Professor of Ophthalmology at the University of Cambridge, you need to revisit that diagnosis.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Martin has the only inkjet printer in the world that can print retinal ganglion cells (RGCs) and glia, and deliver a live product. He and colleagues Barbara Lorber, Wen-Kai Hsiao and Ian Hutchings recently published the method in <a href="http://iopscience.iop.org/1758-5090/6/1/015001/article"><b>Biofabrication</b></a> (1), and it's a story of happenstance, cross-pollination of ideas, and just giving things a go. Conventional wisdom had it that the cells of the rat central nervous system (CNS) are too fragile to be fired down a piezoelectric printer head; that printed glia wouldn't function to provide support and nutrition to neurons, and that printed RGCs wouldn't grow neurites (which are essential to communicate with other cells). Martin and colleagues did the experiments anyway. And they worked.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
As loss of certain retinal cell types is characteristic of many eye diseases, from age-related macular degeneration to glaucoma, the possibility of replacing them with cultured cells that function in situ is exciting. We spoke to Martin about it.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>How did this project come about?</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Barbara has been working in my lab for a number of years, trying to get RGCs to regenerate but this particular project was pure opportunism. Basically, it stems from a conversation with her husband, who works on inkjet printing technology, on the overlap between what we do and what he does. It turned into a Friday afternoon experiment: they decided to see if the cells could survive the printing process. Much to everyone's surprise, they did. So it started there.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Has this been done with CNS cell types before?</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
There are no reports in the literature of adult CNS cell printing being achieved successfully, so this is a first - we don't know how many people have tried and failed.</div>
<div style="text-align: justify;">
<b><br /></b></div>
<div style="text-align: justify;">
<b>How exactly was it done?</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The technique that we've developed involves separating adult retinal cells and loading them into a specially built piezoelectric inkjet printing device. (See illustration.) This allows us to fire cells out of the print head (Figure 1) at about 30 mph, that's about a thousand cells per second, and we can print them in precise patterns (Figure 2). This potentially gives us a way to recreate adult neuronal structures using printing technology.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhPYEGlGhu7DsvYwMUAy67ydiG47BnTUerkNjCX5amU3uZ4ShT1Oaf2PvIHxySyqp70MEc_di9iPOuqzjxpAYZKc7f4VXh0i7FUULgRc9Nnxmg33d5GSvqDk-NilP1IyQQjQahb/s1600/document3.gif" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhPYEGlGhu7DsvYwMUAy67ydiG47BnTUerkNjCX5amU3uZ4ShT1Oaf2PvIHxySyqp70MEc_di9iPOuqzjxpAYZKc7f4VXh0i7FUULgRc9Nnxmg33d5GSvqDk-NilP1IyQQjQahb/s1600/document3.gif" height="232" width="400" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Inkjet Setup</div>
</td></tr>
</tbody></table>
<div style="text-align: justify;">
<br /></div>
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh33ayjW-5Ggo-Fw5NDeqtvZVt-Hq3gNY40Fp388Yb4W9XdcRlp3_zVNnD-OLAM2Y_5aQc6y35cMFl4Y7kUgdUf0bAsUavTOnQqlrNOiqdzYYnd6gnJf0gwy9qkTvaqYCy2kO8I/s1600/0214-502-fig1.png" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh33ayjW-5Ggo-Fw5NDeqtvZVt-Hq3gNY40Fp388Yb4W9XdcRlp3_zVNnD-OLAM2Y_5aQc6y35cMFl4Y7kUgdUf0bAsUavTOnQqlrNOiqdzYYnd6gnJf0gwy9qkTvaqYCy2kO8I/s1600/0214-502-fig1.png" height="306" width="400" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Figure 1. Retinal Cell Printing. Image sequences of (a) retinal cells
and (b) purifed glial cells as they are ejected from the nozzle, labeled
with image capture time (1).</td></tr>
</tbody></table>
<br />
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg4hmM3ttmS1YeHwrBCR_mMd7eoqmA69XXi8E0LU4VF2pSQFeFT6FSQTWMTU1JKTS2sqeRCCtNBiXjS0G9Yd0GsJPy7ip-UC9pERHNrgwg4bIbdz88wXPhp5Vm4Qr9TvypRMMYK/s1600/0214-502-fig2.png" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg4hmM3ttmS1YeHwrBCR_mMd7eoqmA69XXi8E0LU4VF2pSQFeFT6FSQTWMTU1JKTS2sqeRCCtNBiXjS0G9Yd0GsJPy7ip-UC9pERHNrgwg4bIbdz88wXPhp5Vm4Qr9TvypRMMYK/s1600/0214-502-fig2.png" height="400" width="297" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Figure 2. Photomicrographs of ßIII tubulin (a marker of retinal ganglion
cells - red colour) and Vimentin+ (a marker of glia - green colour) in
cell cultures from: control retinal cells (a),(d), printed retinal cells
(b),(e) and control retinal cells plated at the same number as the
printed retinal cells (c),(f), either on their own (g)-(i) or with the
retinal cells additionally having been plated on (j) control glia, (k)
printed glia or (l) control glia plated at the same number as the
printed glia (1). Scale bar: 50 µm.</td></tr>
</tbody></table>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
(Open in a new tab to enlarge each of the figures and the illustration above.)</div>
<div style="text-align: justify;">
<b><br /></b></div>
<div style="text-align: justify;">
<b>Is the goal to produce a retina that you can implant into a patient to replace a damaged one?</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Well, that's a long way off. There are a number of more immediate ways that this might be useful. For example, printing retinal pigment epithelial (RPE) cells or photoreceptors, cell types that are lost specifically in certain conditions. One could envisage using the printing technology to create an implant outside the eye and then inserting it. With further miniaturization, it may be possible to spray cells within the eye, as part of vitreoretinal surgery. That's what we're looking to do, but it is far too early to talk about achieving it.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Might the optimal combination be a retinal prosthesis sensor and appropriate printed cells around it?</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Yes. I think the biggest advances will come not from using one of these technologies alone, but by combining them, coming at the problem from different approaches. The interface between the electronic and the biological approaches is one such combination.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Ultimately do you plan to build a retina? If so, what's the scaffold that you'll build it on - glia? Do other cell types, like those of the vasculature need to be incorporated?</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
We're certainly looking at other cell types. Glial-neuronal interactions are obviously very important for the health of neurons - they can't function in the long term without the support of glia. In terms of regeneration, the glial effect really promotes the axonal regeneration; we saw far better axon regeneration from the RGCs.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
We are a long way from being able to replicate the vasculature. But there are other ways of stimulating blood vessel growth. In degenerative diseases, the blood supply is not so much of a problem. For ischemic conditions it might be, but we're sticking to the neurons and glia just at the moment.</div>
<div style="text-align: justify;">
<b><br /></b></div>
<div style="text-align: justify;">
<b>In a decade's time, where do you think this technology will be?</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
We'd like to be using this as part of the treatment for regenerating the retina - that's our main goal. As I said, I don't think that this is the whole solution but it will help. We will look at manufacturing artificial neuronal tissue and also at repairing what's already there.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Will it be in clinical trials in 10 years' time?</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Yes, that's the timescale we're looking at. In terms of printing RPEs and photoreceptors it might even be a bit quicker than that, as those are more straightforward cell types. We started in RGCs because my main interest is in glaucoma - a crucial element in the pathophysiology of all forms of glaucoma is RGC death. However, people who have looked at the work are saying that it may well be more relevant to replacing RPE and photoreceptors.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>What about the cornea? Could you repair selectively damaged areas with inkjet cell technology?</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
I think that's perfectly possible, and it may well be easier than the neuronal cell types. I'm not sure anyone has tried as yet. This is a very adaptable and modifiable technology and if fragile neurons can survive it, then I'm sure that corneal cells will.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEilYTieD_UKXvMISvJB6dSLsDulffeHAeSDtOxxYiq_s4IozWfA5uLiCE-s3MHZ2Xa1Jj9UCyF598LtzRmElOgPWQd3u4yWluWH1KGkUDB6YEBwW4xReHRieaekCrPtnDlzJI2g/s1600/0214-502-Barbara.png" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEilYTieD_UKXvMISvJB6dSLsDulffeHAeSDtOxxYiq_s4IozWfA5uLiCE-s3MHZ2Xa1Jj9UCyF598LtzRmElOgPWQd3u4yWluWH1KGkUDB6YEBwW4xReHRieaekCrPtnDlzJI2g/s1600/0214-502-Barbara.png" height="200" width="170" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Barbara Lorber</td></tr>
</tbody></table>
<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: left; margin-right: 1em; text-align: left;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgc8o2BkcjhTx8_7iNK_EraJDsCqffGJZuutcGWy2a60yT7rFixJ9XSb6TCRU0eNlA-wn9UuTHpuJat4AWcQYsKFcGIlY2d46Q4IUxF8WMXbjiCI5mjamI11qdMLUDzceYgi7ui/s1600/0214-502-Keith.png" imageanchor="1" style="clear: left; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgc8o2BkcjhTx8_7iNK_EraJDsCqffGJZuutcGWy2a60yT7rFixJ9XSb6TCRU0eNlA-wn9UuTHpuJat4AWcQYsKFcGIlY2d46Q4IUxF8WMXbjiCI5mjamI11qdMLUDzceYgi7ui/s1600/0214-502-Keith.png" height="200" width="170" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Keith Martin</td></tr>
</tbody></table>
<br />
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<br />
<br />
<br />
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Referenc</b>e</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<a href="http://iopscience.iop.org/1758-5090/6/1/015001/article"><b>"Adult rat retinal ganglion cells and glia can be printed by piezoelectric inkjet printing"</b></a>, B. Lorber et al., Biofabrication, 6, 015001 Epub ahead of print] (2013). doi:10.1088/1758-5082/6/1/015001.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Abstract</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
We have investigated whether inkjet printing technology can be extended to print cells of the adult rat central nervous system (CNS), retinal ganglion cells (RGC) and glia, and the effects on survival and growth of these cells in culture, which is an important step in the development of tissue grafts for regenerative medicine, and may aid in the cure of blindness. We observed that RGC and glia can be successfully printed using a piezoelectric printer. Whilst inkjet printing reduced the cell population due to sedimentation within the printing system, imaging of the printhead nozzle, which is the area where the cells experience the greatest shear stress and rate, confirmed that there was no evidence of destruction or even significant distortion of the cells during jet ejection and drop formation. Importantly, the viability of the cells was not affected by the printing process. When we cultured the same number of printed and non-printed RGC/glial cells, there was no significant difference in cell survival and RGC neurite outgrowth. In addition, use of a glial substrate significantly increased RGC neurite outgrowth, and this effect was retained when the cells had been printed. In conclusion, printing of RGC and glia using a piezoelectric printhead does not adversely affect viability and survival/growth of the cells in culture. Importantly, printed glial cells retain their growth-promoting properties when used as a substrate, opening new avenues for printed CNS grafts in regenerative medicine.</div>
<br />
<br />Irv Aronshttp://www.blogger.com/profile/05719664806219249867noreply@blogger.com0